	Page 1
1	Public Meeting on Patient-Focused Drug Development for
2	Stimulant Use Disorder
3	
4	Moderated by Robyn Bent and Lyna Merzoug
5	Tuesday, October 6, 2020
6	12:30 p.m.
7	
8	
9	Virtual Event
10	Silver Spring, Maryland 20910
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	Reported by: Irene Gray
21	JOB No.: 4140492

	Page 2
1	APPEARANCES
2	List of Attendees:
3	Ms. Robyn Bent, OCD, CDER, FDA
4	Dr. Brett Giroir, U.S. Department of Health and Human
5	Services
6	Dr. Theresa Mullin, OCD, CDER, FDA
7	Dr. Maryam Afshar, Division of Anesthesiology,
8	Addiction Medicine and Pain Medicine
9	Dr. Marta Sokolowska, OCD, CDER, FDA
10	Dr. Celia Winchell, Division of Anesthesiology,
11	Addiction Medicine and Pain Medicine
12	Dr. Tiffany Farchione, Division of Psychiatry
13	Dr. Javier Muniz, Division of Psychiatry
14	Dr. Jana McAninch, Division of Epidemiology
15	Lyna Merzoug
16	Shannon Cole
17	Jessica Hulsey
18	Brendan Welsh
19	Scott Sheldon
20	Pam L.
21	Paula Walsh

		Page 3
1	Brandee Izquierdo	
2	Philip Rutherford,	
3	Michael Galipeau	
4	Kevin F.	
5	Charles Smith	
6	Amy Griesel	
7	David	
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		

			Page 4
1		CONTENTS	
2			PAGE
3	Ms. Bent		5,32
4	Dr. Giroir		9
5	Dr. Mullin		15
6	Dr. Afshar		23
7	Dr. Sokolowska		213
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			

PROCEEDINGS

2.

2.1

MS. BENT: Good afternoon. Good afternoon, everybody, and thank you for joining us for this FDA-led patient-focused drug development meeting on stimulant use disorder. My name is Robyn Bent.

I'm the director of patient-focused drug development with the Center for Drug Evaluation and Research here at FDA. I'll serve as the discussions facilitator for today's meeting, which is part of the FDA initiative called patient-focused drug development.

We have a really full agenda today and I'm going to briefly walk you through it. We're going to start off with opening remarks from Admiral Brett Giroir, the assistant secretary of health. And he'll be providing opening remarks in just a few minutes.

After Admiral Giroir's opening remarks, we'll hear from Dr. Theresa Mullin, Associate Director for Strategic Initiatives in the Center for Drug Evaluation and Research -- who will talk a little bit more about FDA's patient-focused drug development efforts.

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

panel.

Page 6

We'll then spend some time hearing from Dr. Maryam Afshar from the Division of Anesthesiology, Addiction Medicine, and Pain Medicine, who will provide us with a background on stimulant use disorder. The use of stimulants such as cocaine, methamphetamine, crystal meth, or the misuse of prescriptions like Adderall or Ritalin. Then we'll move onto our discussion with individuals who are living with stimulant use disorder and their loved ones or advocates. We'll have three sessions. Our first session will focus on the health effects and daily impacts of stimulant use disorder that matter really most to individuals. Our second session will focus on your thoughts about current approaches to managing stimulant use disorder. And then our third session will focus on the impact of COVID-19 on stimulant use disorder. I'll better explain the meeting format and the process right before we get into our first

2.

Page 7

Logistics. So a few logistics and housekeeping points. This meeting is taking place in a fully virtual setting and is focused on hearing from people who have personal experiences with stimulant use disorder. Throughout the day, we'll have polling questions and you'll have the opportunity to share your experiences by either using the chat feature in the bottom right corner of the meeting screen or by calling the phone number that we'll be putting up on the screen throughout the meeting.

Recording. This meeting will be webcast and the live webcast is being recorded. Both the webcast and transcripts of today's meeting will be archived on our website.

So I'm going to start now -- we're going to start with opening remarks, and it will be my pleasure to introduce Admiral Brett Giroir who will provide these opening remarks to us. Admiral Giroir is the 16th Assistant Secretary for Health -- or the ASH -- at the U.S. Department of Health and Human Services, and leads more than 6,000 officers in the

Page 8

U.S. Public Health Service Commissioned Corps. As the
secretary's principal public health and science
advisor, the ASH is leading America to healthier lives
through promoting vaccination across a lifespan,
developing the nation's report card for health, called
Healthy People 2030, working to end America's HIV
epidemic, working to improve the lives of those
suffering health disparities, and bringing a spotlight
to the importance of preventing and treating substance
use disorders. In addition to his role at the ASH,
Admiral Giroir represents the United States to the
World Health Organization Executive Board and was
appointed on March 12th to lead the coordination of
COVID-19 testing efforts across health and human
services. He has served in numerous leadership
positions in the federal government and in academic
institutions. Most notably serving as the acting FDA
commissioner in 2019, and the first position to serve
as an office director at the Defensive Advanced
Research Projects Agency in 2007. As a pediatric
critical care physician, Admiral Giroir brings that

hands-on patient-centered perspective to his work at the ASH.

Admiral Giroir, thank you for joining us today. The floor is yours, sir.

DR. GIROIR: So good afternoon to everyone and thank you, Captain Bent, for that very kind introduction and for all the great work that you and your team are doing.

I think as all of us know in the virtual world, we are in unprecedented times as we deal with COVID-19. And while we continue to face such tremendous challenges with COVID, our efforts to address substance use disorders and overdose deaths is even more critical now as people face new barriers to care and treatment.

Indeed our nation's substance abuse crisis has been one of the most pressing public health challenges we have faced, and the crisis continues to evolve.

While we have made great strides against prescription opioids, more and more people are

impacted by prescription and elicit stimulant misuse and addiction.

2.

I wanted to be clear how we view substance use disorders so there is no misunderstanding or disagreement. Substance use disorder is a chronic brain disease. It is not a moral flaw. This is a public health crisis and we are committed to addressing it in that way. That is precisely why Secretary Azar declared this a public health emergency.

Our goal is not to make bad people good, but to help sick people get better. Today, we focus on stimulants such as prescription stimulants, cocaine and methamphetamine. Some of the most potently addictive substances on the planet. They trigger rushes of dopamine and other neurotransmitters like nothing else. Household survey data from 2019 show that nearly 4.9 million people, Americans, misused prescription stimulants in that past year, and on average 2,500 people a day, aged 12 or older, initiated prescription stimulant misuse. In the same

survey, two million people reported methamphetamine use and 5.5 million people reported cocaine use in just the past year.

2.

2.1

Recent CDC data show increasing overdose deaths related to psychostimulants like methamphetamines and cocaine, with a 28 percent increase in methamphetamine-related overdose deaths and a 13 percent increase in cocaine-related overdose deaths for the 12 months ending in February 2020.

We don't know the exact reasons for the increase, but there have been significant increases in drug supply across the border by Mexican drug cartels.

Much more polysubstance use among those with use disorders and dangerous trends in toxicity and mixing of drugs, like methamphetamine and fentanyl.

For instance, in 2017, almost 73 percent of cocaine-involved deaths also involved opioids. And the data suggests that increases in cocaine-involved overdose deaths from 2012 to 2017 were driven primarily by co-use of synthetic opioids like fentanyl.

2.

2.1

Page 12

A study published earlier this year of over one million urine drug test results from 2013 to 2019 found a 14-fold increase in the rate at which samples testing positive for fentanyl also tested positive for methamphetamines, and more than a sixfold increase in cocaine. And the study my team published last month in JAMA, comparing urine drug tests before and after the COVID-19 emergency declaration showed significant increases in positivity rates for cocaine, methamphetamine and fentanyl among people diagnosed with or at risk for substance use disorder.

efforts for prevention treatment and recovery services, and to strengthen our research capacity and data surveillance systems to understand trends in stimulant use. To effectively coordinate activities around the department, together with SAMHSA, my office established an interagency methamphetamine task force that aims to expertly inform HHS efforts related to methamphetamine use. CDC is continuing to conduct

2.

2.1

Page 13

research to understand trends in methamphetamine and cocaine-related morbidity and mortality, including how these trends are similar to opioids and how they're different. NIH is leading several research projects to develop new treatments. We're at least fortunate for opioid use disorder to have medication-assisted treatment, many forms. We don't have that for cocaine or methamphetamines. Some of the exciting new treatments, including a monoclonal antibody, that could alter methamphetamine disposition.

HHS agencies continue to expand flexibilities across programs. This has been very important. The state opioid response program, which is literally billions of dollars, did not allow that opioid money to be used for stimulant misuse. But after working with congress, we now have that flexibility for states to use these billions of dollars to focus on people who are suffering primarily from cocaine or methamphetamine misuse. And through the combined efforts from FDA, like today's meeting,

2.

2.1

Page 14

understood as we continue with our effort. Your input is indeed the most important. It's what matter. How can we help you? What is your experience? What do you consider to be a success with a new treatment recommendation? And I want to say how much I respect you and admire all of you for your courage to have your voices heard today.

In closing, I want to reaffirm that HHS is committed to addressing stimulant use disorders and build a sustainable system for prevention and treatment of all substance use disorders. And imperative to our success in addressing stimulant use disorder is your input. The individual perspective and experience is critical to the work that we do, so I would like to extend my gratitude to everyone speaking today for your willingness to share your stories. Our strategy will continue to be grounded in evidence and have a whole of government, whole of society, patient-centered approach.

Again, thank you to the individuals participating in today's meeting and for the FDA

1 housing this forum. I welcome you to increase your 2 engagement with the federal government as we all 3 continue to push hard for sustainable holistic solutions that help everyone. 4 5 MS. BENT: Thank you, sir. And thank you so much for taking your time to remind us why 6 7 we're here today and for putting the weight of your office behind the prevention and treatment of 8 9 substance use disorders, including stimulant use 10 disorder. We really appreciate it, so thank you very 11 much. 12 With that, I would now like to invite Dr. Theresa Mullin to unmute and turn on her video to 13 provide a little background on the FDA patient-focused 14 15 drug development program, because it really is a 16 program unique among FDA public meetings. Dr. Mullin? 17 Thank you, Robyn. DR. MULLIN: 18 MS. BENT: Thank you. 19 DR. MULLIN: -- thank you. It's an 20 honor to follow the admiral's remarks. And I'm going 21 to give you a guick overview. Hopefully you can hear

me. Hopefully you can hear me at this point in --

MS. BENT: Yes, we can. I'm sorry. I

3 -- yes, we can hear you.

2.

DR. MULLIN: Robyn will tell me if we can't. Yes. Thank you. And I'm going to give you a brief overview of our patient-focused drug development initiative at FDA. This meeting is a patient-focused drug development meeting.

So next slide, please. And so to begin with -- and I hope you all can see this and it's much bigger on your screen than it is on my screen right now -- but I want to begin by giving you a little bit of background about FDA's role in medical product development and evaluation. FDA's mission overall is to protect and promote the public health. And part of that is to evaluate the safety and effectiveness of new drugs. And while we play an important oversight role in drug development, we're just part of that process. We do not -- FDA does not develop drugs and we do not conduct clinical trials for the development of drugs. Instead, we have our review divisions of

2.

2.1

Page 17

medical specialists, statisticians, clinical pharmacologists, toxicologists, chemical engineers and so on. And we provide regulatory oversight during drug development, and we make decisions on whether a drug can be approved for marketing based on the evidence that's submitted to us from that development program.

Next slide, please. And so how does patient-focused drug development fit into this? Well, patient-focused drug development, we define that as a systematic approach to help ensure that patients' experiences, perspectives, their needs and priorities are being captured and meaningfully incorporated into drug development and drug evaluation. And so this program helps us to do that.

Next slide, please. And so the voice of the patient is very critical to FDA's understanding and ability to make those kinds of assessments and oversee this process. Patients are uniquely positioned to inform us in our understanding of the clinical context and what matters to them, and that is

Page 18

important to us in our decision-making and our
assessment of this evidence that we receive about
drugs and whether they can be approved for marketing.
Before we had these PFDD, as we call them, meetings
that the only mechanism we really had for obtaining
input from patients would be limited to those
discussions that would occur around a particular
application or particular product such as an
advisory committee. And only a few patient
representatives typically would be involved in that
and because it would be about a particular product,
there would be extensive conflict of interest
screening that would have to occur in order to even
have those people participate.
PFDD meetings have allowed us to open
it up and get a much wider view of the community. And
it's been a more systematic way for us to get
patients' perspectives on the severity of the
condition and the impact of their condition on their

daily life and their views on how well the currently

available treatments are working for them.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Page 19

Next slide, please. This gives you a little bit of a timeline for the patient-focused drug development effort and initiative. We began having these meetings and established this in 2012. And since that time and over those years, we've had -- as of now, FDA's conducted over 25 of these diseasespecific meetings and we have also established an externally-led PFDD option because we found that many disease areas where people wanted to have these kinds of meetings, it kind of was greater than FDA's capacity to conduct and plan the meetings. And so the externally-led's been a really valuable addition to the program. And we greatly value the input that we get from patients and their caregivers and family during these meetings. And so we continue to have them and continue to greatly benefit. Next slide, please. This just gives you a quick sort of overview of the many and very different disease areas that we -- some of them that we've had to date. And as you can see, there is

really guite a large range here of conditions that --

and many, many more that we need to hear from. There have been already over 30 -- in addition to the ones listed here, over 30 externally-led meetings as well that patient advocates have organized and run.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

And next slide, please. And so this is to give you a sense of how these meetings are done. And the patient-focused drug development meetings are really different from what's our normal federal agency approach to a meeting, and they're really more like a townhall-style format. And we begin these meetings with having an overview and we have our senior clinical staff provide a clinical overview of the condition and the currently available options for treatment. That's followed by a focus on the symptoms and daily impacts of this condition on patients and people close to them that usually starts off with a panel of patients and caregivers that reflect on their own experiences -- directly on their own experiences --- with the condition. And that provides a good launchpad, if you will, for a discussion involving everybody else in the meeting and their experiences,

2.

2.1

Page 21

and how what they've experienced with regard to the impact of the condition. And then that's followed by a session on current treatment options. And again, we start off with a panel of patients and caregivers talking about their firsthand experience with different treatment options and how that's worked for them, or where it's fallen short. And that's followed and provides a good basis for that facilitated discussion that follows, to build on that and hear from others and how -- what their experience has been. How it's been similar or different, and it provides a useful kind of springboard for us.

Next slide, please. So each of these patient-focused drug development meetings is tailored to the specific needs of the disease area, although they do tend to follow that standard format. And we do encourage that patient advocates, researchers, drug developers, healthcare providers and other government officials attend these meetings, but our focus is to hear directly from patients and their caregivers. So we ask that others remain silent and in listening mode

Page 22

during these discussions because the meetings are really a platform for us to hear directly from patients and caregivers and patient representatives with the disease. And after these meetings, we develop a voice of the patient report where we try to capture very faithfully what we've heard and the way it's been described to us in the meetings, and that input that has been shared with us by patients and caregivers.

Next slide, please. And so with that, I thank you again for joining us today. We really look forward to hearing from you, hearing your perspective on stimulant use. And I'd like to now turn it over to Robyn, actually, who's going to introduce the next speaker. So thank you very much.

MS. BENT: Thank you so much, Dr.

Mullin. Obviously, I'm a bit biased, but I think the

PFDD meetings really hold an important place in

incorporating the patient voice into the medical

product development process, and I really appreciate

you taking your time to kind of share that overview

1 with us.

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Now, I would like to ask Dr. Maryam Afshar to unmute and turn on her video to begin her presentation that will provide us with kind of an overview of stimulant use disorder. Dr. Afshar?

DR. AFSHAR:

Good afternoon, everyone, and thank you for joining us today. I'm Maryam Afshar. I'm a medical reviewer in the Division of Anesthesiology, Addiction Medicine and Pain Medicine.

Since our audience have varying degree of experience and understanding of stimulants use disorder, I was asked to provide a brief overview. The slides you will see contain more information than we can review in 10 minutes, but they will be available on the FDA website for your reference.

I would like to first go over some general definitions and then talk about definition of stimulant use disorder. Misuse is the intentional use of the drug by an individual in a way other than prescribed. Misuse is in the context of therapeutic Drug abuse is in the context of non-therapeutic

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Page 24

use and is using the drug in order to experience psychological or physical effects. Tolerance is needing to use more of a substance to get the desired effect, or experiencing a weaker effect while using the same amount. Withdrawal is experiencing psychological or physical symptoms in absence of the drug, or using the drug to avoid the symptoms. Dependence can be physical or psychological. By physical dependence, we mean that if the drug is decreased or stopped, the individual will experience withdrawal symptoms. Psychological dependence is when the individual has lost control over drug use or experiences psychological distress if not able to use. This corresponds to the familiar term, addiction. The currently used general medical term is substance use disorder. Over the years, some of the terms that we have been using have changed. The Diagnostic and Statistical Manual of Mental Health Disorders, or DSM-4, that was published in 1994 had substance use disorders categorized under two groups: substance

2.

2.1

Page 25

abuse and substance dependence. The criteria for substance abuse was one or more symptoms out of three social problems due to substance use or risky use. The criteria for substance dependence were three or more symptoms out of seven, including tolerance and/or withdrawal.

In DSM-5, substance use disorder is a single diagnosis with different severities that are based on the number of symptoms that are present.

based on the number of symptoms that are present.

Similar to use disorder is substance use disorder involving use of substances such as cocaine, methamphetamine and prescription stimulants. In DSM-5, stimulant use disorders is a single diagnosis with different severities that are based on the number of symptoms that are present. Also craving or strong desire or urge to use a substance was added as a criterion.

Another change in DSM-5 is amphetamine use disorder and cocaine use disorder were combined into a single stimulant use disorder diagnosis.

In general, the signs of any substance

use disorder are categorized into four groups: loss 1 2. of control, risky use, social problems and drug 3 effects. Examples for loss of control are: 4 5 using more than intended, spending a lot of time getting the drug, using and recovering from the 6 7 effects, a strong -- sorry. A strong urge to use, 8 repeated attempts to stop or cut down, and risky use 9 or using stimulants when it can be physically 10 dangerous, continuing to use despite experiencing physical or psychological problems. 11 12 Symptoms of social impairment are: not 13 being able to take care of responsibilities at work, 14 school or home because of stimulant use, using 15 stimulants despite problems in relationships and socially, or not attending social or recreational 16 activities because of stimulant use. 17

Drug effects are tolerance or withdrawal, which we already talked about.

18

19

20

2.1

Stimulant use disorder can be diagnosed when 2 of 11 symptoms are present in a year. Mild

2.

2.1

Page 27

stimulant use disorder can be diagnosed with two to three symptoms, but it's important to know that if those two symptoms are withdrawal and tolerance, that does not qualify for a diagnosis if the individual is taking a prescription stimulant medication as directed. Patients who are on stimulant medications can develop tolerance, and if the medication is stopped, they can experience withdrawal, but this does not mean they have stimulant use disorder.

Moderate to severe stimulant use disorder is diagnosed if more than four criteria are met and corresponds to roughly what we think of as stimulant dependence or addiction. As mentioned, stimulants include cocaine, methamphetamine and prescription stimulants. Stimulants release monoamine neurotransmitters and result in increase in activity, euphoria, talkativeness, decreased appetite and cardiovascular symptoms such as changes in heart rate and blood pressure.

Withdrawal symptoms include dysphoric mood, fatigue, vivid and unpleasant dreams, and

1 increased appetite.

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Signs of stimulant intoxication include nausea, vomiting, psychosis such as auditory or tactile hallucinations or paranoid ideation, irritability, anger, aggressive behavior, seizure, confusion and coma.

As mentioned, DSM-5 puts all stimulant use disorders in one category, but it doesn't seem like it all can be the same. Individuals using stimulants use for different reasons. Some use for social reasons. It's not to cope or to enhance their energy, to perform better at work or school, or to enhance sexual performance. People use stimulants for very different reasons. As a result, the response to pharmacological treatment can vary. If someone is using stimulants to be socially accepted, we don't expect pharmacological treatment to be helpful. On the other hand, if one uses stimulants to cope with depressed mood, pharmacological treatment and therapy to improve coping skills can be beneficial.

What is the role of agonist or

Page 29

antagonist treatment based on the reasons to use?	
Also, all stimulants are not the same. This class of	
drugs include prescription stimulants, cocaine and	
methamphetamine. Let's look at methamphetamine and	
cocaine first. As you can see, there are several	
differences. Methamphetamine is highly addictive,	
more potent and has longer-lasting effects.	
Initially, results in desirable effects like euphoria	,
increase in attention, wakefulness and self-	
confidence. There can be risk of infection because of	£
risky sexual behavior or injection practices, can	
result in severe dental problems, weight loss or	
cognitive problems and psychosis. Signs of overdose	
can include hyperthermia, convulsions, arrythmia,	
stroke and even death. Years ago, methamphetamine use	9
increased due to production in labs. After 2005	
when congress passed a Combat Methamphetamine Epidemio	C
Act, the precursor chemicals such as ephedrine and	
pseudoephedrine that were used in production of	
methamphetamine were regular, and now much of the U.S	
methamphetamine supply is from outside.	

1 Cocaine is plant-based and different preparations have very different potencies, has 2 3 similar desirable effects as methamphetamine, such as increase in energy and sexuality, decrease in 4 5 appetite, and euphoria. There is risk of cardiac problems, including heart attack and arrythmia. 6 case of overdose, it can cause seizures, cardiac 7 arrythmia, respiratory failure or stroke. 8 9 The other group is prescription stimulants that includes substances such as 10 11 amphetamine, dextroamphetamine like Adderall and 12 Dexedrine, and methylphenidate like Ritalin and All are classified as schedule II and 13 Concerta. 14 misuse can result in stimulant use disorder. 15 Stimulants are prescribed in treatment of ADHD, 16 narcolepsy and obesity. Stimulants, including methamphetamine, 17 18 are the world's second most used illicit drug class. 19 There's region of variability and overdose deaths 20 involving stimulants, including methamphetamine and 21 cocaine, have increased in the recent years.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Page 31

Stimulant use disorder is a multifaceted problem resulting in social, legal, economical, physical and mental health problems. Treatment options include different behavioral There are currently no pharmacological treatments. treatment that have shown to be effective. There is ongoing research for medications, vaccines and devices including non-invasive brain stimulation. Some of the challenges in medication development are the population to enroll in the clinical trials, ways to measure the response to treatment and how long to measure. As we discuss people who use methamphetamine, cocaine and prescription stimulants are different, and the reasons for use vary widely that suggest they can't be combined all into a single study. Can people who use a same substance by different routes be combined in one study? Considering the heterogeneity of the population, the response to the same treatment can be different. What are the best methods of detecting

2.

Page 32

response to treatment? For example, a test that detects any and all use could be useful for a treatment to stop using the drug, but not suitable for treatments that the goal is use in moderation.

What are the problems that bring individuals into treatment? What is considered treatment success? Just based on drug use or other parameters, like clinical or functional improvement and how the individual is doing? How long should the studies be to see a response to treatment? Can we see response in a short-term study if there is sporadic use? What else should be considered that would be important to patients and caregivers? The answers to these questions will help us better assess treatment options from a regulatory perspective. We are looking forward to your comments.

MS. BENT: Okay. Thank you so much,
Dr. Afshar. I think that it's really helpful for us
to hear from someone at FDA who represents the
division that will be reviewing any medicines
developed to treat stimulant use disorder, and for us

to really understand the type of information that FDA thinks will be necessary to make those decisions, so thank you for that.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Moving on, I'd like to share with you a little bit about how this meeting mainly will proceed and you can see from this slide up here that we're going to talk first about topic one, and then move on to topic two and topic three. And for those of you who need to jump on and off of the webinar, please be aware that topic one is going to -- or session one is going to start as soon as I stop talking. And then we'll move on to session two around 2:50 this afternoon. And so I wanted to start out by saying that it's really been truly an honor to work with the panelists that you'll meet in just a moment as we prepare for today's meeting. And thank you to Doctors Mullin and Afshar for the really helpful presentations that give us some context to think about what the next part of the meeting -- which is really all yours -- is going to discuss.

If you're new to this area of what FDA

does and what medical product development is, then I hope we gave you a little bit of background on that, and especially some of the key terms and words that we'll be using today.

2.

where those of you with lived experiences with stimulant use are really kind of the stars of the show, I just want to share a little bit of information in terms of kind of an orientation to help you understand the meeting structure and why we set it up this way -- and kind of build on what Dr. Mullin said because it's really -- what we've done is really very purposeful and intentional so that those of you who are here representing yourselves or your loved ones with lived experience of stimulant use disorder, you're really the experts. And the expertise that you have is what we're really here today to hear.

And so we kind of flipped the script on the kind of meetings that most of you go to where you have a lot of medical professionals giving presentations and having discussions while you listen.

Page 35

Today, we've reversed that. We've heard some opening remarks from some experts in their fields, but you are the experts in your field. You're the ones who know what stimulant use is like to live with. And so we setup this meeting, like I said, in kind of three pieces. And we'll have two panels of your fellow experts who are going to share their experiences. And let me tell you what a courageous act this is. Not only in terms of sitting up and kind of being the first to speak and share their truths and their stories, but also in all of the preparation that has gone into these remarks.

And so first we're going to focus on

what it's like to live with stimulant use disorder.

In particular, the health effects and the daily impacts, how stimulant use disorder affects day to day life. Kind of life on the best days, life on the worst days, how it's changed over time and what really worries you the most.

And then we come back after a little break and we're going to focus on current approaches

Page 36

to treatment for stimulant use disorder. Your
experiences and your perspectives on that, what you'd
like to see in an ideal treatment, if future
treatments could be better, how could they be better.
Starting again with the panel of experts, but in-
between these panels, we're going to break these open
and we've got a number of polling questions and
discussion questions that we really hope that you will
call in or send us comments through the internet
about. And finally, we're going to finish up with a
discussion of how COVID-19 has impacted you or your
loved ones' stimulant use disorder because as the ASH
mentioned, you know, we're seeing some things changing
because of COVID-19 and it would really be helpful for
us to understand from you what you're seeing changing.
And so throughout the day, polling will
be done by a computer or cell phone and, as I
mentioned previously, we're taking comments from
online through the meeting chat feature and via
telephone if you've got something to add. So this is
your opportunity to build on the kind of invitation

2.

Page 37

that the panel creates to open up what's really kind of a tough subject matter. And we know that -- so just feel the empowerment that you have in this meeting today to be heard, not only by the FDA, but by representatives from medical product developers, researchers and policy makers about stimulant use disorder and what you'd like to see happen for those with stimulant use disorder. So please, again, take this opportunity and we hope that this will be your invitation to participate with us in this discussion.

With that being said, there are a few things that will help us. One is if when you call or present your comments, if we can stay on the topic that we're discussing -- whatever topic we're talking about. If we're talking about symptoms or if we're talking about daily impact. So try to think about what that topic is and stay close to that topic. It's going to be a little challenging in the virtual setting just because there's about a 20-second delay between when I speak and when you hear me speak. It's also helpful if you can keep your points to maybe just

two or three things so that we can go to as many people who want to speak as possible.

2.1

And when speaking, you can remain anonymous if you want. I mean, you don't have to give us your names. You can state your names if you want, but what's important to us isn't what your name is.

What's important to us is really what your experience is. And so if you're submitting comments via the webcast, you can provide whatever name you'd like.

Don't worry about us being overwhelmed by comments or by phone calls, we can handle it. We'll try to summarize them as much as possible. We'll also encourage you to, again, call via phone to share your comments because, again, you don't need to share your name if you don't want to.

You can also send your comments after the meeting as well. We have a website. It's called a public docket through the federal register which is really just the way that people in the real world can talk to FDA. And the docket is open until December 7th. So you have about two months to comment on

something if something was really interesting or if 1 2. you have more to say, you can send it in. If you have 3 friends or loved ones or others who you think have 4 something to say, you can encourage them. Anyone is 5 welcome to comment, so you don't have to be an individual or family member to submit comments to the 6 7 docket. You can also submit your comment as 8 And I want you to keep in mind that if you anonymous. 9 submit to the public docket, that is the word public 10 is there for a reason. This will go to the website. So please think about how much personal information 11 12 you want to share. We don't need your personal 13 information. Again, we don't care -- it's not 14 important to us what your name is or where you live. 15 We care about your experience. So please keep that in 16 We really want you to share this information 17 with us. When you get to the form, you can just say 18 anonymous, anonymous, or leave the part empty where 19 they may ask what your name is. 20 Okay. So there's a few rules that are 2.1 important to go through, and I say this with all

seriousness about the meeting today. We want to hear from individuals and family members and we really hope that you will feel comfortable lending your voices.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Advocates -- we have a lot of individuals online, and so advocates are going to ask you to kind of play it by ear. If you're an advocate and I know you wear many hats, we all kind of wear many hats, but if you also have personal experiences, we're going to ask that you put kind of your personal experience hat on and speak from your lived experience with stimulant use disorder or with a family member or someone with stimulant use. Everyone else really is here to listen. And that means our FDA panelists, who I'll introduce them in a minute. We'll be turning to them periodically to see if they have any follow-up questions, but we're really here in a listening mode. And you may have questions for us and we may not be able to answer all of them, but we are making a note of all of your questions.

If you're viewing as a medical product developer or a healthcare provider or other interested

person, we ask you to just kind of stay in listening
mode. And moving on, I think the views expressed
today are personal opinions. And they're not just
opinions, but they're personal stories. And everyone
has their own story and their own perspective, and we
respect that. And throughout this meeting, really,
respect for one another is paramount. We have
different views on things today and differing
experiences, and we'll listen respectfully. We'll try
not to spend too much time on one given perspective,
so we will keep the conversation kind of moving along.
Our discussion is going to focus on
health effects and treatments. We know that this is a
very, very complicated issue and there are many
concerns and many questions that you have, and things
you have to think about living with stimulant use
disorder and getting the support you need. And those
are all important. As it's been described, our
discussion today is focused on stimulant use disorder
effects, daily impacts and management approaches. And
we understand that there are several important issues

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Page 42

to ensuring that individuals get healthcare, treatment and support that they need. Today, we want to focus on the topics that FDA needs most input on so that we can best fulfill our role in medical product development and decision-making. Our discussion may touch upon specific treatments, however, the discussion of specific treatment should be done in a way that helps us understand the broader issues such as what aspects of your stimulant use disorder are being addressed and how meaningful that is to you and your family. And so now on the screen, you can see information on how to submit comments or call in. while you're taking in this information or maybe jotting down that phone number, I'd like to take this opportunity to ask my FDA colleagues on the FDA panel to turn on their video and introduce themselves. I'm going to start with Dr. Sokolowska.

DR. SOKOLOWSKA: Good afternoon, everyone. My name is Marta Sokolowska and I lead the controlled substances program at the Center for Drugs

Page	4	3
------	---	---

at the FDA. Our group advises for center director of 1 2 policies in initiatives to address control --3 controlled substances and to relate it to public health consequences and to facilitate development of 4 5 treatment of -- for substance use disorder. I want to take the opportunity to thank everyone, especially the 6 7 patients, the family members and the -- and the -action groups that are on the call who will help us to 8 9 learn about this disease. So thank you very much, 10 everyone. 11 MS. BENT: Thank you. Dr. Winchell? 12 DR. WINCHELL: Hi, I'm Celia Winchell. I lead the team that reviews applications for drugs to 13 treat all types of drug addiction in the Division of 14 15 Anesthesiology, Addiction Medicine and Pain Medicine 16 at FDA. 17 MS. BENT: Thank you. Dr. Afshar, once 18 again? 19 DR. AFSHAR: Hi, I'm Maryam Afshar. 20 I'm a medical reviewer in the Division of 21 Anesthesiology, Addiction Medicine and Pain Medicine.

	Page 44
1	MS. BENT: Dr. Farchione?
2	DR. FARCHIONE: Hi, I'm Tiffany
3	Farchione. I am the acting director of the Division
4	of Psychiatry at FDA, and we're the division that
5	approves the stimulant drugs for treatment of ADHD,
6	narcolepsy, things of that nature.
7	MS. BENT: Dr. Muniz?
8	DR. MUNIZ: Hi, good afternoon. I am
9	Javier Muniz. I'm a psychiatrist and I work for Dr.
10	Farchione in the Division of Psychiatry products.
11	MS. BENT: Thank you. Dr. McAninch?
12	DR. MCANINCH: Hi, good afternoon. I'm
13	Jana McAninch. I'm a senior medical epidemiologist in
14	the Division of Epidemiology. And I work with the
15	non-medical use team, so we work on issues of drug
16	safety that involve things like drug misuse, abuse,
17	addiction and overdose. So I'm very honored to have
18	the opportunity to participate today. Thanks.
19	MS. BENT: Great. Thank you so much.
20	And we'll also be joined a little bit later by Dr.
21	Michelle Campbell, our senior clinical analyst for

stakeholder engagement in clinical outcomes from the Division of Neurology products here in the Center for Drug Evaluation and Research.

2.1

And so now, as I previously mentioned, from time to time during the meeting, we're going to turn back to our FDA panelists to see if they have any follow-up questions. I'd also at this time like to introduce my colleague, Lyna Merzoug, who will be keeping an eye out for comments that come through the internet. She'll be sharing those comments throughout the meeting and she'll be coordinating with our other colleague, Shannon Cole, who you'll speak with if you call to provide comments via phone. Lyna?

MS. MERZOUG: Hello, everyone. Good afternoon. Thank you all for joining today and I'm definitely looking forward to this meeting.

MS. BENT: Great. Thanks so much. And so as I mentioned before, we will have some polling questions today and we're using a third party application, Mentimeter, to run our polling. Polling on Mentimeter's site, menti.com, is anonymous and can

be done via cell phone or on your laptop or tablet.

2 | Please note that we're not tracking individual

3 people's answers and we'll only see the responses

4 grouped by option.

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

You can access the Mentimeter poll in two ways. You can use your cell phone camera to view the QR code that's on the slide, which will take you to the survey, or you can go to www.menti.com and use the digital code on this slide to enter the survey.

For some questions, you'll have one answer. For others, you may have multiple answers. These polling questions are really meant to just be a discussion aid today. They're not meant to be a scientific survey.

And so with that, let's begin with a polling question just to kind of get things going. So please get your cell phone ready. All right. So for question one, we're going to start with just some basic demographic questions that can get you familiar with the polling platform. And the first question is, "Where do you live?" And it looks like -- because

there's a little bit of a delay and people responding,
we're going to give us a few minutes to kind of get
responses. But already, from the responses we're
seeing, I think we're really seeing the advantage of
virtual meeting because, you know, a lot of times we
hold these public meetings and we have a large
contingent of people a large contingent of people
who are from the local area, and sometimes we don't
get as many people from outside of the national area.
And so I think that this is really an informative kind
of poll, even though completely unscientific. Just
getting an idea of where people are joining us from.
And so this is great to see. So thanks so much,
everybody, for this. And we'll just give it another
few seconds to really get people's feedback on this.
Hopefully you guys are able to access
the poll. It looks like we have climbing numbers, so
that's great. All right. All right, great. So this
is really helpful and it doesn't look like we're
having any challenges with the application, other than
just a little bit of lag time.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Page 48

So with that being said, let's move on to the next question. And we're asking the next question to really get an idea of who we have participating in the meeting. I understand that many of you may fit into more than one category, so please choose the category that you most closely identify Okay. So question two, "Which statement best with. describes your experience with stimulant use?" unfortunately, it's showing up a little blurry on my screen, so I'm not 100 percent sure that I can share the results with you. Let me see. I'll try and make it a little bit bigger. I am not able to see the Okay. So that's a challenge. results. I hope that you guys can -- I know you're also able to see the results, so I hope that you can see the results on your screen. Hopefully that will be easier for you to see than for me to see. But from this point on, we're going to

But from this point on, we're going to ask that each polling question be answered only by individuals with stimulant use disorder, or family member on behalf of a loved one who uses stimulants.

2.1

Page 49

And so question number three, "How old are you or how old is your loved one who uses stimulants?" And good news, I can tell I'm going to be able to see the answers to this one. Okay. It doesn't look like we're getting any responses to this question, so we'll give it just another minute. We might be having some technical difficulty, so we'll just move on to the next question.

"How long have you or your loved one used stimulants?" And really, this is kind of a complicated question. We're trying to understand how long you've used stimulants, but if you were prescribed something like Ritalin or Adderall as a child, please don't include that time unless you were misusing your prescription. If you're no longer using stimulants, please let us know how long you actively used for. And if you've had times where you've started using and then stopped and then started again, please just give us an estimate of how many months or years you actually actively took stimulants for.

Okay. And so we're seeing responses

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Page 50

and it looks like, you know, we have a great variety of people on the call today -- on the webinar today, ranging from one to two years, to 20 to 30 years. Some people not exactly sure. Really, it looks like right now, we have a majority of people in the three to four year use range. And so that is -- that's really helpful for us to know and thank you so much for providing us with these responses. It's also really great for us to see that we have a good number of people online who have personal experience with stimulant use disorder, and I hope that you guys will consider, in addition to answering the polling questions, also giving us a call or sharing with us your thoughts as we move forward today. So thanks so much for that.

And we have just one more question before we move on to our first panel discussion. And the question is, "Which region of the United States do you live in?" I know that we asked earlier about the demographics from inside D.C., outside D.C., but this gives us a better idea of kind of where in the U.S. or

Page 51

where in the world you really are coming from. And that's really helpful for us because we know that, you know -- we know that stimulant use is really a problem that is crossing the United States. And so this gives us a good kind of idea of what our demographics for this meeting in particular look like.

And it looks like we've got a strong contingence on the northeast and some from the west. It looks like more people from the Midwest are joining and we thank you for that. We try to make the meeting late enough in the afternoon that nobody had to wake up at the crack of dawn. So we're really grateful that you were able to -- or are able to participate with us. So thank you.

This was really great and I think that you'll see as we go through the meeting, we're going to kind of bring in some other polling just to really set the context for the conversation.

And so with that, I'd like to start our first panel now. And so I think this is why we're kind of all here and we're really excited about this.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Page 52

So as I mentioned, topic one will focus on the health effects and daily impacts of stimulant use disorder. And we'll have five panelists who will start off the session by sharing their experiences. And in about 25 or 30 minutes, when our panelists are done sharing their experiences, we'll move on to the interactive portion of the meeting by asking you about your experiences. So if there's something that you hear from our panelists that really resonates with you or you want to share a bit of your experience, please consider, again, sharing your comments via the web, or closer to the end of the 25-minute period -- maybe around 1:50, 1:55 -- maybe give us a call at the 1-800-527-1401 phone number to share. And so I'd like to start by inviting Jessica to share -- to turn on her video and unmute, and to share her experiences as a loved one of a person with stimulant use disorder. MS. HULSEY: Thank you so much for having me today, and a very big thank you to the FDA

for focusing on and building a PFDD on stimulant use

disorder. All I've really wanted for Christmas for a couple decades is a medication to treat stimulant use disorder, so all of these efforts to learn more and hear from patients, we really care about.

2.

2.1

My name is Jessica Hulsey and I'm an impacted family member, and I'm also the founder of Addiction Policy Forum. We advocate for patients and families impacted by addiction, and I'm very grateful to our members who are joining -- either participating in the meeting or as panelists today. Thank you for your courage and sharing your experiences so we can advance our treatment of this illness.

Both my parents struggled with stimulant use disorder. My dad struggled with crack cocaine and opioids and my mom struggled with heroin and cocaine. I've lost both of them, so I can share a little bit of my experiences as a loved one, and a little bit of my hopes for how we can advance our approach to this illness.

I think first and foremost, you know, we had a very good overview of the physical effects of

methamphetamine and cocaine and other stimulants, but
they are very profound. And how difficult the
physical effects, the side effects, the long-term
consequences are really create a lot of challenges for
our patients. Whether it's the intense cravings which
come on very quickly and are hard to manage.
Withdrawal lasts much longer than it seems like for
other substances. Some of the health effects that are
cognitive, whether it's paranoia or psychosis, the
mood swings can have a very dramatic impact on
patients. It can hurt relationships with family and
friends. It can create unfortunate situations where
there's criminal justice involvement. And then as our
patients get help and are in recovery, sort of picking
up the pieces from those consequences is really
difficult. And we work and try to do all we can to
help with the self-stigma that's around stimulant use
disorder, of helping people learn how to forgive
themselves, and understanding some of the behaviors
and changed priorities that come from addiction, and
stimulant use disorder, and understanding how that

happened, to really learn how you find that selfforgiveness.

We talk about the hijacker as a metaphor to describe addiction, and how it hijacks the brain and that list of priorities that you have, and how you behave and conduct yourself. I would say that when it comes to stimulants, the hijacker's a little bit meaner. It comes on quicker. It's harder to get rid of. It does more damage in your life and then you're left picking up those pieces.

I also think that there are long-term effects that we don't talk about. My mom was in recovery when I lost her, but between cocaine and heroin use, she had not only suffered opioid overdoses, but several heart attacks as a result of cocaine use. And that created some very significant issues with her heart.

Similarly, my father struggling with crack cocaine, huge impact on his lungs and other health systems that it ended up creating a lot of issues long-term. Whether it's diabetes or lung

cancer, heart disease, arrythmia. Managing those while you're also trying to manage all the pieces you need for your recovery plan can be really very difficult.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

And two other things. I'm trying to stick in my three to five minutes. Success for our patients isn't about abstinence. Slips are a part of any chronic health condition. I have asthma and no one sort of monitors me or I don't sort of lose ground or feel embarrassed if I have to use a rescue inhaler because I'm not managing my symptoms. And similarly, this is a chronic health condition and slips happen. Success is returning to your life. Success is working. Success is taking care of your children. Positive relationships and getting back to sort of prosocial activities. It's sleeping well. sleeping through the night on your own and managing those such difficult symptoms of insomnia that are so hard to manage. Success is being heathy and having overall wellbeing.

2.

Page 57

add is I think the stigma around stimulant use disorder, particularly when we talk about individuals struggling with methamphetamine, with crystal meth, with cocaine, it feels greater than other substances.

And stigma hurts our patients. It keeps us in the shadows. It keeps us from coming forward to seek help because stigma's just a fancy word for discrimination. And not treating those who struggle with this illness with the empathy and compassion that they really deserve.

and so I think that when we better explain the symptoms, even the really tough ones -whether that's increased aggression or psychosis, or some of the cognitive pieces to some of the nervous ticks and things that we don't understand in the physical symptoms. If we really break those down and we reassure families and the public and patients that there is a way through, that we're working on medications, that we can treat this illness and we can get better, we need to address that stigma. And I feel like it has potentially been made worse by, you

2.

Page 58

know, when you compare this with the opioid epidemic.

We have this narrative that so much of opioid use was about prescribed medications that went off the rails.

And then our patients that are struggling with stimulants feel that we end up in the category of other where there's more stigma and more blame on us and our behaviors than there is for others that are even struggling with a different type of substance use disorder. And I think it's really important that we tackle that.

I'm not sure it really matters why we started using stimulants. Whether you are trying to fit in or being social, you're managing your own anxiety, you're using this for some type of enhancement or a sexual reason, at some point when you start to actually develop a stimulant use disorder -- when you're developing a moderate to severe addiction to a stimulant, our symptoms are very similar. Our struggles are very similar. We need more help to make those tools in the toolbox be more readily available so we can find them.

And I do think that we can sort of build together ways 1 2 to share those success stories with our patients and 3 families that are really struggling with this illness. 4 MS. BENT: Thanks. Thank you so much, 5 Jessica. Thanks for being the first one to speak, but also to kind of sharing a little bit about your mom's 6 7 experience and your dad's experience. We're now going to move on to Brendan, 8 9 who is going to share with us his experience. 10 Brendan? 11 (End Media 1.) 12 (Begin Media 2.) 13 Thanks so much. MS. BENT: 14 MR. WELSH: Thank you. Good afternoon, 15 everybody. First, I want to share my thanks both to 16 the FDA and Captain Bent for this opportunity. My 17 name's Brendan Welsh. I'm a person in long-term 18 recovery. What that means to me is that I've not 19 found it necessary to use drugs or alcohol in coming 20 up on nearly 10 years now. And honestly, as a direct 21 result of that recovery, I have the pleasure and honor

2.

2.1

Page 60

of joining you guys today to really share some of that firsthand experience of what it was like to live with a stimulant use disorder. Again, I actually grew up with a stimulant use disorder. And the reason I say grew up with is because I was introduced to stimulants at a fairly early age, in my teenage years in high school through parties with friends where cocaine was available. And while I will tell you that introduction to cocaine was something that I remember as clear as yesterday and I remember the instant energy rush and the mania that came along with that.

Because of the lack of availability of cocaine, my true addiction or misuse of stimulants wouldn't come until a few years later when I met a doctor who I said the right things to and introduced me to Adderall through prescription. And what I can tell you now is looking back, I can see that time period where I went from using my Adderall as prescribed to really help me focus in school and I started noticing what would happen if maybe I didn't take one Adderall the day I was supposed to, but then

double up the next day. And the mania that came along with that I chased after.

2.

And looking back now, I even realize in high school that there were times that I was starting to go through that physical withdrawal that they were talking about in the clinical presentation where my mood plummeted. My energy plummeted. I wanted to isolate and be around no one else until I had that substance again.

And what I will tell you is from the time that I was in high school through my early 20s I chased that feeling of euphoria and rush that came every time I would take one of those Adderall. And I desperately, desperately wanted to avoid not only the physical exhaustion, but the mental and emotional exhaustion that would come with the withdrawal if I didn't have my medication that I was trying to utilize.

I will tell you as far as daily impacts of my drug use, my life became a constant chase because what started as a prescription would

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Page 62

eventually be taken away from me because my doctor noticed signs of my abuse because of my extreme weight And so then I had to go find that prescription out on the streets. So whereas energy could have been focused on my career and profession, I was using that time and energy to go find my drug that I needed to get through work. And ultimately what would happen is I would lose any sort of employment that I had as a result of that chase. And being a person that, at that time, needed those substances, I did what I knew I needed to do in order to make money and that was my introduction to sex work. And what I will tell you is my drug use directly impacted those choices that led me to that work.

And while that all was unfolding, the rest of my life was, too. My relationship with family and friends were becoming more and more distant because if I couldn't use my substances in those settings or around those people, I just chose not to be around those people.

And so looking back now, after being in

recovery for some time, at the health impacts that
were going on in my life then, I can clearly see where
the constant grinding of my teeth and other oral
issues that I left to neglect caused extreme dental
problems in the years that would be my early recovery
that I would have to then correct.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Additionally, at the time during my active use, one of the major health impacts that I didn't realize was I had been -- or I had become HIV positive, but was not yet diagnosed. And early in my recovery, as a matter of fact within the first six months of being introduced to recovery, I had to come to terms with all of those health impacts. looking back now, I mean, the positive that has come as a result of the recovery is amazing. I'm more healthy today than I've ever been, but looking back, I know directly that my use of substances, specifically stimulants, led me to situations and behaviors that would ultimately have life-long impacts on my health. And knowing now that there's a possibility for some sort of medication to intervene in people that are

Page 64 abusing substances, specifically stimulants, it really 1 2 just -- it gives me a lot of hope for people that are 3 out there that are still using and having those health impacts on a daily basis that they won't have to have 4 5 the same long-term effects that myself or other people that have come before them have. 6 7 So again, my gratitude to the FDA and Captain Bent for this opportunity. Thank you very 8 9 much. 10 MS. BENT: Thanks so much, Brendan. suspect that many of the experiences that you 11 12 mentioned here are going to resonate with a lot of our 13 meeting participants, and we're going to touch a little bit more on a lot of these topics during the 14 15 panel discussion. 16 Now, we're going to turn to Scott to 17 share his experiences. Scott?

18

19

20

2.1

MR. SHELDON: Hello. Hopefully you can hear me all right.

> We can, thank you. MS. BENT:

MR. SHELDON: My name is Scott Sheldon.

I am in abstinent recovery for just over five years now and I want to thank you for asking me to participate in this. I think finding something that addresses specifically stimulant use disorder will be extremely beneficial to anyone who has had to deal with this.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

I started experimenting with alcohol, marijuana and hallucinogens as a young teenager and that very quickly gained me introduction to stimulants through cocaine and crystal meth, much like Brendan, mentioned, going to parties and kind of utilizing them for staying up and for a lot of the traveling involved in that. We would kind of use it -- use stimulants like crystal meth to stay up for 6 to 10 hours while we were at these warehouse parties, and then driving up and down the east coast. And cocaine was often utilized. We kind of saw it as a status, you know, a status symbol based on the cost and the complications of acquiring it. And then for a long time, I would use it in combination with other drugs and often I would utilize opioids in order to help quell the

cravings that came with my stimulant use. I found	
that I would not go through hundreds of dollars' wor	th
of cocaine or crystal meth if I also combined it with	h
opioids. And soon that led into kind of multiple	
problems at the same time and the cost of that use	
became the focus of all of my energy. You know, like	e
doing things to get more money, to get more drugs.	
And then often times that would lead to my	
incarceration. And in the later period of my using,	
that often came offered with treatment for the opioio	d
aspect, whether it was methadone or buprenorphine.	
You know, there was some way that they would want to	
help me address my opioid use disorder, but that	
didn't kind of change my cravings and desire for	
continued stimulant use. And that continued use kind	d
of took center stage in my problems and in my	
development of, my thinking and my motivations. It	
wasn't till I was finally about 37 when I finally	
decided that, you know, like, I couldn't make things	
work, but up to that point, I'd been incarcerated in	
like 14 different institutions. My average use got	up

to over \$200 a day with cocaine, crystal meth and
heroin all combined. And it went from, you know, like
swallowing ecstasy pills to snorting crystal meth and
cocaine, to then smoking it, to then IV use and all
those things led to a number of health problems. None
of these I have entirely store-bought teeth. I
don't have any more teeth left. I lost I was down
to about 11 by the time I decided to just kind of
replace them. And most of that was as a result of,
you know, continued damage through my use and the
constant dry mouth that comes with the use that
prevents your mouth from kind of taking care of
itself. And the IV use led to multiple infections and
abscesses. I had a number of hospitalizations related
to that specifically. I lost more than one dear
friend to overdose related to stimulants. One person,
she didn't know that she had heart problems until
well, I guess we all found out kind of after the fact,
but the stimulant use kind of exposed that. A little
too late to do something positive about it. But, you
know, the along with that came the kind of

depression of if I wasn't in the pursuit of acquiring
more money and more coke or crack or crystal meth,
then I also felt kind of lost. And so I would relate
it to kind of a depressive state as well. So, you
know, I stayed distracted in my use. I stayed
avoiding dealing with myself and other
responsibilities and problems. And so on a regular
daily basis, I was dealing with several issues.
Infections, depression, all related to my stimulant
use and the fact that there was a lot of development
focusing on opioids. You know, like, I would actually
utilize that sometimes because I did have a problem
with that as well, but I also found that that was more
a path of me managing my stimulant use. And so it
took me a lot longer to find help and direction to get
out of that cycle.
And I hope that through shared
experiences and ideas, that some more focus can be
turned back towards stimulant use treatment and I
appreciate your time. Thanks for letting me share.
MS. BENT: Thanks so much, Scott. We

really appreciate you sharing your story and you brought up more topics that I think we're going to need to kind of unpack during our panelist discussion. So, thanks so much for that.

2.

We're now going to turn to Pam. And so, Pam, thank you so much for joining us today.

PAM: Thank you so much for the event as well as inviting me. Thank you. Good afternoon. My name is Pam and I work in the field of addiction, primarily in harm reduction. I started an organization that works throughout the state, it's called Harm Reduction Michigan. I'm here today though because I came to talk about the using of injection cocaine for 22 years of my life. Predominantly to manage ADHD, unbeknownst to me at the time.

Due to adverse childhood experiences, I had a significant problem with depression and also had ADHD, both of which were unmedicated. I started snorting cocaine, much like the gentlemen who have shared before me, in high school when I was 17, but like one of the gentleman shared, where I lived,

cocaine was not really available. But I went to U of M in Ann Arbor, and in Ann Arbor and the Detroit area, it was readily available.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

And in my senior year at the University of Michigan, I began to inject. Some of the people in my peer group started to experiment with injection. Because cocaine, like other stimulants such as methamphetamine has a very harsh come down and very strong cravings -- as all of our panelists have spoken about -- I began to add heroin into my cocaine injections. Of course I then became opiate dependent. Twenty-two years of an injection drug problem led to significant and expensive health problems such as MRSA. I was twice hospitalized with sepsis and septic arthritis. I now have 18 years in long-term recovery, and two years ago, I finally allowed myself to be prescribed medication for ADHD.

Because I am still very afraid of ever being drug dependent again, I prefer to attempt to manage my continued issues with depression through exercise. As a person who has both personal and

2.

Page 71

professional experience, I would ask that we be cautious in focusing our efforts in addiction on one substance or category of substances. The stimulant use disorder panel is very panel. Please, I'm not trying to diminish that; however, if people don't have the luxury afforded to get at the underlying causes of addiction, which is really in its root emotional, it will simply move to a different substance or sometimes a behavior.

I think I have observed, as a professional in this field in the last decade, as we as a country demonized heroin and opiates, I have seen many of my patients in clinic who are addicted to heroin or opiates switch to readily available methamphetamine, which certainly provided the dopamine spike that their brains were looking for.

It was interesting to me to hear the other panelists because I think, you know, our paths were in ways different, but so many of the same things that were a part of my path as well. The chase, the time people spend chasing down the substances in the

Page 72

street, and so it's really life-changing. It's hard when asked to click which of these buttons I mostly closely identify with, but because I think so many people like myself and some of the other panelists, when you live through something like a heroin or a cocaine or a methamphetamine addiction, it's such a significant impact on your life that it's really hard to identify primarily as anything else.

So I'm grateful for this summit and I'm very grateful for all the expertise that we have here today. And I'm very grateful for the opportunity to share my comments. Thank you very much for your time today.

MS. BENT: Thanks, Pam. And I now that we're really kind of hoping to get to the point where we kind of talk about the polysubstance use and the challenges because it doesn't -- it isn't something that packs nicely and neatly up into little boxes.

So as our final panelist, we're going to hear from Paula who's going to share her experience as a family member. Paula?

Page 73

MS. WALSH: Hello. Hi, my name is

Paula Walsh. I actually live in Boston, Mass. I'm

actually a mother who has already buried a child to

overdose four years ago. My son Mark passed away from

a fentanyl overdose.

So three months after my son Mark passed away, my only other son who's 27 years old now started using drugs to get rid of his pain of losing his only brother and his best friend.

So Joey first started out by using cocaine and then Joey went on to using meth. So about a month before the COVID started, my son, Joey, started doing meth. To me, that was a whole different ball of wax. That was something that I've never seen in my entire life. I didn't know how to deal with it. I didn't know how to cope with it. I didn't know how to help him. So every time he would use meth, he would go into a psychosis. He would hallucinate. He would see things and it made me really scared for my son and his life. And I felt like he wasn't Joey anymore. He became somebody else. He was suicidal

2.

Page 74

quite a few times, so there were many times that I've had to actually call the police to my house in the past four months just so they could help my son get into an ambulance because he wouldn't go on his own to the hospital, so that he could be brought down from his psychosis.

Sometimes they would give him Haldol, sometimes they would give him Thorazine. Sometimes they would send him back out the door and give him nothing and put him back into the streets with no treatment. And that made me very sad.

So, you know, my son, also, his heartrate would go extremely high. It would go up to 160 and my son actually had a prior stroke. So he was at risk of death when he does these drugs. When he was high one time, he threatened to jump in front of a commuter rail train because he was not Joey anymore. He did not know what he was doing. He thinks he can walk on water, you know? And he could walk across a highway and not even realize the dangers that he's putting his life in.

Page 75

Also, actually on one occasion when my son was brought to the hospital, he was actually tased by the police because he started to get agitated. So they tased him instead of treating him in a human way for his stimulant use disorder. Another time, my son was found at 5:00 in the morning overdosed in the middle of the street, right around the corner from a hospital. And they brought him to the hospital and the hospital actually gave my son a couple Ativan pills and -- to help him crash, and it actually worked. I felt -- to me, I felt that was the most humane treatment that my son received at a hospital in a psychosis.

So I've had many issues where they won't accept my son into a detox because detox is, you know, they say methamphetamines and stimulants are not addictive, and they are addictive. But the problem is the detoxes do not have the medications that they need to give these patients who are on stimulants. So that they -- the patients that are on stimulants can't get treated like anybody else who has a disease. The SUD,

2.

2.1

Page 76

substance use order and the stimulant use disorder, I feel like it goes hand in hand. And, you know, my son should be able to walk into a detox and get a medical treatment, so that's why I'm hoping that they can come up with a medical treatment for meth and any stimulants so that they won't have the desire to use them anymore, just like they have suboxone and naltrexone and vivitrol for people that do opiates.

Like, something similar to that that will take away their urge to even -- in their brain, so they won't even consider going in that direction.

I also -- I've done a lot of research

I also -- I've done a lot of research online and I've found that like California, where methamphetamines and stimulants really started up, I found that they have a lot of treatment centers out there for stimulants. And I've even tried to get my son a scholarship because he didn't have the insurance to go to treatment out there so he could get a medical treatment for stimulants and meth, and to no avail. I could not find that for my son.

And basically, you know, as the mother

who's already had to bury one child, I'm going to continue to advocate for people who have a stimulant use disorder. I want them to get the medical treatments that they need. I want them to be able to stop using. I want to save their lives. I just want to thank you for letting me speak.

2.

MS. BENT: Thanks so much, Paula.

There's a lot to unpack in these experiences and we really need to thank Jessica, Brendan, Scott, Pam and Paula, not only for just sharing their experiences, but also for going back to a place and a time that I understand is really, really difficult for a lot of people to go. And they really -- they've done this to help us move the field of stimulant use disorder treatment forward. So thank you so much for that.

And for those of you who would like to call or submit comments to be shared, as a reminder, at the bottom -- as a reminder, here's how to do it.

You can either add -- click on the comment box on the corner of your screen, or you can call into the 1-800-527-1401 number to share your experiences.

2.1

Page 78

So again, I'll ask you guys kind of, how many of you heard your or your loved ones' own experiences reflected in the comments shared by the last ones of our speakers? Obviously in a virtual setting, it's not really possible for me to see you nodding or applauding in the way that we usually see during our patient-focused drug development meetings. So we're going to use more polling questions to kind of get feedback from all of you who are joining us online.

Again, polling is limited to participants who have a lived experience with stimulant use. Whether it's users or family members or loved ones, we're not really defining what family members or loved one means, you define it for us. If you have someone that you cared about and you have experiences that you want to share and reflect in the polling, then please do.

So now we're going to just kind of move on to the polling. And we're going to start with just a pretty basic kind of straightforward question.

2.

2.1

Page 79

"Which stimulant did you or your loved one start using first?" Okay. And we have some different options.

Cocaine, methamphetamine, crystal meth, prescriptions, other stimulant not mentioned, and I'm not sure. And so we'll just give it a minute for everybody to be able to respond as well as just to kind of think about the experiences that we just heard about from our panelists.

Okay. So we see that we have some responses coming in and it looks like a number of people started using cocaine first, as well as prescription stimulants and methamphetamine. Just give it another moment. Okay, great. And so it looks like a lot of people have started using -- started with using cocaine. And that's really -- that's helpful for us to know. It looks like just a few people started with something -- another stimulant not mentioned.

And so before we move onto the next question, let me just turn to any of our panelists who may have touched a little bit about this in their

talk. But let me see if there's anybody who has anything they'd like to add to this before we move onto kind of current -- talking about what people are currently using.

So to any of our panelists, did you have -- any of our panelists, do you have any questions or anything to add that you wanted to touch on? Okay. So -- and I think -- I mean, I think that makes sense because we've heard from your talks, you kind of shared those experiences.

So let's move onto our next question which is, "If you or your loved ones are currently using stimulants, which stimulants are you or your loved ones currently using?" And again, it looks like we have the same options, but this is really kind of to help us understand what -- kind of the progression of the stimulant use. We'll just give it a few minutes. It's great to see that a lot of people are not currently using stimulants. We'll just give it a few minutes because, like I said, there's a little bit of a lag time between what I see and what you hear.

1 Okay. All right. So it looks like --2 while we saw a number of people start with cocaine, it 3 looks like a lot of people are either no longer using or are using methamphetamine. A few people are using 4 crystal meth and prescription stimulants. And so 5 that's really helpful. 6 7 Lyna or Shannon, let me turn to you and see -- do we have any comments related to this or 8 9 anything that anybody would like to share online yet? 10 MS. MERZOUG: Hi, Robyn. We have gotten some responses online to Jessica 11 12 who is -- this comment's directed to our panelist, Jessica, just basically saying thank you so much for 13 14 sharing. You were spot on on pretty much everything 15 you shared. I really appreciate the fact that you 16 brought some awareness to addicts being discriminated 17 against when it comes to their disease. It is hard 18 for people to understand how and why addiction is a disease and not a choice. Again, like, educating them 19 20 on the effects of -- be part of the solution. 21 MS. BENT: Great. Thanks, Lyna.

1 was a great comment. Do you have others or is that 2 what we've got for now? 3 MS. MERZOUG: It looks like that's what 4 we have for now. Oh, we just got one more. So we 5 have Jennifer who shared a comment just saying, "I appreciate all the comments and commitment to people 6 7 with substance use disorder. Thanking all of our 8 panelists for speaking up and speaking out. And this 9 community's committed to listening and making a 10 difference in order to support these experiences." So thank you, Jennifer, for sharing. 11 12 MS. BENT: Great. Thank you. All So let's -- at this point, let's kind of move 13 14 onto our next question -- our next polling question. 15 "If you or your loved ones are currently using a 16 stimulant, how frequently are you using that 17 stimulant?" And so we have multiple options from

And just as we're waiting for the results to come in, I think that I'm also going to

just a few more seconds.

daily to not currently using to other. We'll give it

18

19

20

21

Page 83

switch up this question just a little bit and maybe turn to our panelists and ask when you were using, like, did the frequency of use kind of change over time? It would be really helpful for us to kind of understand what that looks like. Did your frequency of use change over time? For the people who use more than one stimulant, was the frequency of use different depending on the stimulant that was being used?

And so looking at this, we have -- I mean, we have a small number of responses, but it looks like a majority of people who are currently using are using daily. Some are using more than once a day and we did not do a good job of guessing what their -- what their frequency of use was when we gave these options.

So that's really good information for us to know. And I wonder now if any of our current panelists, would you be willing to talk about kind of the frequency of Use and how that might have changed over time. Do we have anybody who might be willing to talk to us a little bit about that?

Page 84

PAM: Hi, this is Pam. I'm willing to talk a little bit about it. Initially, I used very, very occasionally because, again, I did not live in a part of the country that cocaine was readily available. But as soon as I moved to Ann Arbor and it was more readily available, I used it as frequently as I could afford to. And then I heard somebody else talking about Adderall for school and I really used it for procrastinating. I would wait until about the last month of school and then I would try to stay up for about a month straight on cocaine to do all of the work from the entire semester.

But anyways, long story short, then once I began injecting, it just went straight downhill from there. You know, having ben addicted to both opiates and cocaine. Cocaine, by far, had for me a much stronger component of craving, never enough. It just has a level of viciousness that, I mean -- yes. It was awful to be drug sick from opiates. That's a really awful experience that I've had a lot of times; however, the cocaine cravings were just a different

Page 85

level of -- like I tell my clients, people on cocaine you know what you're about to do is really crummy and you know you're going to hate yourself for I don't know whether it's, you know, hocking your favorite jewelry or whatever it is that you're going to go do to afford the cocaine, you're going to hate yourself for having done it, but you're going to do it anyway. And so there's something really vicious about that whole feeling.

And so then it became just every day, all day, as much as I could possibly get until I was hospitalized with sepsis. And even then, you know, the nurse from our program was saying, "Well, you know, you don't really have to go to the hospital."

Meaning you will die if you don't. But at that point, the septic arthritis had gotten to the point that I really couldn't even continue to inject. So that was really what pushed me to go on into the hospital. But yes, it increased.

And I guess I also wanted to make the point that I now am on a prescription stimulant, but

1	I'm very, very careful with it because I don't ever
2	want to be dependent on something to the point that I
3	can't stop. So even though I didn't have the choice
4	to select a couple times a week, I will sometimes make
5	myself go a day without it because I'm just afraid to
6	not to just be that dependent. And yes, if I go a
7	day without it, I'll feel the tiredness at about, you
8	know, 3:00 in the afternoon, I'll be very, very tired
9	if I haven't had my stimulants. But I just wait it
10	out, I get through it. And so, you know, I just want
11	to know I can do that and so that's why I do it that
12	way sometimes. So just wanted to share that.
13	MS. BENT: Thanks, Pam. I think that
14	that was really helpful and it really gave us a lot of
15	good information.
16	Do I have any other of our current
17	panelists who would be interested in sharing a little
18	bit more information about that?
19	MR. SHELDON: I would be happy to.
20	MS. BENT: Okay, great. Thank you.
21	MR. SHELDON: And this is specifically

1 about the usage, like, the amount of usage.

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

MS. BENT: Yeah. The usage, if it's changed over time. Maybe even kind of what drives that frequency. Is it the cravings? Is it the access? And anything kind of related to that, yeah.

MR. SHELDON: Well, I know for myself, initially, it was very sporadic, you know, and kind of And then, you know, that was -- whether it on a whim. was ecstasy or MDMA and occasional crystal meth use in order to just stay up, you know, like, it wasn't something that I felt like I needed. But it eventually with cocaine, you know, like at the time of the use, I would want whatever I could get, but then, you know, as long as there was like a night of sleep or some time, then it wouldn't necessarily kind of take over my thoughts. But then eventually, over the years, there was less time in-between using to the point of where I was literally only limited by how much money I could access and how much -- you know, how much drugs I could access. So like based on the availability of it and whatever finances I could

1 acquire, which eventually became almost by any means.

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

So there was, you know -- I guess in the growing years of my use, it was for a while recreational and occasional, and then eventually it became obsessive and daily. Almost, you know, like only ever, like -- I guess there was only ever any ceasing to it when I would pass out or be required to do some things in order to get money. You know, like so my -- my time and my energy all became focused on the acquiring of it. In areas where I lived, right between Baltimore and D.C., there's pretty much no clock or limit to the availability of it. There's a lot of open air drug markets, even when I was in Seattle. I moved there for a few years and the crack and heroin problem that are on the streets of Baltimore, it's more like crystal meth and heroin is the problem in Seattle, but it's just available on the streets. You know, like, all you have to do is head for certain areas and you don't have to know anyone. It doesn't matter what time of day. You know, and so that kind of availability and understanding that I

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Page 89

could just go somewhere and make eye contact with somebody and possibly have it offered to me made it so there was really no limit other than what I was willing to do to get the money to get it.

And yeah, so really incarcerations or incapacitation were really my only limits eventually. And, you know, whenever I would get clean usually by force, like by being incarcerated, I would get out and have the intention of not getting back into that cycle and chase. But without getting a full grasp on how to deal with it, seeing others who would recreationally use or others who didn't have the problem that I did would make it easier for me to think maybe -- maybe if I just did it a little bit differently this time, it wouldn't turn out the same. And that wasn't the case. You know, like, I would kind of turn it back on just by exposing myself to it. And even if I did other drugs, stimulants were always my favorite. anything else that I did would simply kind of spark the desire and the craving for the stimulants. you know, there was no kind of picking a different

- path or finding something else. It was always leading back to that somehow. Sometimes right away and sometimes over periods of time, but eventually back to daily use and empty bank accounts and various other problems related to that.
 - MS. BENT: Thanks, Scott. That was really helpful information. Brendan, did you want to say something? I see your video on.
- 9 MR. WELSH: Yeah. I was listening.

6

7

8

13

14

15

16

17

18

19

- MS. BENT: I didn't mean to put you on the spot, I was just interpreting that to mean that you would like to say something.
 - MR. WELSH: Yeah -- the format leads itself perfectly for that. So thank you. Listening to Scott talk about frequency and even some of the other people, I mean, the pattern I keep hearing over and over again is -- specifically with stimulants in my experience was there was never enough. And the frequency was just more.
- 20 And I was thinking back specifically to
 21 my Adderall use when I was -- where I could actually

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Page 91

see my use progressing into misuse and beyond. And I remember getting my 180 Adderall and it was supposed to be three a day. Or I'm sorry, it was 90. day for 30 days. And I would, in the beginning, like, take as much as I could while allowing myself to have one pill for each day to avoid withdrawal. But even then, my addiction would overcome that and I would end up taking the ones that I had laid out to prevent withdrawal and just more, more, more. And it was just interesting to hear that across all the panelists that have spoke. MS. BENT: That's really helpful information. And I think actually that might tie into some of the comments that we're seeing online.

information. And I think actually that might tie into some of the comments that we're seeing online. So thank you for that. And, Lyna, let me turn to you and say -- find out if we're really -- if we're seeing some comments that are similar in nature to that, or really kind of touch on something similar.

MS. MERZOUG: Yes. Thank you, Robyn.

Yeah. I see a comment that came in from Dina [ph].

She's saying, "I go to CNA meetings, the 12-step

meetings, and one of our -- what started out as a 1 2 weekend use gradually became daily use. My experience 3 was I ended up using all day long, every day I could. I've been in recovery 12 years now. I never imagined 4 I would go 12 minutes without crystal meth." We have 5 that one from Dina. 6 7 And then based off of what actually our panelist, Pam, was talking about earlier, we have a 8 9 comment from Liz about stimulant prescription in 10 childhood. I think it would be very important to find out how many people who have stimulant use disorder as 11 12 adults were prescribed stimulants, like Ritalin, as 13 children. And if it may have predisposed their -- of desired stimulants to be able to feel normal. 14 15 So just touching on -- or following up 16 on two of the comments from our panelists. 17 Thanks, Lyna. MS. BENT: Great. 18 so please, everybody who is watching online, please be aware that we are monitoring both the phones and the 19 20 any comments that you submit. And we will be happy to

share them to really kind of include you in the

21

discussion to the extent possible.

2.

2.1

Now I'm going to take a little bit of a turn and I think that I'm going to turn to our FDA panelists, and particularly maybe to Dr. Sokolowska. I think that she might have a question that she would like to follow-up on, ask our panelists, and anybody online to kind of follow-up on something that we heard from Jessica. So, Dr. Sokolowska?

DR. SOKOLOWSKA: Thank you. Jessica, in an earlier comment you mentioned and you spoke quite passionately regarding the impact of stigma on substance use disorder, especially on stimulants use disorder. Could you speak more regarding that and could others maybe provide additional breakdown and framework on how FDA can address the issue of stigma. And to what -- and some of the aspect of stigma that we should be more conscience about.

MS. HULSEY: Absolutely. You know, just from personal experience with my own loved ones and then doing this work at my current position, you know, stigma comes in many forms, right? And I think

when we really dig into sort of empathy and
compassion, you know, willingness to engage with our
patient population, and I don't think we fully
understand the differences between different types of
SUD and different opinions or attitudes that are
attached to them. I feel just as loving people who've
struggled with stimulant use disorder and opiate use
disorder and lots of other things, that we seem to
have more blame that gets focused on us when we have a
stimulant use disorder. I think that opioids, there's
so much narrative around in a way, like, we've
somehow, in some ways, improved stigma by sort of
focusing on prescription opioids and leading to
dependence and sort of getting out of control, but
then all the rest of us that are struggling with non-
prescription of our use patterns, I feel like it
makes stigma worse for us in a way. And I think that
was an unintended consequence of how we've organized
and approached patients that are struggling with
different types of SUD. And that doesn't even really
get into we've found within our patient community

that three out of four are struggling with
polysubstance use. Individuals just don't typically
struggle with one particular drug over the other. It
ends up being a polysubstance use disorder. But I
think we've pit some of these diseases against one
another and I feel like I worry. You asked earlier
about what keeps us up at night or what's on our worry
list. I, in many cases, worry the most about our
patients that are struggling with methamphetamine and
cocaine and crystal meth because there can be more
blame. There can be more misunderstanding of their
symptoms. Some of our symptoms are hard, right? Sort
of psychosis or aggression, mood swings. Some of the
physical differences of being really thin and losing
our appetite and being agitated or dental problems.
So this can physically make us look differently and I
feel like we are treated less than, even within the
patient community, of substance use disorders.
So I think we need to have more
understanding. I firmly believe and we're about to
launch a really big project around how we stop stigma

1	around addiction, but I firmly believe that education
2	is the key to that. Addiction literacy. When you
3	take the time to teach everyone from our family
4	members to healthcare providers to criminal justice
5	professionals, about what addiction is. How it
6	affects the brain. How it changes our priorities and
7	our behaviors. We build empathy and compassion and we
8	help people understand this as a health condition
9	rather than a moral failing. And I think that's
10	incredibly important, particularly in the context of
11	those struggling with stimulants. Because I think
12	that we get treated the worst out of the bunch.
13	MS. BENT: Thanks, Jessica. Again,
14	very insightful and really, really helpful
15	information.
16	Lyna, did we have before we return
17	back to kind of our panelists to see if they have any
18	thoughts on this as well, did we have any comments
19	from people who are participating online, or I mean
20	viewing the meeting online?
21	MS. MERZOUG: Yes, we do. Thanks,

Page 97

Robyn. So we have a comment from Jay [ph] and it's about stigma. So, and he's saying that a major way stigma plays out is in hiring. So many organizations that pledge themselves to do great work stigmatize use by hiring only or majority of those with learned experience over lived experience. And then we have another comment from -- also on stigma. "The scare tactics used as a prevention strategy, especially -- get hard by -- crisis, have really done a lot of damage. Not only by reinforcing stigma, but also by the invisibility of early -- use." So those are the two comments we have right now on stigma.

MS. BENT: Okay. Great. So did we have any of our other panelists who wanted to kind of share their thoughts on stigma? And at this point, I think I'm going to open it up a little bit. And so if you are scheduled to be a panelist in our next treatment session and you have something that you want to share related to stigma, please feel free to turn on your video and share that if you would like. Okay? So I see Brandee and then we see Phil. So I'm going

to start with Brandee because I saw her video first, and then move onto Phil. And then we'll reassess.

2.1

Thank you, guys.

MS. IZQUIERDO: Phil looks like he's in a big city. I love it. Phil and I go back a ways.

No, thank you. I appreciate you opening that up. I think one thing -- one component we miss when we're talking about stimulant use disorder, specifically around stigma, is the stigma internally to the recovering community. So we often talk about external stigma. We talk about internal stigma, but there's also stigma associated with the recovery community that one drug is better than the other, one drug is worse than the other. You can get treatment for one drug, but you can't get treatment for another drug.

We tend to also minimize stimulant use disorder in numerous ways, that it's not that bad.

Sorry. I have puppies in the background. My apologies. But that it's not that bad, that you can get over this hump, that you know, it's not as addictive. So I think there's a lot of myth and

Page 99

misconception in the recovering community, which definitely adds to the stigma associated with stimulant use disorder. And I also think that quite often we pinpoint specific drugs within this disorder framework. And I'm going to leave it at that for right now because I'm the next panelist, so I'll bring a little bit of that up and how that progresses over time, but we have to take a look at how we stigmatize each other or the negative public perception as people in recovery.

MS. BENT: Great. Thanks, Brandee.

And I'm going to turn to Phil. And then after Phil, I
think we've got a comment from somebody online that
Lyna can read for us. So, Phil, please go ahead.

MR. RUTHERFORD: Thanks. And I'm going to do my best not to go into the subject area that I'm going to talk about in the next panel, but I was just thinking about a fun exercise that we could all take and that is if you think about if you think about who's more likely to break your window and steal some stuff out of your house, a crackhead or a person with

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Page 100

a Percocet problem? Which of those two is more likely in your head to break in and steal some stuff? A meth addict or someone with an OxyContin problem? There -we have stigmatized stimulant use disorder specifically to be more violent and more likely to commit crime than opioid use disorder. Now I'm not trying to say which is worse or one gets a better ride than the other, but some of the -- we're here to talk about stimulants. Some of the specific stigma around stimulants is the criminalization of people with stimulant use disorder. And unfortunately, the crime data doesn't bear that out. It doesn't -- it turns out use disorder is an equal opportunity offender in terms of criminal acts.

So when you said stigma, that kind of popped into my head and I've got some other stuff on that this afternoon -- or in the next session.

MS. BENT: Great. Thanks so much. And I'm going to turn to Lyna for comments that we received online, and then I think, Jessica, you had your video back on which I'm taking as an indicator

1 that you'd like to add something else. So maybe once 2 Lyna has the opportunity to speak, we'll go to 3 And then Michael also has his video on, 4 which I am again interpreting to mean comment. So, 5 Lyna, go ahead. 6 MS. MERZOUG: Yeah. Thanks, Robyn. So 7 Lisa's actually responding to what Jessica said so 8 well and it's that even within the addiction culture, 9 she's saying that "I feel terrible biases. 10 current care specialist, I am -- by all the biases I see in the professionals against us. People still 11 12 feel it's a choice. Once using, it is not a -- once using, it is not a choice. We cannot stop, that's why 13 14 we need a substance to get off and back on our feet. 15 We need to learn how to be back on our feet again." 16 So that was -- thank you, Lisa, for your comment. 17 That was really, really important. 18 Thanks, Lyna. And I know MS. BENT: 19 that we're coming kind of up on the end of our time. 20 We have about 10 minutes left and we have a few more

questions that we want to get to, so I'm going to go

21

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Page 102

to Jessica and then kind of back to Michael. And then I'm going to have us move forward with some of our next questions. And if there's other people who want to share their comments online or submit them to the docket, that would be really helpful to us.

So, Jessica, please go ahead.

MS. HULSEY: And thank you, Lisa, for I'll try to make this really quick, but your comment. I just also wanted to share that -- sorry. Dogs and teenagers in the backyard. It's hard to find a quiet space these days with tele-school, etcetera. But even sort of the term stimulant use disorder can be sometimes confusing to our patients, to our individuals in recovery, our families. If we -- we have done a few small research projects with our community and if you ask about stimulant use, most will talk about their caffeine use. So I do think that this is going to be sort of an important organizer for how we describe this disorder. In the community of patients and individuals in recovery and families, we sort of more self-identify as struggling

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Page 103

with cocaine or methamphetamine or crystal meth or prescription stimulants. And sometimes when we say stimulants, we sort of think of that in the prescription category. And so sometimes it might be helpful to explain that and sort of break it down, and also make sure that we are acknowledging the substances that are really tough to struggle with, like methamphetamine and crystal meth and cocaine. And including and using the words, and using language that our folks identify with. So it's sort of a one off, but I was reading some comments just among the panelists that I think sometimes even the term stimulants can make us feel like we're not included. MS. BENT: I think that that's a really good point and I know that one that we kind of talked about internally as we're talking about this meeting and really kind of sharing information about this meeting where we kind of created a meeting where people didn't really know what we were talking about because the clinical term isn't so -- as related to

real life. And I think that's a really good point.

So, thank you. And let me now turn to Michael.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

MR. GALIPEAU: Yeah. Thank you. And I appreciate you guys welcoming our input today. And I just wanted to add a little bit to the conversation, especially around the topic of caffeine and nicotine and other legal, more regulated, more widely accepted stimulants. You know, we don't often put stimulant use disorder or stimulant use in general into like a normative spectrum of use that ranges from infrequent, casual, recreational to daily use, to severe, persistent and chronic use. And we don't include the full scope of stimulant-related activities, like coffee shops and places where people go to smoke cigarettes, which are all stimulants. And you'd probably see a similar pattern of drug-seeking behavior from a large number of people if we were to suddenly ban coffee shops and ban coffees from markets and deny people, you know, basic consumer rights, basic consumer protections. You know, access to a safe and regulated supply. Access to product testing and accountability for manufacturing. And I think

2.

2.1

Page 105

this points back to the impact of stigma, which is really discrimination and how it impacts our social determinants -- I mean, even just looking at the stratification of stimulant users themselves in our criminal justice system, we see a vast difference between the crack cocaine user and how they're treated by the criminal justice system as opposed to somebody who uses powder cocaine, which is, you know, very similar drug with a lot of very similarly presenting qualities in terms of problematic use.

And so it's really unfortunate that, you know, kind of the backseat driver of this experience is this stigma that creates a false dichotomy or a false set of associations that doesn't really look at a full spectrum of human behavior that we have in most other chronic health management disorders.

MS. BENT: I think that is a really good point. And I think we have one more comment from somebody online, and then we're going to move onto our next discussion question. But thank you so much,

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Page 106

Michael, and thank you to all of you who kind of help us really kind of get a better understanding of what's going on with stigma. And I think we probably will touch a little bit on that as so mentioned in our next session as well. So, Lyna? All right. MS. MERZOUG: Thanks, We have a comment from Adam about stigma. Robyn. he's saying that, "I think one thing that needs to be understood about internal stigma is it plays into the denial aspect of the disease. Individuals begin to contemplate their use, but do not speak out due to the stigma attached to stimulant use." So thank you, Adam, for sharing that. Thanks, Lyna. And so MS. BENT: Okay. that was a really great conversation and we're now going to move onto our next question which is really, "If you or your loved ones are currently using a stimulant, are you also using any other illicit drug?" And so we'll get that up on the screen in just a

I gave the producers a little bit of a

curveball with the question about stigma, so we'll

give them a second to kind of catch up and move us onto the next question.

1

2

21

3 Okay. There we go. So -- perfect. We're seeing the -- okay. We see a few people saying 4 5 they're also using other illicit drugs. We don't really have anybody saying that they're using -- oh, 6 7 okay. So now I'm seeing one person who says they're only using stimulants, but it does look like -- and I 8 9 think some of our panelists touched on this a little 10 bit earlier, that there really is -- there is kind of a combination where people are using more than one 11 12 substance. More than just a stimulant, but maybe 13 using something else. And so I would love for 14 somebody to kind of give us a call and help us to 15 really understand why -- what does that look like? 16 Can you tell us a little bit more about why you or 17 your loved ones are using drugs in addition to 18 Maybe share a little bit about that with stimulants? us because it does look like -- now we're looking at -19 20 - I don't want to really do math real time, but we're

looking at maybe about 60 percent of people saying

they're using more than one. And about 40 percent
saying just a stimulant. So maybe if we have -- Lyna,
do we have any comments online about that? I know
we're kind of early, but do you have any thoughts?

And if not, maybe do we have any thoughts from our
panelists on that? Lyna, you're muted.

MS. MERZOUG: Sorry about that. No comments yet from online.

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

MS. BENT: Okay. I am asking for very rapid typing I think. So -- and I think that maybe one thing that we can do is just kind of -- again, kind of adjust on the fly and if you do -- if you guys do have comments, because there is that lag time that we don't really see in the face to face meetings that we're seeing kind of in this virtual setting, I think maybe what we can do is kind of -- or I think when we start session two, we can kind of go back and recap any comments that we received related to some of the topics that we've asked about in this session. Just to give people the time and opportunity to kind of get to the typing and share that.

1 So let me see. So actually, because we 2 don't really have anybody online to kind of answer 3 this question, Lyna, did you have some kind of -comments about stigma that you wanted to share with 4 5 us? 6 MS. MERZOUG: I'm happy to jump back on 7 with another comment about stigma. We have a comment from Jamie basically saying that she'd like to 8 9 underline what Jessica said, exactly true. So there's 10 another one for Jessica. And education as well, even healthcare work is extremely important. The nation 11 12 did with depression, so surely there are ways that people can get the information out in a similar way. 13 14 Additionally, impacting substance use 15 disorders, adding to the stigma is incarceration and criminalization around it. Once those were battling 16 17 through -- disorder and other substance use disorders 18 -- the criminal justice system, they're now not only labeled as addicts, but criminals. So thank you, 19 20 Jamie, for sharing that. 2.1 MS. BENT: Great, great. Thanks, Lyna.

2.

Page 110

I think in the interest of time, because we are about at our break, I just -- I wanted to kind of -- we are right at the break, right? Sorry. My ability to memorize our schedule is a little -- is a little impaired. So yes, 2:35 is our break and I know that we didn't get to kind of all of the questions that we had hoped to get through in this session, but I think that we heard a lot from our panelists, and we learned a lot. And so I think maybe this was a heavy session and I think that we are going to go to break now.

We'll kind of keep an eye on incoming comments. And depending on how our treatment talk goes, we might come back to some of our questions.

So with that being said, it is now 2:35 eastern time. We'll go to break until 2:50 I believe, at which point we will reconvene for session number two. So let me just, once again, give a huge thank you to all of our first session panelists, and to our second session panelists who jumped in early and kind of shared their experiences and thoughts on stigma with us. And we'll see you guys back here in about 15

1 minutes. Thanks so much, guys.

5

6

7

8

9

10

11

12

13

14

15

16

17

18

20

2 (End Media 2.)

3 (Begin Media 3.)

4 MS. BENT: Hello. Welcome back,

everyone. Thanks so much for returning. I hope that you were able to make good use of the break and maybe grab a snack or something. I just -- I wanted to take this opportunity as we were returning to really kind of touch on something that I think we mentioned, but I didn't really properly emphasize. And that's really -- all of the comments that we hear today, all of the comments from our panelists, all of the comments that have been submitted electronically. If anybody wants to call in, any comments that we hear from online -- from people who called in, as well as any comments that are submitted to the federal docket will be

meeting summary that can be used by people as they're

summarized and included in our report, which we call

the voice of the patient report, that will really be a

working -- as they're looking at drug development

21 efforts or even -- or for our FDA reviewers to review.

2.

2.1

Page 112

So please, even if you don't feel like you want to call in today or even if you don't feel like you want to submit a comment today, please remember to take this opportunity and to really kind of share your thoughts and share your experiences with us. Because all of that is really helpful to us and will be captured as part of this report that will live -- I don't want to say forever, but will live for a really long time and be used by a large number of people as they move, you know, treatments and policies and things forward. So, please do take the opportunity to share your thoughts.

And again, the docket is open through

December 7th, so there's no rush. And, you know, just

-- and we would just very much appreciate it.

So having said that, we're still kind of reviewing some of the comments that we received online. And so before we talk a little bit about that, we're going to move onto topic two, which is really meant to focus on the current approaches to treatment for stimulant disorder. Your experiences

and your perspectives on that. What you'd like to see 1 2. in an ideal treatment, if future treatments could be 3 How could they be? And we have six panelists who will start us off -- start off our discussion by 4 5 sharing their experiences. And before we launch into our 6 7 panelists' experiences, I want to let you know that our first question for the open discussion session is 8 9 going to be, "What prompted your journey to recovery?" 10 So we're about 30 minutes away from people kind of sharing their answers to that, but if 11 12 you're interested in responding to that question, please consider sharing it through the comments or by 13 calling the 1-800-527-1401. But with that being said, 14 15 we're now going to launch into panel two and I'm going 16 to invite Phil to share his experiences. 17 MR. RUTHERFORD: Okay. Volume good? 18 MS. BENT: Perfect. 19 MR. RUTHERFORD: Okay. So I want to 20 thank you guys for having me on the call. Ι 21 appreciate the opportunity. Away we go.

2.

Page 114

My name is Philip Rutherford. I'm a black man living in long-term recovery. What that means to me is today I'm living my best life. Every facet of my life has been enhanced by recovery. I have three beautiful daughters and recovery has enabled me to be a part of the entire spectrum of their lives. Now my wife will tell you that recovery is the key to a happy marriage. My parents will tell you that recovery is the key to a good relationship. Employers, community members, probably even law enforcement -- well, you get the idea. They'll all tell you recovery's good for me.

You probably also noticed that I introduced myself as a black man in long-term recovery and since this is a video meeting, if you're looking at your screen, you probably figured that out all by yourself. I introduced myself that way for a very important reason. Today, we're here talking about stimulant use disorder and seeking treatment methodologies that will be successful. Not too long ago, almost an entire generation of people who look

2.

Page 115

like me were vilified, demonized and locked away under the guise of public good. Many of these people simply suffered from untreated stimulant use disorder. A condition that I am living proof of the fact that treatment is effective, and more importantly, that long-term recovery is possible.

Recovery has also enabled me to lift my voice and advocate for social justice of which recovery justice is a part. As a matter of fact, for me, there's no separation of the two. Recovery doesn't occur in a vacuum. I recovered in a world that bored stigma to my disorder and bias to the color of my skin.

Now, like many people, I sought treatment for my illness as a last resort. And I say that because rarely, at least in my case, seeking treatment was not a starting point. It was clear pretty quick that my reaction to the substance was abnormal, but a lot of people around me had similar responses. And I think there's a leveling thing that happens where you attempt to justify your use by

saying things like, "Well, I'm not as bad as that guy."

Sometimes you'll hear people say that treatment wasn't successful. I couldn't disagree more. I went to seven treatments. Every single one of them was wildly successful in that I survived. And I picked up enough information and fortitude to make it through to the next one.

I'd also like to dispel the myth that a return to use is a failure. My returns to use taught me a lot about my ability to manage the use of the substance. Now, I believe that there are people out there perfectly capable of recreational stimulant use. I have no opinion on that, but my personal returns to use made it clear to me that I wasn't.

I also said that my treatments were successful. I did not say they were effective. Many of them lacked cultural responsiveness and an understanding of an intersectionality of recovery.

What I mean by that is what I said earlier that recovery pathways don't always look the same for

different groups. In my case, I -- there were some differences that probably needed some attention. And that was a while ago, but these days we're at least moving along that path.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

I was able eventually to navigate a pathway that included mutual aid groups, those are 12step, smart recovery, that kind of stuff. And I practiced that pathway in addition to a number of other wellness practices. These approaches worked particularly well once I found a place to fit in. fitting in is a really important point as all of the use disorders thrive on isolation. It's really important to find a place to fit in. And it's appropriate for me to talk about recovery capital here which is a set of tools that I had available to achieve treatment, remission and recovery. Because whatever we talk about, it happens within the frame of recovery capital. For example, I had stable housing, I had some financial resources, I had a supportive environment, I had reliable healthcare. And by the way, that includes psychiatric care. And I found a

number of previous attempts, I had some of these things, but not always all of them. And I think the sum of all of these components is greater than the individual parts. You know, obviously not everyone has all of these resources, but until we begin including this sort of -- this perspective in treatment and recovery planning, I think we're not operating at full capacity. So I think that's a key component to looking at treatment and obviously, if we're talking about medication, that fits into that frame.

2.

2.1

In general, I believe as a country, we could benefit from the overhaul of the acute care approach to treatment which is sort of the 14 to 28 day stay with some after care follow-up to a more holistic chronic care model that engages acute treatment when necessary, but provides longitudinal or sort of treatment along the path of recovery. That's all I've got.

MS. BENT: Great. Thanks so much,

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

Page 119

And I know that -- I think that our FDA Phil. panelists are going to have some follow-up thoughts or questions to kind of dive deeper as we move forward. But for now, we're going to move onto Brandee who is going to share her experience. So, Brandee? Thank you very much, MS. IZQUIERDO: And Phil, great job as usual. I wouldn't Robyn. expect anything less and I appreciate that. I just want to take you along the small path of my journey into treatment and recovery, and I am a person in long-term recovery. For me, as I prefaced -- or as I talked about earlier about stigma, you know, my specific stimulant use disorder started with a prescription drug, and it wasn't any of your typical or normal -- into these conversations. It was actually phentermine. And it was a weight loss drug. And one of the issues with the weight loss drug is that, you know, I would do everything that I possibly

21 experience was in contract negotiations and all of

could. It was the doctor hustle or the doctor

shopping hustle. And not, you know -- for me, my past

that, so I knew how to negotiate with doctors where they would actually prescribe me in bulk. So those particular prescription pills that I was taking, I was only supposed to take three of them a day, but I was up to at least 10 a day. And coupling that with NoDoz.

2.

What really brought me to my knees and my addiction was not the stimulant disorder, it was the criminal justice system as Phil had mentioned. I had no idea that I had a problem. I didn't think I had a problem. But really, you know, from the phentermine and moving into the cocaine use and the partying and the ecstasy, to come down from that, I had to use alcohol.

So when I entered into the jail system, it was my gateway into treatment and it wasn't a pleasant gateway. Because again, I still didn't recognize that I had a problem. I just thought that I was getting in trouble for -- and realize now that it was an indirect result of my using. In the jail system, the first thing that they treated me for was

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Page 121

the alcohol. Obviously, you know, with detox and the possibility of death with alcohol, that was what they treated me for. And when I was shipped over from -and I say shipped because that is literally what it I was shipped in a van over from the jail -- the prison in Pennsylvania over to a Maryland-based treatment center, I learned about the disease of addiction. But I, again, still thought I only had an alcohol problem. So it wasn't until I got to a point where I said, "Okay. I can no longer use alcohol, but I can surely still use cocaine because cocaine's not the problem. It was the alcohol." And that's where my thoughts began. And I never really got treated properly for the cocaine or the thoughts on the cocaine. It was more the cravings and really figuring I knew that, for example, cocaine out the system. would stay in my system for about three days, so that if I could manipulate the system and move around probation and drug testing and all of that, I could still continue my cocaine use.

And, you know, what I've found through

2.

Page 122

these systems specifically is stimulant use disorder is not a crisis. So if it's not a crisis, I'm not going to get the proper treatment that I need for that particular substance use disorder. And quite often, especially right now, we're having more of an issue with the opioid use disorders. So there's quicker access into treatment if you either have an opioid use disorder, an alcohol disorder. And the only reason for the alcohol disorder is because there's liability attached to that should you die from the detox.

So I never truly got to the bottom or the root cause of -- or the root part of my stimulant use disorder. And I say that because I am a person in long-term recovery and I'm coming up on 10 years. And one of the -- there were a couple of reasons I used stimulants to begin with, and one was not feeling good about myself. So I'm not a thin woman. I prefer to call myself juicy. Little big boned. And there's always been issue or a complex for me that I needed to stay thin, so that was one of the reasons that I initially started using the phentermine. So that

coupled with the fact that I have four children, which 1 2 I did lose during my active addiction to Child 3 Protective Services and then eventually their father, you know, I was -- I needed to run circles around 4 people. I felt like I needed to run circles and stay 5 as busy as possible. So I don't even use typically 6 7 the word stimulant use. It's more of the uppers. I'm not a downer as much as I am an upper. Not realizing 8 9 that I'm actually countering the upper with alcohol. 10 So it's a complex disease. And there was never a talk 11 about that. 12 So I can tell you right now, I'm going to be honest and open about this. Caffeine is a huge 13 14 part of my life at this point and I am a smoker. So I 15 didn't start smoking till I was 30 and in my active 16 addiction. So it's not like it's gone and it's not 17 like I haven't tried to use or utilize resources to 18 stop or curb my cravings, but they still manifest. My addiction still manifests in different ways. 19 20 So just trying to find the treatment. 2.1 I mean, I know there are specific prescriptions out

there for smoking. I haven't used them because I know the side effects can cause anxiety and depression which is something else I deal with on a daily basis.

2.

2.1

So I have to remain vigilant at all times in my recovery. And even working with individuals in a direct service capacity, it's extremely difficult because we're seeing a shift to the stimulants. Methamphetamine, cocaine, crack. And it's the barriers associated with accessing treatment are exponential. I mean, you just -- you can't seem to get people in unless they're dealing with an opioid crisis. So it's an extremely frustrating piece.

And like I said, you know, with the treatment component, it's not just about treating one specific substance, but we have to really take a look at all substances because just -- I may be able to arrest my cravings for one specific substance, but then again, you know, it moves onto something else and can manifest. So I'm hoping that we can do better. So, thank you.

MS. BENT: Thank you so much, Brandee.

Again, I think we're going to come back to you and 1 2. kind of maybe ask you a few more questions maybe a little bit later, but for now, we're going to move onto Kevin who is going to share his experiences. 4 Kevin, go ahead. Thanks so much.

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

KEVIN: Good afternoon and thanks, Robyn, for asking me to participate. My name is Kevin and I'm a recovering crystal meth addict. I last used crystal meth in May of 2018.

As a little bit of background, I first started using crystal meth in my late 20s. For the first 10 years, I mostly used on weekends. At most, maybe once or twice a month. However, by 2014, my use had intensified and the consequences had started to build, as we've heard from many other people, too.

My then partner found out that I was using and reasonably demanded that I stop. I sought an evaluation and was referred to an IOP program based on the progression of my disease. I was unwilling to admit the problem -- that my problem was this bad and I declined that offer. Instead, I started working

Page 126

with a counselor and I attended weekly recovery support group meetings. I kept this up for about six months, but I could not stop using. And so instead, I ended that relationship. I moved to a new city with the hopes of leaving meth behind that way. It's commonly called a geographic.

From 2015 to 2018, my meth use increased to nearly daily use. My addiction impacted my job performance and spawned a vicious cycle of using. During my last eight months, I went from leading a team of 40 to injecting meth daily. I lost my job and my health, I started dealing drugs and I became completely isolated from my family and friends.

In May of 2018, I was arrested on drug distribution charges. This turned out to be a good thing for me because it made me get serious about quitting. And I was ready to quit, but I had no idea how to do it. I'd been too embarrassed to ask for help. My legal situation meant that I could no longer hide my problem though, and that I had to stop or I would face additional serious consequences.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

in with him regularly.

Page 127

During these early days of recovery, I really struggled to figure out what to do. My habit use limited my ability to think clearly. I still carried a lot of shame that prevented me from picking up the phone and getting into an inpatient treatment I was extremely isolated. All of my program. friends, and I use that in quotation marks, at the time were using friends. My primary care physician couldn't offer much help. There weren't any prescriptions he could write and he struggled to recommend good treatment programs. Once I was honest about my situation though, I had a group of non-using friends who were willing to step forward and help. I still had access to health insurance, some savings and a stable place to live. One of my friends was a drug counselor and he helped me find a therapist with experience treating gay men with crystal meth addiction. I started meeting with that therapist weekly and I still check

My former partner also introduced me to

Page 128

a sober coworker of his, and this friend introduced me
to Crystal Meth Anonymous, a 12-step program focused
on meth recovery. He took me to my first meeting the
day after we met. And in that meeting for the first
time, I encountered a group of people who had actually
achieved long-term sobriety from this drug. In pretty
short order, I threw myself into a robust program of
recovery centered on the steps. I did this because,
really, nothing else I had tried had worked and I was
desperate enough by this point in time to try
anything. I attended meetings daily. I made new
sober friends which ended the isolation I felt as a
gay man that had helped fuel my addiction. I found a
sponsor and started to work the steps. This helped me
deal with the spiritual nature of my disease. I found
two different part-time jobs which allowed me to focus
on recovery and put some money in my pocket, gave me a
sense of purpose again, and most importantly, kept me
busy. Pretty quickly I became involved in service
work. I started sponsoring other men in the program.
I started volunteering. It was a lot of work, but

1 it's what I needed to do to keep me sober.

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

In hindsight, I would probably do a lot of things differently with regards to treatment if I knew then what I know now.

I would have asked for help a lot sooner and treated this disease as the serious matter it is. I would have enrolled in an IOP program that was first suggested to me. And when my therapist suggested maybe trying out a CMA meeting as part of my treatment, I maybe would have been brave enough to go into that first meeting instead of standing outside and being afraid to do that because everyone inside was laughing and having a good time.

But with addiction, I found that my denial, lack of readiness to change, shame and stigma of this disease are huge barriers to overcome to start the road to recovery. But with the help of many others, I found a path to long-term abstinence from a drug that I had given up any hope of quitting.

I still don't completely understand why it worked this time, but it has worked and I'm

- grateful that it has and continues to work. Thanks.
- 2 | That's all I have.
- MS. BENT: Thank you so much, Kevin.
- 4 We're now going to hear from Charles.
- 5 MR. SMITH: Hello. My names Charles.
- 6 I'm 43 years old in long-term recovery. I've
- 7 struggled with stimulant use disorder and alcohol use
- 8 disorder since before I was 18 years old. That's over
- 9 25 years for those who don't want to do the math.
- Today, I've been free from drugs and
- 11 | alcohol for 20 months. I first sought treatment at
- 12 | the age of 22 at a charity residential treatment
- center as my personal life was spiraling out of
- 14 | control. I was facing a divorce and custody battle, I
- was kicked out of the home I was living in and I had
- 16 mounting legal troubles. Since then, I've been in and
- 17 out of a dozen treatment centers with programs ranging
- 18 from 30 days to one year. Some programs I completed,
- 19 others I did not.
- I've been arrested many times. I've
- 21 also had several inpatient psychiatric interventions.

I participated in intensive outpatient programs, group therapy sessions, and 12-step programs.

2.

2.1

I've used therapists covered by my insurance provider and paid out of pocket for therapists. I tried neurofeedback therapy and medication-assisted treatment. I will not say that these approaches did not work for me, more likely I needed a well-rounded education in treatment. I will not -- to get to where I am today.

Today, I use smart recovery and naltrexone for my alcohol use to manage my cravings. I've been practicing smart recovery for six years now and it has done wonders in reducing, even stopping my drug and alcohol use. I also maintain a daily meditation practice.

The difference I see in the smart recovery program as opposed to all the other methods I've tried is the fact that it empowers me to make my own decisions regarding my drug usage. It uses a science-based approach to teach me to retrain my thinking to processes more useful to me rather than

trying to teach me what to think.

2.

2.1

Methods that empower me to make my own decisions and offer concrete techniques work best for me. In other words, I'm looking for help and setting and maintaining my own goals.

Also useful to me has been the refuge recovery program which utilizes Buddhist principles as a recovery approach. I do not consider myself a Buddhist nor do I recommend a strictly spiritual approach to recovery, but the meditations and teachings have been helpful to me.

What has not been helpful to me has been the one size fits all treatment approach consisting of substance abuse education and mandatory 12-step meetings. Too many times I've walked into a treatment facility and have been offered the same treatment program. Long lectures on how drugs affect my dopamine levels, the dangers of being hungry, angry, lonely or tired, and the importance of building a support network. Then I'm handed a list of meetings and told how many I need to attend per week and off I

1 qo.

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Sometimes I'm assigned a case worker, a counselor, who makes vague references to a treatment team that I never meet that makes decisions concerning my program based on economic factors.

This is expected and almost forgivable in low or no-cost charity providers, but for large healthcare providers, I expect better. My recovery should not depend on how many people you can fit into a room to lecture.

Another obstacle to my recovery has been access to quality programs based on my insurance At times when I'm in most need of intervention and treatment, I have the least insurance During these times, my only available coverage. options are charity spiritual-based programs which have proven to be the least effective for me. Science-based programs seem to be in short supply. Since the beginning of the COVID-19 pandemic, access to my recovery programs -- choice has

gotten easier. Smart recovery has expanded their

- online services and moved in-person meetings to Zoom.
- 2 | I have greater access to more meetings than ever
- 3 before. Because of this change, I have taken online
- 4 training to become a meeting facilitator and I now run
- 5 an online meeting.
- 6 There's a bright side to a global
- 7 pandemic. It has increased access to resources. Zoom
- 8 | meetings may not be enough for everyone, but at this
- 9 stage in my recovery, it's just what I need. Thank
- 10 you.
- 11 MS. BENT: Thanks so much, Charles.
- 12 And we may kind of come back to you and ask you a
- 13 | little bit more during the COVID panel, if you're --
- 14 or the COVID section if you're up for that, because I
- 15 think we want to kind of do a -- learn a little bit
- 16 more about the impacts of COVID. And so hopefully we
- 17 | will see you soon.
- 18 | So now we're going to move onto Amy.
- 19 Okay.
- MS. GRIESEL: All right. Hi. My name
- 21 | is Amy Grisel. I'm honored to share with you my story

in hope that it'll better help other people that are suffering.

So I am grateful and fortunate to be alive today. With my addiction, with the stimulants, it really started when I was in my 30s, but I believe that if I would have gotten help with my opiate use disorder, that the stimulants never would have came.

So in my 20s, I had gained a -- gained, whatever you want to call it, an addiction to opiates by getting a prescription. And throughout that 10 years, it just got worse and worse, and to the point where I was shooting up heroin.

I overdosed and at that point, I knew I had to stop. And when I quit shooting up heroin, I had a horrible mental break. I didn't realize I was suffering from mental illness that was untreated. So I turned to stimulants. And these, at first for me, actually made me better. It took away all the paranoia, the things that I was seeing and hearing, and then all the sudden it got much worse to the point where my kids were taken away from me. And at that

moment, I knew I needed to seek treatment.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

I am in a city, but it seems like a small town because the way it's set up. And my location, I'm kind of away from everybody. So I wasn't able to really connect with the treatment centers that were in town.

My family did help me find one treatment center, unbeknownst to me that it was not a cooccurring. So I spent about a week in that facility, and within that week, they realized that they didn't want me because I was a cooccurring person and they kicked me out on the street. And that night, it happened to be Christmas Eve, and I came home and I decided I was done with the world. I decided that I was not worth anything and I didn't deserve to live, so I attempted suicide by fire. And at that point, I was put in jail and charged with arson. And once they put me through their system, they let me out and put me into a mental health facility. At that point, that's where I was able to be diagnosed with my mental health diagnoses and start to get treatment.

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Page 137

And another thing that was beneficial about that court encounter was I had the opportunity to participate in the felony therapeutic mental health court and kind of just really get rehabilitated. that's where I think treatment is so important. able to get wraparound care. I was able to get a therapist. I was able to get connected to different group settings, cognitive behavioral therapy, DVT and wellness recovery action plan. I also got inpatient treatment and then -- for my substance use, and outpatient treatment. They also connected me with different support groups throughout the community. And just like a previous panelist said, the one that he really enjoyed was refuge recovery. That is what connected to me also just because of all my anxiety. That meditation was able to make it so that I was able to participate in the support groups because it slowed my mind and calmed me down. Throughout that process, I really realized that creating a foundation for someone that has stimulant use disorder is important. I now have

2.

Page 138

my children back. I have a great relationship with my now husband and I'm thriving in my recovery. I work as a peer support specialist. I went back to the same court system that I did a two-year program with and became a peer counselor through them in order to show the participants that what worked for me and connecting them to their foundations that work best for them.

Some of the things that I noticed that were barriers throughout that process, for one, that first facility that kicked me out on the street just because I didn't fit for them. I didn't think that was right. Other places that I had been through with inpatient and outpatient treatment, including hospitals, the way they also have that stigma. You know, where they're judging me because of my meth use. And it made me feel uncomfortable. That's another reason why now I work in the hospital as a peer in order to normalize and have that non-judgmental approach. I really feel that trauma-informed care is important -- really important. Being able to connect

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Page 139

with individuals and let them know that you're there. With stimulant use also being able to have that time away from the drug, I think that's one big reason inpatient is important, and those skills. I remember a point where I was curled up on my couch crying, calling my prescriber telling them I need something, I need something. I'm either going to die -- kill myself -- or go to the hospital. There's only two options because of the anxiety that I had. receive disability for a couple years while I was able to just really focus on my mental health and getting better. So I thought that was a really good benefit But I just really -- I'm really hoping that for me. these type of things are going to help other people connect to the same type of services that I was able to connect to. And same with the last participant, COVID really sucks, but these support groups and how people are so openminded and able to create new systems and create new things, I also facilitate a

very low barrier support group over the phone.

1 not over a Zoom so that anybody with a phone can just 2 call in. And the people that do have that anxiety 3 disorder and they need to stay home, they can now participate even if their screens are off. So knowing 4 that there are some things that have came out of it 5 that is good, but that's all I have. So thank you. 6 7 MS. BENT: Thanks so much, Amy. That was a really -- thank you for sharing your really, 8 9 really powerful experience. And now we're going to 10 turn to Michael who is going to share his experience. 11 Michael? 12 MR. GALIPEAU: Yes. Good afternoon and thank you everybody for being here, and thank you to 13 the FDA for, you know, hosting this wonderful feedback 14 15 call. 16 So my experience with stimulant use 17 really started nearly as early as I can remember. 18 Very early on in life, I was put onto prescription 19 drugs for a number of cooccurring mental health and 20 physical health disorders that I was dealing with 21 simultaneously. Among those was a diagnosis which

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Page 141

was, you know, later on overturned for bipolar disorder, ADHD, Tourette's Syndrome. Later on I was finally diagnosed with ankylosing spondylitis, which is a rare kind of genetic condition that affects inflammation and just kind of causes, like, general discomfort throughout the body. It can make sleep very difficult. And then in addition to that, more recently I've finally been diagnosed with sleep apnea. So all of these conditions fed in a variety of ways to the role that stimulants have played in my life. depending on the stimulant, I would say that the role of stimulants in my life have not been one dimensional. I would say certainly my relationship with crack cocaine much farther down the line when my social determinants of health were at probably an alltime low, I was much different than the recreational use of methamphetamines or MDMA or other stimulants in my life more recently that is much less problematic in nature.

And so I do identify as a person in long-term recovery. I also identify as a person who

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

Page 142

uses drugs. And the pathway that I practice is moderation management in combination with a whole variety of whole held strategies that includes yoga, it includes -- it includes some history doing 12-step When I first got involved in my 12-step experience, I recognized that this was going to look very different for me because at the time, I had been a very long participating patient in the state's medical cannabis programs. And part of the reason that I still identify as a person who uses drugs centers around the human rights and continuity of care conversation that still needs to be had about treatment with medical cannabis. Going back to my journey, so very early in life, you know, I was, you know, committed to one of the group home institutions as, you know, what I call myself a drug war orphan because of cannabis use that was supplementing the -- just the lack of adequate care that I was receiving from traditional

21 institutionalized, I spent about four and a half years

pharmacotherapies. And so when I was

of my life, from the age of 12 until the age of 17, being heavily medicated in an environment that was completely full of traumatic experiences.

2.

And so I was being forced to take, you know, as much as 13 pills a day. Staff would pin you to the ground and force you to take medications that were ordered by a doctor. And if your behavior was non-compliant, they would simply up your dose. And so this is what really planted the seed for what I felt was a fertile ground for problematic use later in life because what I had learned was that if there was some way in which I could not be compliant or manage my behavior, that there was a drug that could sufficiently do that for me. And so all I needed to do was to find the right drug.

And so this kind of pattern of drug seeking really began early on. And when combined with traumatic experience, I had been involved in an environment where young men were routinely sexually assaulted, where people who, like myself, were violently assaulted. Often times the only physical

2.

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

shaped and formed.

Page 144

contact we ever had with any human being was with a staff member being restrained physically for violence. And there was no contact with the outside world. There was no contact with people of the opposite gender, of our age group. It was a really bizarre and insulated bubble in which my life experience was

And so by the time I had reached the armed forces, I was definitely shaped in a way that had changed my life and shifted the trajectory that I would take for a number of years. And so as I was discharged, you know, fully, honorably from the armed forces for those disclosures -- the treatment records that were found from my DCYF time, as I had, you know, entered the service from a homeless shelter at the age of 17, then turning 18 throughout the process. know, I found myself discharging into the streets. I was literally homeless again. The armed forces had lost my records, and so kind of my first introduction to street stimulants occurred during that period of homelessness right after I found out that my unit had

2.1

Page 145

been ambushed in Iraq just after I had gotten
literally pushed out the doors, they were being
deployed just a few months earlier. And I found
myself with nowhere to stay. No way to prove that I
could be employed. No access to benefits. No access
to any kind of a meaningful opportunity. Because the
assumption is that if you don't have a DD 214 or
documentation that you've been discharged or a way to
obtain that, then you're presumed to be AWOL and
you're not actually legally allowed to do most things
that a human being would need to do for survival.

And so the role of stimulants was always twofold at this point in my life because it was both a financial support and survival mechanism. In addition to a way of coping with the distress of my environment and being able to stay awake for long hours on the streets when I felt like it was unsafe to relax.

And so this led to kind of a cementing of problematic use patterns that persisted for pretty much the entire duration of my chronic homelessness,

which is a little bit over four years.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

It wasn't until my family had held an intervention and had sent me to California where I encountered the state's first medical cannabis program in 2006 that I found another way forward. Because of the lack of federal oversight, I was able to get gainful employment through the medical dispensary. Ι started working again. I got housing. I became stabilized. I became a patient in the state's cannabis program. And that was a big turning point for me. And it was something that I had learned, you know, through self-medicating when I was using stimulants that as I was withdrawing, I could use cannabis to help manage the cravings and the withdrawals and some of the discomfort. And so I realized that I could use that as a strategy even without using stimulants intermittently, right? So that was one way of effectively addressing the cravings.

Now, much later on into, you know, my journey towards wellness, I realized that there aren't

2.

2.1

Page 147

a lot of, you know, licit alternatives that were mild in their effect that I could use to address the functional conditions that I was trying to treat with stimulants. I use coffee. You can see the last of my cup here, you know? And that was something that I started doing while I was incarcerated. And a lot of folks that were incarcerated who struggled with stimulant use had substitute black coffee similarly. So this is widely accepted.

So, you know, being a person who's a Native American, I have a big belief in plant medicine. And so cannabis fits really well into my beliefs around treatment. And I feel that, you know, there are other alternatives that are available. You know, we have teas and coffees, and then whole plant cocoa which really has largely been unexplored. We've really only looked at the cocaine salts, but the role of coca in indigenous societies as a medicine and as a social agent and a talking aid has not produced the kind of addictive patterns of seeking behavior that cocaine salts have. And with a very good reason. We

Page 148

have what is called the entourage effect in whole plant medicine which is very well researched at this point in the realm of cannabis, but remains largely unexplored in terms of whole plant coca. And so having these times of licit, like, low threshold, low risk alternatives that are widely available in the community, even in non-medical settings, circumvents a lot of the barriers to treatment that I encountered when I was chronically homeless and was not legally entitled to access any benefits. So thank you guys for inviting me here today.

MS. BENT: Thanks so much, Michael.

That was really -- that was really a lot to kind of take in and I'm so sorry that you had a lot of these experiences that you shared with us. But I thank you for sharing them.

And at this point, I'd like to kind of turn to our FDA panelists and just see if you have any questions that have come up -- any clarifying questions or anything that you'd like to dig a little deeper into for any of our panelists, and that may

1	possibl	y be	for		opening	it	up	to	our	panelists	from	
2	the pre	71011	7 70	aaid	n ag wa	1 7						

So, yeah. I see that Dr. Winchell, I see that your camera has come on, and so I'm interpreting that to mean yes, you have some questions. So please, go ahead. You are muted again. Yes. Hey, guys. Can we unmute Dr. Winchell? There is the little phone in the corner, hopefully you can see it. Okay. All right. So it looks like -- I guess it looks like the phone call dropped and she's going to call back in. So let me take this opportunity to ask maybe one of my other FDA colleagues if they have any questions that they would like to ask. Please go ahead. Great. Go ahead. You are unmuted.

DR. MCANINCH: Hi. This is Jana

17 McAninch. Can you hear me okay?

3

4

5

6

7

8

9

10

11

12

13

14

15

18

MS. BENT: Yes.

DR. MCANINCH: Okay. Thanks. First, I
just want to thank all the panelists for sharing your
stories. This is so helpful for us. I wanted to

follow-up on a comment that Kevin made. I think that 1 2. you said, "I wish I would have asked for help sooner." 3 And this sort of -- I guess it's a question about early intervention. A lot of you described your lives 4 5 really spiraling out of control and having some really awful, painful experiences. And I'm wondering if you 6 7 have thoughts about if there was some point earlier on in your course where someone may have recognized a 8 9 problem and helped you to seek treatment, and engage 10 in treatment and enter into recovery sooner and avoid some of those consequences. And what that might have 11 12 looked like for you at that early stage versus later 13 in the course of your illness. 14 And so Kevin, or really any of the 15 panelists, I would love to hear your thoughts on that. 16 Thank you. 17 KEVIN: Sure. 18 So let's start with Kevin MS. BENT: 19 and then I see Michael has a comment. And so we'll 20 start with Michael -- or Kevin, and then go to 2.1 Michael. Thanks. Go ahead, Kevin.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Page 151

Thanks. Sure. That's a great KEVIN: question, you know? And it's actually something that I've thought about a lot. You know, I think one of the challenges for me with my addiction was, one, not wanting to admit that I had a problem. And that it really had progressed into something. You know, I think as a gay kid who grew up in Southern Indiana, a town of 500, you know, I learned from a very young age how to take care of myself and figure things out on my And for a long time, you know, that was a skill that, like, really helped me. But, you know, then as I moved along into my addiction, you know, sometimes things that are assets that kind of like help you get through life actually become real liabilities.

And so for me, that asking for help or even just admitting that I had a problem was like a really long struggle. And I don't know. I don't know what it would have taken to have gotten me to stop earlier. I'd like to think that if someone had really said something or sat down, but you know, it -- I'm not sure, you know? I think sometimes you just have

to get to a certain point with it, you know, where 1 2. you've suffered enough and you are tired of suffering. 3 But it's a -- it's a really good question that I don't have an answer to, but I think there are a lot of 4 things there that, like, work against asking for early 5 help. Definitely a lot of it the stigma of, you know, 6 7 admitting that you have a problem played a huge role for me and wanting to hide it for a long time. 8 9 hid it very well. 10 You know, I think a gay man, I had a lot of experience with compartmentalizing things and, 11 12 like, keeping things very hidden from other people. 13 So, thanks. 14 MS. BENT: Great. Great. Thank you. 15 So it looks like Brandee has also turned on her 16 So we're going to start with Michael for a 17 minute or two and then move onto Brandee. 18 I would say for MR. GALIPEAU: Yeah. 19 me, that journey was nonlinear. Like, there was 20 certainly periods of chaotic and problematic use that 21 certainly qualifies the most severe disorder into the

spectrum, but I would say all along that journey, there were different varieties of help that were available.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

I mean, I think back to my first -- I had two overdose experiences related to stimulant use. One of them is due to fentanyl contamination, the other one was just using way too much crack cocaine. And it was other drug users who were in the room with me in the motel who, like, convinced me, even though I couldn't remember what happened, that I was having seizures and, like, it would be really unsafe for me to continue to use. Like, I probably would not survive that. And so there was help along the way, but I feel like the engagement with formal systems and the linkages to some of the social determinants of health, which really were a defining characteristic in my recovery trajectory. Those linkages were not low threshold enough to really meet me where I was at when I was in patterns of use. And the history of recurrence in my experience of us has also largely been tied to traumatic events. You know, I had a

girlfriend that I found dead at one point, and that was literally the last major period of recurrence that I had. Of course, you know, all of those involving some degree of polysubstance use.

2.

But really, I've said this over and over, that trauma was my gateway drug. And so having treatment systems that were truly trauma-informed and low threshold I think really are the key to defining features of the current shift in my own work, serving people in our community.

MS. BENT: Great. Thanks so much. And Brandee?

MS. IZQUIERDO: Yeah. Just quickly, for me, being a woman in recovery, I think, you know, gender, sex, race, all of that plays a contributing factor in when and where and why and how we reach out for help. And I think we definitely need to consider that. As I mentioned, you know, prescription -- the prescription use. I didn't think I had a problem because I was prescribed. From there, moving into the cocaine. Still didn't think I had a problem. Alcohol

5

6

8

9

Page 155

brought me to my knees only through the jail and 1 2 prison systems. But more importantly, and I don't think we emphasize this enough specifically around treatment options -- kids. There are not a lot of 4 treatment centers that either will work with women and children or men and children, or families and 7 children. And underneath of all of it, there is a huge fear based piece for me because I -- I didn't want to lose my kids. That was the only thing in my 10 world that I -- for a while, had the sense of entitlement as a parent and felt like I was a failure 11 12 with guilt and shame. And telling anyone that I had a 13 problem would immediately -- I'd immediately lose my 14 kids. And again, I think one of the issues or 15 barriers or challenges within our public behavioral 16 health system are there are not enough facilities that 17 allow children or families. 18 MS. BENT: Great. Thank you. I think 19 that brings up something that we haven't actually 20 talked about. And actually, just before we go back to 21 Dr. Winchell, I wanted to kind of just quickly jump

over to Lyna because I think we had a comment earlier
in the day that kind of talked a little bit about
pregnancy. And I know, I don't think I told you I was
going to jump back to this, but it just really builds
so cleanly into what Brandee was just saying.

So, Lyna, would you mind kind of sharing that comment with us?

MS. MERZOUG: Sure. Yeah. So like Robyn mentioned, we did get a comment earlier about pregnancy. And it's from a young lady who didn't put her name, but she did mention that "I'm interested in whether pregnant individuals are being considered in your approach to developing new treatment medications for stimulant use disorder.

I work at a syringe access program in Northern Michigan and I've noticed that the lack of treatment options for methamphetamine use, which is such a heartbreaking situation for our pregnant women. That was the comment about pregnancy, yeah.

MS. BENT: Great. Thank you. And I think while I have you on the line, I think that we

received some comments about treatments that people have submitted? So maybe you can share those and then we'll turn back to Dr. Winchell to ask some more clarifying questions.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

MS. MERZOUG: Sure. Yeah. So T actually have comments that kind of hit on a lot of the points that our panelists talked about. And so I have one individual saying that "I work with Mountain Area Health Education Center in Ashville, North Carolina. We are working to spread a hub and -- model for addiction treatment in the state by connecting health departments and community health centers. I just want to affirm that what we are hearing across North Carolina is that -- is the need for treatment for stimulant use disorder, contingency management and effective care for folks experiencing stimulant use disorder." And again, giving a big thank you to Jessica for her courageously telling her story and talking about all the work that she has done. definitely a big thank you to Jessica.

Another comment that I see is about a

2.

Page 158

current approach, about -- actually has experience with -- themselves. And saying that "I was almost turned away for detox from crystal meth. I was able to get into a recovery program called Add Care [ph] which doesn't focus on harm reduction. I was paired with a clinician that works, but it's been only mental health-based." That's about -- that was a current approach.

And then I actually have a comment from a gentleman named Jonathan [ph] regarding the homelessness point that actually Michael made. And also talking about his experience and saying that just a little portion of people around him are using stimulants, and that his experience has showed that in many cases, homelessness actually makes it more difficult for people to make any changes.

MS. BENT: Okay. Great. Thanks so much, Lyna. And now, before we move on to kind of our polling session, I did just want to turn back to Dr. Winchell who I understand has fixed any audio issues and give her the opportunity to ask her -- any

clarifying questions that she might have.

2.

DR. WINCHELL: Hi. I have a lot of questions, but I'll try to keep it short. So I — this has been so helpful and so enlightening, and also very hard to hear because it's a very difficult situation that people are in. And access to treatment is a major issue. And a broader issue of our treatment system and our healthcare delivery system in the United States is well outside the scope of anything we, in my division, can do. But what we do have a chance to do is really think about how one would go about designing a study to test a new medication to see whether it would be helpful to people who have these disorders.

First, I want to make sure I understand correctly. It sounds like most people do think that lumping all stimulant use disorder together, as if Adderall and methamphetamine and intravenous cocaine are kind of all the same problem. That doesn't seem to be the case. We hear -- in people who have opioid use disorder that they freely substitute whatever --

they might have a favorite, but they'll use whatever 1 2. new agonist they can get their hands on. So that was 3 one issue I heard. And another issue I heard related to polysubstance abuse is that many of you seem to say 4 5 that you actually -- the underlying issue for you was And somehow, the opioid use disorder 6 stimulants. 7 developed as some attempt to manage some of the symptoms of your stimulant disorder. And then others 8 9 who had started with an opioid problem and the 10 stimulant was layered on top of that. 11 So in these situations, we're often 12 asked how would we go about developing a drug for 13 polysubstance use. It sounds as if perhaps there's a 14 way to drilldown and if -- if you receive good 15 treatment for the cocaine problem, maybe there 16 wouldn't have been an opiate problem, or the opiate 17 problem would have taken care of itself eventually. 18 I just wanted to check if I'm 19 understanding correctly these messages. Thanks. 20 MS. BENT: Great. Thanks. So, Phil, 21 did you want to kind of kick off a response to Dr.

1 | Winchell's comment or question?

2.

MR. RUTHERFORD: Sure. And I appreciate the sort of narrowing of the focus that you -- we can't solve all of the world's healthcare challenges in this narrow space.

On the subject of medication, yes. I
think there is reason to focus narrowly on a
substance, but I was just thinking about -- the reason
I turned on my camera was I was thinking about the
distinction between what happens with distribution of
buprenorphine versus the distribution of methadone.
So what my thought would be, whatever the substance
is, it would be critical that that is freely
available. Because like right now, buprenorphine is
narrowly available whereas methadone is much more

So whatever it is that you do from a medication standpoint, I would think that we would want to make sure that it is not limited to socioeconomic strata. Because right now, that is precisely what is happening with buprenorphine. And

widely available in urban settings.

1 again, I recognize that you're not necessarily in 2 charge of what happens with drug costing, but the fact 3 of the matter is the -- it is a fairly effective treatment and there's a large group of people that 4 5 simply don't have access to it. That is all. 6 MS. BENT: Thanks so much, Phil. And, 7 Michael, do you want to add a minute or two on your 8 thoughts? That would be great. 9 MR. GALIPEAU: Yeah, sure. I mean, for 10 me, there's kind of like two things that are being managed, right? There's like, you know, somebody's 11 12 underlying reason for taking stimulants and then 13 managing this come down period or, you know, sometimes 14 accompanied by periods of really intense anxiety. And 15 I think that those are managed by much different 16 medications. 17 That's kind of the intersection where I 18 found, you know, medical cannabis treatment to be 19 really effective because I can take like a really low 20 intensity stimulant, like drink coffee or in the past, you know, more smoking cigarettes to really, you know, 21

give me some of those compensatory, you know, deficit

overcoming effects without the very long-term effects

of some of the stimulant medications.

2.1

A lot of the medications on the market are not as mild and much longer-acting, and tend to aggravate my Tourette's. So there's some interactivity with my neurological disorder that makes it very uncomfortable for me to take most of those medications.

But I find a more milder effect, something that has a more limited duration that's a little bit more user friendly, controllable, that's helped me to manage a much more recovery-oriented lifestyle and actually have a better quality of life than I would have had on traditional pharmacotherapies.

MS. BENT: Great. Thanks so much,
Michael. And Dr. Winchell, I don't know if you have
further questions or Dr. Muniz has a question? Okay.
So go ahead, Dr. Muniz.

DR. MUNIZ: Okay. Good afternoon again

Page 164

and thank you very much for sharing all your
experiences. It's been very enlightening to me as
well. I want to preface this because I want you to
understand where I'm coming from. When I was I
used to be in the Air Force and I had a one of the
largest treatment facilities in the Air Force for
substance abuse, but our experience was very limited
because you may have maybe one chance, maybe a second
chance if a command was particularly permissive to let
you go back to treatment, otherwise, you get kicked
out of the military. So my perspective was very
limited in that sense. I could try to help someone
once, maybe twice, and that was about where my
experience stopped. And I've heard that there were
struggles, that there were your ability to fight
against the disease and that you guys went through a
variety of treatment. And I was wondering about what
was the most transformative thing in your treatment?
The most transformative experience that made you
change for that treatment to kind of maybe grab hold?
Or what was the most helpful thing when it came to

treatment? So I was wondering if you guys could share something with us that could help me understand a little more of that.

MS. BENT: Okay. So why don't we -- do we have -- and, Michael, I'm going to go to you, but I just wondered -- because we want to hear kind of a diversity of voices as well, if we have anybody else who kind of wanted to start by responding to this question. But -- okay. Jessica, I see you up in the corner. Sorry, it's hard to manage all of the Brady Bunch look on the screen. Thanks.

MS. HULSEY: So responding again as a family member and also just folks that we work with who struggle, the difficulty is that we don't have enough treatment options available. You know, we have so many amazing, brave individuals that are our panelists today, sharing experiences and writing in comments, but for far too many, when you reach out for treatment, there can be a lot of misinformation or wrong numbers. And we heard one person share they were kicked out of programs because there's a myth

2.

2.1

Page 166

that this is hard to treat or harder to treat. And we don't have medications like we have for opioid use disorder. We don't have medications like we have for alcohol use disorder and nicotine use disorder.

That's why today's meeting is so important and sort of pivotal for all of us in this community to dream of more tools in the toolbox to treat -- and treat and intervene early with stimulant use disorder is a dream

-- and something just so critical.

I think right now, far too few individuals in healthcare and folks that you work with use a matrix model or use contingency management or the things that we know work in treating methamphetamine or cocaine use disorder. So I think it's about understanding which combination of therapies. Even listening to individuals today, the benefit of mutual aid support group is so important. And scientifically, the components that you get from that which is healthy attachment and prosocial engagement and the spiritual components of recovery that are so important are critical. We know that

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Page 167

works for prevention. We know those are really important for managing chronic health conditions. I think thinking through how medications could be supportive for this. And not just for my interest area, it's not just the cravings and those acute needs, but the long-term health effects that our patients are trying to manage over time. Whether cognitive or impact on other organs, whether it's your lungs or your heart, I think that there's so many dimensions within our patients that we can look towards healthcare and pharmacotherapy development to potentially have some new solutions for us. I think CBT and DBT are such critical components combined with some of the social areas of recovery that we need. And I think that our -- this is a tricky illness. we've even heard today that it's the layering effect of these behavioral therapies that end up being so useful to our patients. Having additional tools in that toolbox, again, for layering, is really what we want to sort of turn our attention to.

Page 168 1 (Begin Media 4.) 2. MS. BENT: Thanks so much, Great. 3 Jessica. So we'll turn to Michael and then Kevin, and then I think we're going to move onto some of our 4 5 polling questions as well to kind of bring the audience or the viewers back in. 6 7 So go ahead, Michael, and then we'll go 8 to Kevin. 9 MR. GALIPEAU: Yeah. Thank you, 10 Javier, for sharing that. And it really just refreshed, you know, some of my own memory with my 11 12 experiences in the armed forces. And ultimately what 13 led to my discharge, which was disclosure that was 14 made during treatment I was receiving to address, you 15 know, some early signs of an alcohol use and substance 16 use disorder that led to the uncovering of my 17 traumatic experiences at DCYF. And my really untimely 18 discharge just before getting deployed with my unit probably saved my life looking back on it because many 19 20 of them did not survive that deployment.

But thinking about what has been less

2.1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Page 169

effective or not present and also has been more effective, certainly there were not any meaningful role models that would show me what moderation management pathway would look like. And certainly nobody who was speaking out about that as nonabstinence being its own path to recovery. And also, there was no mutual aid societies. Now there fortunately are a couple. Harm Reduction Works which is founded by my friend, Jess Tilley. And, you know, what used to be the -- Positive Change Group which is now the Substantial Improvement Group, that people are now meeting and providing this kind of basic support. And one of the really kind of essential, pivotal parts of my change process -recovery housing. Just having that kind of supportive environment. Again, improving upon my social determinants of health, giving me a really basic foundation of stability as I was being released from incarceration gave me something that I could build

working on a social work degree, start working a

I was even able to go back to college, start

1 regular job. And that really began my current period, 2 a very longstanding and upward trajectory in terms of 3 my quality of life and global health improvement. Excellent. Thank you. 4 MS. BENT: And. 5 Kevin? You know, who knows what will 6 KEVIN: 7 I mean, and I think that's the thing with work. stimulant use disorder or with my journey. You know, 8 9 unfortunately, like with this, there are no 10 medications or anything you can do to deal with the cravings that you have that cause you to use. 11 12 really no medication that will deal with, like, the crash that you're feeling when you stop using and kind 13 14 of, like, crash out. And there's nothing that really, 15 you know -- like, can relieve, like, the feeling of 16 that rush that you get when you first use as well, You know, that brings you kind of back to -- you 17 18 know, that brings you back to those cravings. 19 And I think really from my experience, 20 it was really, you know -- it was really a lot of 21 trial and error. You know, of like, you know -- of

Page 171

going back out and relapsing again, trying to stop.

And, you know, finally, you know, was there, like -what was this transformative thing in my treatment?

It was honestly watching, like, the sun rise over the
holding cell over Lake Michigan as I was waiting to be
booked in, you know, into the court system. And, you
know, just having this like epiphany, and I don't know
what happened, but it was just like, wait. I don't
have to live like this anymore. And I don't want to
live anything like this anymore.

And then for me, it was like really a two or three-week very -- very confusing period of trying to figure out what to do next. And I do think, you know, when I walked into my first 12-step meeting and met a bunch of other -- mostly gay men who had been exactly where I was and were happy and sober and had put their lives back together, that I first found, like, a hope that I might actually be able to get better and beat this. And then, you know, the social networks that I was able to build kind of like -- and utilize that network for support was really, like,

	Page 172
1	that transformative impact for me. Thanks.
2	DR. MUNIZ: Thank you very much to all
3	of you.
4	MS. BENT: Okay. So now I understand -
5	- thank you so much. And did you have additional
6	questions, Dr. Muniz or no? Okay. I'm going to take
7	the video turning off as cue that you're good to go.
8	And so I just I wanted to turn now we actually
9	have a few callers on the phone. And so we're going
10	to take a caller on the phone. We're going to start
11	with David who has been patiently waiting for a little
12	while I think to talk about approaches to treatment,
13	and maybe his thoughts on approaches to treatment.
14	And so, David, I know that you've been
15	very patiently waiting, but if you could kind of give
16	us a high level idea of your what you'd like to say
17	now, go ahead.
18	DAVID: Sure. Thank you so much. Do
19	you hear me well enough? I'm actually
20	MS. BENT: Yes.
21	DAVID: calling in from not a great

1	spot. There's a internet, so just was checking.
2	Great. You know, I just wanted to chime in. I'm
3	actually I have not had stimulant use disorder or
4	any substance use disorder. I've been fortunate about
5	that, but actually, I wanted to talk to you about coca
6	leaves. And so even though I haven't had an issue
7	with it, my father actually has been in and out of
8	recurrences for his entire life. And that has led me
9	to be very, you know, focused on understanding
10	alternatives. And in South America, in particular in
11	Columbia, Peru and Bolivia, there are a number of
12	psychiatrists as well as therapeutic communities that
13	have started using coca leaves as a way of supporting
14	people particularly with craving relief, as well as in
15	terms of how build communities around this plant.
16	So and I think why that is probably
17	requires a tiny bit of explanation. The coca leaf is
18	the source of the molecules with which you produce
19	cocaine hydrochloride as well as cocaine sulphate. In
20	South America, the typical substance of use is called
21	basuco. It's a smoked form of coca paste. But in

2.1

Page 174

general, what these kind of innovative experts are trying to do is use the leaf, both in its full plant format as well as the culture around the leaf. The leaf is used in a number of traditional practices and basically getting together and telling stories and, you know, discussing what the problems for the community are.

So using those concepts as part of their treatment strategies to build these communities that seem to be such a big part of all the narratives that have been shared today. So I think that's something that is very interesting and that deserves taking a look at. You know, coca leaf is not associated with any form of health risk or of addiction. It is -- it's a very effective stimulant, but it's very mild and only lasts as long as it is being held in the mouth in the way that indigenous people of South America use it.

And once people, you know, are finished using the leaves, the effects of coca just wears away within minutes. You know, and people can go to sleep

1 or what have you.

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

So the pharmacology of it as well as all the practices that surround the coca leaf or the cultivation -- the making of the different product formats which tend to happen in a community setting I think are really interesting input for this discussion. You know, cocaine wasn't --

MS. BENT: Yes. Thank you so much,

David. That is really something that is -- I think

Michael may have touched a little bit upon that

earlier, so thank you so much and I'm sorry to cut you

off, but we need to move onto some of our other

callers as well. But we do very much appreciate your

feedback and that will certainly be included as part

of the voice of the patient report.

I think that we're now going to go -- I don't think I have a name, but we're going to go to somebody who would like to share their experiences as a family member. So, please go ahead.

UNIDENTIFIED SPEAKER: Is it -- can you

21 hear me?

MS. BENT: Yes, we can hear you.

2.

UNIDENTIFIED SPEAKER: Okay. Yeah. So actually this is -- I was keyed onto this discussion from a family member a little while ago because for myself, personally, I actually have found that, you know, I struggled early in life growing up without prescription medication because I had no idea I had an ADHD disorder. I also did not -- I also had a vision problem which I've had corrected with Lasik in a similar aspect.

Actually, both of those things come together into a beautiful hue that I can actually see the world clearly with each of those aspects of mind and actual vision. But, like, growing up, I quickly - you know, I was a straight A kid up until hormones came around and, like, I could not -- like, my grades started slipping. I started to act up, be the class clown, you know? Get, you know -- just -- I just started to go down the wrong path. I was always -- I started to become the bad kid, you know? And drinking and finding -- and I ended up going down the substance

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Page 177

road because I didn't have any direction. And then eventually, you know, for whatever reason, I even made it through living in foreign exchange in Spain for a year without being able to see because I wouldn't wear my glasses, and also ADHD. But with a totally different culture or, you know, like a freer aspect of life where, you know, like coming back to the United States, I felt more restricted because the kids over there were able to do things. Like, they were given a larger lead on their rope, I would say, earlier. it was a big -- you know, it was a big thing. And I wish I had had something like that for that experience because now that I'm currently a nurse working through COVID, you know, I've been working with other nurses and dealing with situations that I have to be -- I have, you know, a code going on in one corner of my floor, you know? And then I have, you know, vent alarms going off, bed alarms going off, and I have to constantly reprioritize in my mind, you know, A, B, C. And it's forever changing.

blessed. Like, that the doctor that first put me on 1 2 it found the prescription that, for me, it's just 3 Adderall. And obviously, if there was a better alternative, like, that would be great. But for me, I 4 5 have -- I found the right dose and it actually settles me out. So I find a total benefit from the stimulant. 6 7 So I see where there is abuse potential, but just as the same with opiates and all that, you end up with, 8 9 you know, there's treatment options which I also deal 10 with as a nurse with patients and I have to beg for, you know, somebody that's got multiple fractures and 11 12 they're, you know, given half a -- like a tramadol. I'm like, I don't think that's going to cut it -- it's 13 14 45 or something. But --15 Right. Right. So I'm MS. BENT: 16 sorry, but I'm going to have to just ask you to kind 17 of finish up what you're saying so that we can make 18 sure that we hear from as many people as possible. 19 But I think that what you're sharing is very 20 important, so please go ahead and just finish it up. 21 UNIDENTIFIED SPEAKER:

1 MS. BENT: I don't really want to break 2 you off. Sorry. 3 UNIDENTIFIED SPEAKER: Oh, I'm sorry. 4 Yeah. I'm sorry. I didn't mean to go off course 5 there, but that's basically what I wanted to say was that it does have a place. Like, it -- for me, it's -6 7 - without it, it's the same as if I hadn't had, like, the laser surgery for my eyes. Like, where I can see 8 9 20/20 now, and before I was 20 -- I forget, 320 and 20 10 -- 280? So I was legally blind and I would have never been able to fly a helicopter. And that was always 11 12 one of my dreams and I still plan on doing it. So why 13 not? 14 MS. BENT: Great. Thank you so much. 15 Thank you for calling in and thank you for sharing 16 your experience. And we're now going to move onto --17 I think right now our final caller for this section, 18 who we are apparently calling a family member, so 19 please go ahead. 20 UNIDENTIFIED SPEAKER: Yes. Can you 21 hear me okay? Hello?

1 MS. BENT: I think so. It was a little 2 faint, but now it's getting better. 3 UNIDENTIFIED SPEAKER: Oh, okay. I'm a family member of a cocaine addict who had been 4 5 in relapse over many, many years. And she basically was put on modafinil. And let me preface my remarks 6 7 by saying I attended a summit conference in Miami on stimulant disorder. I think it's like an annual 8 9 meeting -- and it had experts from all over. And 10 there was some question, even though the point was made, there's no approved drugs for stimulant 11 12 disorder, but maybe there was some studies that were 13 indicating possible benefits from off-label of 14 existing drugs, particularly of the stimulant 15 category. And I, again, you know, would want to know 16 if any of these members on the panel now have any 17 experience with the use of stimulants to treat the 18 stimulant disorder, prefacing my remarks again, you 19 know, that there are no accepted forms of treatment. 20 Let me say one other thing in --21 conditions just in generally, there's off-label uses

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Page 181

of medications that are not, you know, specifically approved for one condition. And there's so many people with stimulant disorders that may not be able to manage their condition with just support groups and the cognitive therapy, and other forms of treatment, and might be willing to try, you know, promising drugs again off-label. Thank you.

MS. BENT: So thank you. And actually, we did not ask this gentleman to call in, but it actually leads us very, very well into our next polling question which is, "Have you or your loved ones ever used any of the following to manage stimulant use." And so if we can go to our polling questions and maybe use that as a jumping off point to kind of talk a little bit more about what the gentleman just asked, that would be really helpful. So are we able to go to our polling questions? Okay. So we're going to the polling question now and you'll see that there are multiple responses that are available to us. Honestly, I'm not sure I can read them, unfortunately. So give me -- just give me a

Page 182

second while you guys are responding and I'm going to try and pull them up from previously and just see if there's any way -- to our producers, are we able to zoom in on that at all to get a little bit more clarity? Or if not, that would be -- that's fine as well. And what we can do is just go into our -- we can put the results in as part of the voice of the patient report. And we can kind of just turn briefly to our panelists and ask them briefly to kind of touch on what they've used. Of course, they have spoken to us a lot about their choices in treatment. So let me -- apologies while I just kind of get to this point.

So complimentary alternative therapies is the big blue, lifestyle changes right here is in green, peer support or counseling is in red. And do we have anybody who uses -- it looks like medications is -- is this yellow or other approaches not mentioned is yellow.

And so -- okay. So that looks like the results that we have. And so I guess that brings up a question to maybe some of our panelists if you've used

-- if you haven't already kind of shared with us your approaches to treatment or if you've used any other treatments, if you have any thoughts about this question, please go ahead and turn on your video and we'd be happy to hear from you. Okay. Go ahead, Michael.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

MR. GALIPEAU: Yeah, sure. I mean, I've spoken a little bit about, you know, obviously medical maintenance with medical cannabis. Another really important turning point in my story was actually a brief period of self-experimentation where I was kind of trying to use, like, yoga and guided meditation with like a low dose of psychedelics. Particularly, psilocybin mushrooms. And it was actually after that period of self-experimentation, since that time -- quite literally since that time, I have not had problematic substance use with any of the substances that I've had issues with. Even when I've gone out into self-experimentation with the same substances, my relationship to myself and the substances fundamentally changed. And I can't explain

exactly what it is that happened in that process, but

I don't have the same experience when I use substances

now. And really, it's been pivotal in terms of being

able to have control over my life and not feel

completely powerless in the face of a substance use

disorder.

MS. BENT: Great. Thanks. Let me now turn to Amy.

MS. GRIESEL: Yes. I've used multiple of these. I really -- like I said before, I am a peer support. Well, before I became a peer support, I got assistance from my peers. So I went to something that was called -- and it's called a clubhouse. There's one for behavioral health. So it's a place that you go to kind of feel normal -- if that's the way I should put it -- with other individuals that are suffering from the same things. So the behavioral health one I would either -- you know, each person has a job duty. So you can work in the café. You can work in the business unit. You can work in the boutique. And it's kind of just working together,

showing that, you know what? I have skills, you have 1 2 skills. Let's motivate and empower each other. There's another place that is for my substance use 3 that I went through that is a peer-led, peer-ran. 4 It's called the Recovery Café. And they've got 5 support groups there. They serve lunch. They have 6 7 job training things that go on. And it's really like a family environment. You get people that have lived 8 9 experience that is able to empower you. So with peer 10 support, that really is what I thought was important to be able to give back. 11 12 Lifestyle changes, obviously that is a huge thing. Avoiding triggers, learning how to cope 13 14 with triggers. I place myself in treatment centers as 15 an employee so that I can continue the healing process 16 and keep those present in my mind. Because I am 17 someone that forgets those really easily. So seeing 18 that every day will -- it helps me. 19 And then the other approaches I 20 mentioned during my share was cognitive behavioral

therapy. I think that was one of the really big ones

21

- because being bipolar and having some other diagnoses 1
- 2 that my emotional wellbeing is -- I'd get off a lot.
- 3 So being able to learn how to, for one, have
- mindfulness, calm myself down, figure out how to be 4
- 5 rationale and kind of just have emotional regulation
- was really, really important to me and having that 6
- 7 perspective.
- So those were ones that really made it 8
- 9 so that I could be on this journey of recovery.
- 10 MS. BENT: Great. Thank you so much.
- So let me turn to Phil. And I hope, Phil, while 11
- 12 you're sharing, I would also like to -- because we are
- running out of time, is it okay if I move onto the 13
- 14 next polling question while you're sharing? I don't
- 15 mean to be at all disrespectful, I just -- I want to
- 16 hear what you have to say and also kind of get the
- 17 answer to the next polling question. I'm so sorry.
- 18 MR. RUTHERFORD: Well, I'll be quick.
- 19 I just wanted to say --
- 20 MS. BENT: Okay.
- 2.1 MR. RUTHERFORD: I just wanted to say

2.

Page 187

the -- so that was always the things that we -- the tense of it was things that we have used to manage stimulant use disorder. And as it is a chronic condition or as it is an ongoing thing, I just wanted to point out that there are plenty of things that I continue to use on the path of recovery. I continue to use peer support. I continue to use holistic wellness. I continue to use -- my pathway is abstinence. I continue to use these things to stay in recovery, so it's not that a long time ago I did some stuff and that's what worked. It is the continuation of those processes that allow me to continue to have the quality of life that I've come to enjoy.

MS. BENT: I think that's a really important point, and I think that maybe we could have done a better job of wording that question in a way that it wasn't a single point in time. That really -- that it was more of kind of an ongoing process. So thank you for bringing that to our attention and really just bringing it up because I think that it was really, really important.

Page 188

not seeing a lot of responses, which I mean is kind of great. And -- kind of.

2.1

So let me turn now to my FDA colleagues and see if before we move into the -- into talking a little bit about COVID and the experiences of COVID, if you have any additional questions that you'd like us to ask or any other questions that you're kind of waiting for me to get to that I am forgetting. So anyone from FDA? Okay. So I think that one of my colleagues from FDA is typing a question, and so I'm just waiting.

So just to the -- just to give our colleagues kind of an idea of what we were seeing if you're considering new treatments for stimulant use, which would be the which of the following benefits would you consider to be the most meaningful. We had about -- I want to say about 25 percent of people say stop using altogether, 25 percent say decrease the use. We have about -- I'm ballparking, maybe about 20 or 15 percent saying reduce effective stimulant withdrawal. About the same number saying help me

control my use of stimulants so that I can function 1 2 And a few people said other benefits that 3 were not mentioned. So I think that -- so let me just give 4 5 them a second to think about if they have any additional questions. And while I'm doing that, 6 7 please know that we're kind of teeing up the talk about COVID-19 and the impacts. So for those of you 8 9 who are watching who could call in and kind of share 10 any impacts of COVID-19, how it's affected maybe your stimulant use or maybe your recovery or your 11 12 treatment, that would be really helpful for us to

So, Michael, did you have something to add?

MR. GALIPEAU: Yeah, sure. I mean --

MS. BENT: Okay.

13

14

15

16

17

18

19

20

21

hear.

MR. GALIPEAU: -- just from, you know, my personal experience during COVID, really it's been very difficult to access providers. And I've honestly been very resistant to even seeking routine care,

2.

Page 191

whether it's dental, primary care, routine preventive care. Anything that I can, you know, possibly delay without having to go into a doctor's office. I just fundamentally feel like it's just not a safe place to be where people are congregating and potentially being treated for COVID. Certainly any kind of elective procedures or hospitalization. But some of the things that I've seen done really well during COVID, I mean, the transition to telehealth and making, you know, buprenorphine more widely available in our community here in Dutchess.

And also, deploying, you know, basic market regulatory tools, like fentanyl testing. So people are aware of what's in the drug supply that's out on the streets that's making people unsafe.

And so that combination of response during COVID, the real community-centered work has really been remarkable in terms of increasing access, increasing engagement, increasing retention. And I think those are important lessons learned in how we design a system that looks to meet people where

they're at with stimulant use disorder and other existing treatments, like methadone.

We had released a national statement through the union making some pretty scoping reform recommendation that you can find on the Urban Survivors' Union website, specifically pertaining to methadone. But a lot of those recommendations really apply broadly to what low threshold access to services could or should look like for people who use drugs.

MS. BENT: Great. Thanks so much.

Sorry. I kind of locked my cursor there for a moment.

So that's really, really helpful. Dr. Muniz, did you have any questions? Okay. So while we're waiting for people to respond, I think that we're going to turn to Lyna and, again, we're having a little bit of a delay between kind of getting the comments and being able to share them. And so this kind of takes us back I think to our last question, our pre-COVID question, about treatments. And so -- but I think it's a really -- it's a good comment or comment to hear. So, Lyna, if you wouldn't mind sharing it with us, that would be

great.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Sure. Thanks, Robyn. MS. MERZOUG: So we have a comment from Mindy [ph] on addiction and mental health. And she's saying, "In thinking about treating addiction, it's helpful to remember that there are many different underlying reasons why addicts use, such as taking away pain, both physical and emotional, shame, low self-esteem, self-efficacy, unaddressed mental health and so many other reasons. As you know, it's important to address all of these issues based on each patient's needs. an addiction professional and a woman in recovery, I have realized that everyone is different and treatment needs to be different for each individual. Also, treatment is short-term and a way to teach patients the tools they need for their long-term recovery, which is for a lifetime, that is very helpful in blocking the cravings and urges to use. So patients can focus on getting the tools they will need longterm. More and more, I am seeing many patients are not able to have the mental health component addressed

1 because they do not qualify based on the assessment 2. they received. It might be helpful to come up with an 3 assessment that includes patient's mental health as well as their substance use disorder so they can 4 5 qualify and those issue can all be addressed 6 simultaneously. As a treatment provider, we do assist 7 clients with a warm handoff to mental health services; however, many of those clients are turned away. 8 9 are also being turned away from certain treatment 10 programs because of their insurance -- or not having insurance which can be detrimental to these patients." 11 12 Thanks, Mindy, for sharing your experience. 13 MS. BENT: Yes. Thank you so much. 14 And now let me turn to Dr. Muniz. 15 Hi. I hope you can hear me DR. MUNIZ: 16 This question's for Michael. I am -- you know, we, as an agency, we've received a lot of -- and we've 17 18 read in the media about a lot of interesting -- using 19 psychedelic substances to treat a variety of mental 20 health conditions, such as depression, PTSD, substance 2.1 abuse. And I similarly read a number of cases where

2.

Page 195

people have totally lost an interest in perhaps using substances and so on. And I want to be careful with what I'm saying because I don't want to imply that these drugs work, the only thing is we certainly don't know if these drugs are safe and effective, which is what we're supposed to do.

But I wanted to ask you, Michael, a little bit if you don't mind sharing. And I don't know how much you can say here, but in terms of how did that experience change you in this context? If you can. Thank you.

MR. GALIPEAU: Yeah. Absolutely. I'd love to talk about that. There's actually an emerging community of folks that identify with having experience using psychedelics as part of their path into recovery. And for me in particular, it really held kind of a central position in helping me to heal from a lot of the traumatic experience. I had been experiencing really horrible night terrors and not being able to get a consistent night's sleep was really throwing me into survival mode and a very

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

Page 196

reactionary state on a day to day basis. And it was really easy to fall into patterns of use when my really basic daily rhythms and body regulation was so horrible dysregulated by my mental health. And so that was really a big driving force. And why I keep bringing up, like, this really intricate relationship between trauma and substance use that, from my experience, was central to what was driving the disordered use. And I differentiate that because there is such a thing as non-disordered use and it doesn't necessarily mean that once a person has acquired a disorder, that it is always lifelong, right? That every single case is different. And so what works for each case, what

And so what works for each case, what psychedelics work or do not work, are going to be, you know, uniquely tailored to that person's individual needs, their complex bio and psychosocial health, and their social determinants of health at the time that they receive those kinds of services.

So it may have been a combination of being at a particular turning point in my life when I

Page 197

had that experience, but there were certainly some
biological changes and changes in my brain that were
perceivable immediately that allowed me to lead a more
manageable lifestyle and really get a handle on some
of the other things that I was being asked to do.
Like how to figure out doing step work. You know,
when you're in a completely dysregulated state and
you're day to day just trying to figure out how to
survive your own internal body conditions. It's
really hard to focus on the kinds of, you know,
concrete steps of doing, like you know, I need to
come up with a list of like all these things that I'm
resentful about and figure out what that looks like.
And there was like a lot of really, like, deep,
internal work that as somebody wo was living with
complex trauma, it was really hard for me to go
through that where I was. And having participated in
the Horizon Psychedelics conference and having been
trained in, you know, psychedelics 101 by Doctors
Elizabeth and Ingmar Gorman. And a lot of the really
incredible research work that's out there, I would

1 really, you know, strongly encourage a second look. 2 Because these therapies -- again, it's not a one size 3 fit all solution for everybody. If it even alleviates a significant 4 5 portion of the distress for a part of our population that's really struggling to get recovery, then it's 6 7 important to look at our objective evidence that's 8 available. And there's a very good body of it at this 9 point. You know, we're talking multiple decades of 10 really high quality research that can be reviewed and 11 considered. 12 Thank you, Michael. DR. MUNIZ: 13 Thank you. And so did you MS. BENT: 14 have other questions or do we want to kind of turn 15 back to our panel and hear a little bit about the 16 impacts of COVID or their thoughts on COVID? MR. RUTHERFORD: No, thank you. 17 18 Appreciate it. 19 MS. BENT: Okay. Great. Thanks. So 20 now I'm going to turn back to -- I kind of gave away 21 what I was going to do. We're going to turn back to

1	our panel now. And when I say our panel, I mean both
2	our first panel and our second panel, to really kind
3	of share any thoughts that you have on the impact of
4	COVID on your on stimulant use, on access to
5	treatment, people choosing or accessing treatment.
6	Really, anything. And I know that not to call anybody
7	out, but Jessica, I know that you and I, when we were
8	talking, you had had some thoughts on the matter. And
9	so I don't know if you would be comfortable or willing
10	to kind of talk to us a little bit about your thoughts
11	on the impact of COVID? So if so, we would appreciate
12	it. But if not or if you kind of turned away from the
13	meeting a little bit just because I know that you
14	weren't on this panel, we would completely understand.
15	MS. HULSEY: I'm still here. Happy to
16	check in.
17	MS. BENT: Great. Great. Thanks so
18	much.
19	MS. HULSEY: So right when the sort of
20	shutdown began, we did a survey of our patients and
21	families and people that we work with. We had a

little over 1,000 respondents and it confirmed what a lot of us on this call and this meeting already know, that there was quite a lot of disruption and needed services.

2.

We had I think three out of four folks that we worked with reported disruptions and there was a significant impact on substance use and recovery. Four percent report an overdose since the pandemic had begun. And a lot of difficulty switching to, you know, virtual options and sort of disrupting the systems that so many of our individuals in recovery, including long-term recovery, have set up that really builds the components that they need for recovery and for health and wellbeing.

I think Phil put this really beautifully, that these are the pieces that he built into his life that he relies on every day. And we've heard the same. And even individuals who have been in recovery for a long time, sort of seeing as the length in recovery as protective, still really struggled with sort of changing access. Whether it's counseling not

2.

Page 201

available, the biggest sort of reported frustration was with all of the mutual aid and tall step groups not being accessible, that there were Zoom options, but worried about anonymity. There were, you know, folks joining Zoom sessions to be disruptive, which was really hard. And also just missing that sense of community that you get from participating in mutual aid groups.

And one of our people we work with had such an, I thought, appropriate observation. They said that it's frustrating to have all of our meetings shut down when they're keeping liquor stores and dispensaries open. Our society is so twisted. And I think it was really difficult. I think we should prioritize needed recovery services much higher. It's a combination of we're all in the middle of a pandemic. It's stressful. The news is stressful. People have lost jobs. We've lost friends and families to this illness, so we know that there are more stressors and triggers in 2020. And taking away the safety nets that our individuals in recovery from

substance use disorder or are patients need to stay healthy and strong is just really problematic.

2.1

We also heard from our community that about 20 percent were reporting increased use since the pandemic began. Whether they were family members or friends and allies, or individuals in recovery who reported more slips and relapses using alcohol and other substances really as sort of coping mechanisms during this difficult time.

So I think in terms of next steps on this, we've, you know, really focused on how do we get better at telehealth and Zoom and virtual options?

How do we keep other services open? How do we make sure that we're keeping SUD services as safe as possible so people don't have disrupted treatment in recovery support because we shouldn't let that safety net decay during such a stressful time.

MS. BENT: Great. Thank you so much, Jessica. That was really helpful and I think that the results of the survey are certainly very interesting.

I think we actually now have somebody

Page 203

on the phone that we'd like to go to. I think that they're going to speak very briefly about their experiences during COVID, and then we'll come back to our panelists for any kind of closing thoughts. So, caller on the phone, if you want to go ahead and kind of share your experiences with stimulant use disorder in the context of COVID-19, we would very much appreciate it.

UNIDENTIFIED SPEAKER: Yeah. And this is a sidenote real quick, I am a huge advocate for mindfulness, meditation, all that. That is a big component of what I've done throughout my life.

Finding that was an amazing experience and has helped me.

But as far as COVID goes, the one thing I can say from the other side, the perspective -- I was the one that called earlier and, like, I'm a nurse and I work nightshift and it would be, like, some of the regulation has gotten so stringent on the medication that I would be hard-pressed to be trying to figure out what day I'm going to have to be at the

Page 204

pharmacy and what shift I'm going to be working so

that, you know -- there's been several occasions over

the course of my nightshift that I have just not been

able to go to sleep, so that I make sure that I get my

Adderall prescription refilled because otherwise,

those -- with COVID, the lines would get so long. The

-- you know, the pharmacy would be out of the stock

and then they would say they'd have to have a

pharmacist send it to another one.

So essentially, as a frontline worker and if I'm a charge nurse and I have five other nurses underneath me, or four, and we have, you know, say whatever -- however many patients, 24, 28 beds.

You're, like -- you have a guy then that's essentially has -- is without the medication that he does need.

So sometimes that has been pretty tough where there's no wiggle room as far as, like, a day early or a day late or whatever. It's -- that -- impact me, but that's where I'm coming from. But I'll support anybody, you know, that's going through, you know, substance abuse disorder. I mean, that's tough. I

see plenty of it.

2.

MS. BENT: Thank you. Yeah. Thank
you. Thank you for sharing that. So let me turn
briefly to Michael, and then Phil, and then Kevin.
And then we will turn to the comments that we have
online. And I think that that will take us pretty
close to the end of the meeting. So, Michael, please
go ahead.

MR. GALIPEAU: Yeah. I think in a little bit broader lens than personal experience, I want to bring in, you know, some of my professional experience here regarding specifically COVID. Because I think there's some really valuable insight in what I've experienced. And I actually wrote a paper -- I would encourage anybody who's interested in reading it, I co-authored a paper with William White and Ryan Hampton, both very well known in the recovery community, just a few months ago discussing some of the concerns around COVID-19 and the small business program. And just acted, like, institutionalized discrimination towards people with substance use

histories and criminality around the substance use histories.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

It really is, you know, this idea of, like, how the social determinants of health, people having access to meaningful employment and studies that were conducted very recently on, you know, plant closures throughout the Midwest. I mean, literally right before the pandemic hit, they released a really widely scoping research study on the impact of loss of employment and a whole host of other factors that we're now seeing played out in terms of overdose death amongst not only the typical populations. We have, like, the early recoveries, recurrence, people in and out of incarceration, forced abstinence. They did a lot of research on that in Rhode Island, looking at people who were at risk for overdose getting released from incarceration. But also amongst now, people with longer terms of sobriety that, you know, due to the sudden uncertainty about basic needs, downward economic mobility, we're seeing increased rates of recurrence and also subsequently, because of increased

- unsafe conditions in the market, increases in overdose
 death from a whole different population than we're
 used to seeing turn up in our medical examiner's
 office.
 - And this is, you know -- we're trying to keep up with this, you know, because this is obviously changing very, very rapidly. But the last six months have been extremely distressful and there's ripple effects in how that trauma affects our community widely. And now you're compounding it with people who are experiencing sudden losses due to COVID-19. So I just --
- MS. BENT: Right, right, right.

5

6

7

8

9

10

11

12

14

15

16

17

18

19

20

- MR. GALIPEAU: -- that we really need to be proactive in, like, the variety and the widespread access to healing modalities and different pathways to recovery because it's needed more than ever by so many people.
- much, Michael. I'm going to now move onto Phil.
- MR. RUTHERFORD: Yep. I think in a

2.

Page 208

real simple way, COVID is the big bad wolf. And when I think about the effect on the recovery community -- and I -- there's a little bit of kind of morality in the big bad wolf analogy in that, you know, the pigs built their house with straw or sticks or stone, and that's like their own personal choice. I don't think that's -- that's not the measure that I want to use, but for whatever reason, there are people within recovery that their only defense is straw, right? And they don't have some of the recovery capital tools that I described earlier. So the big bad wolf, COVID, shows up and knocks the crap out of them, right? So the effects of it are horrific.

And then I think people with more moderate defense against the big bad wolf, the people in the house with sticks, they fear better. And people with much more support, much more tools -- like I think of -- in my own personal experience, we simply moved online, right? We simply moved -- I have access to highspeed internet. I've got a community of people around. We simply moved our meeting online and within

a week of deciding that we couldn't go to our meeting 1 2 place, we were online and then over time, as the city has opened up again, we occasionally will go out for 4 coffee in an outdoor space and meet in a safe, socially distanced way.

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

So I have protection there, but I think the concern that I have is the broader recover community at large, there are systemic things in place that -- where people are completely vulnerable to the effects of COVID. Not just the illness, but what it has done to societal interaction and the -- I believe that we're going to pay the price for that over the next 5, 10 years.

MS. BENT: Thanks so much, Phil. And I am told that I went out of order, so my apologies to you, Kevin. I did not mean to go out of order. please go ahead.

KEVIN: No problem, Robyn. And, you know, I just wanted to reiterate, too, a lot of what Phil said actually -- he kind of took a little bit of my thunder. You know, I'm always interested in what

the recovery community here in Chicago where I live is, you know, we basically, you know, lockdown pretty quickly. And within, like -- actually, within three or four days, we had more 12-step CMA meetings going on online than we actually did in person meetings.

So, you know, I think one of the things that those of us in recovery should give ourselves a little bit of credit for is we are resilient.

And, you know, but I think gong back to what Phil said as well, you know, there are a lot of people who are new to recovery I think who are really struggling to come into recovery, you know, in this online format. You know, people who are having to do IOP virtually. I've got a couple of men that I sponsor early in recovery, you know? And the complaints about that and just the experience that it is for them, you know, is just not the same. And I think we have to just acknowledge that and accept that.

You know, and I think, too, the other thing with -- that I think about with this is, you

know, in some ways, you know, for me, I suffered from a disease of isolation. And, you know, when we all had to go into lockdown, you know, we all had to isolate out of our community's health and out of our own health. And, you know, I think that has hit a lot of us really hard. So yeah, thanks.

2.

MS. BENT: Great. Thanks so much for sharing that, Kevin. And we're now going to turn in our last -- perhaps for our final comments from our online viewers, we're going to turn to Lyna to kind of share some of these final comments, and then we'll move onto our closing remarks.

But before we do that, I just want to thank everybody who has participated in the meeting today. So go ahead, Lyna.

MS. MERZOUG: Thanks, Robyn. All right. So we have the final comment from someone who wishes to remain anonymous. And that is that, "I know that COVID has created difficult situations for many; however, a silver lining for those who are not comfortable in social settings, which is a push for

many recovery programs, and does not fit a portion of 1 2. the population -- because not everyone is naturally 3 social -- has allowed people who are not social to thrive in this new social setting online." So thank 4 you so much for that comment. I think it definitely 5 wraps up what our panelists were just talking about. 6 7 Thanks so much, MS. BENT: Great. I really appreciate you kind of sharing that. 8 9 And so everyone, thank you so much for an amazing 10 meeting. What you shared really provided us with valuable insight. And again, if we weren't able to 11 12 get to your comments today, that doesn't mean that they aren't valuable. So please consider sharing them 13 to the federal register and we will include them in 14 15 the voice of the patient report. 16 I'm now going to turn over to Dr. Marta Sokolowska, Associate Director for Controlled 17 18 Substances in the Center for Drug Evaluation and 19 Research, who's really kind of the driving force 20 behind today's meeting for closing remarks. So 21 please, go ahead.

DR. SOKOLOWSKA: Robyn, thank you very much for leading this meeting. I just wanted to take the last few minutes to really thank everyone for making this an insightful and interesting afternoon.

2.

In these closing remarks, I want to summarize some of what we have heard today from our panelists and audience members, highlight the FDA's commitment to advancing drug development for substance use disorder and stimulant use disorder specifically, and thank the people who have made this event possible.

We have had the opportunity today to learn more about the impact of stimulant use disorder, the challenges of seeking treatment and the need to develop effective treatments. We heard from the individuals who are struggling or have struggled with the use of cocaine, crystal meth, methamphetamines and misuse of prescription stimulants.

We also heard from family members, advocates, caregivers, and other individuals who have seen the impact of misuse and stimulant use disorder

firsthand.

2.

2.1

We heard that there are a number of reasons why individuals might begin -- taking stimulants. You mentioned participating in social activities, increasing focus, treating diagnosed and undiagnosed mental health conditions, and coping with pain and trauma, among others. You also talked at length about the polysubstance use, including cocaine, methamphetamine or other stimulants, and opioids.

We heard about how stimulant use disorder affect health and wellbeing. You brought up short-term physical effects such as overdose, psychosis, mood swings, intense cravings and withdrawal. But you also mentioned longer term physical health impacts such as issues related to oral health, infectious diseases, health conditions.

We heard that stimulant use disorder affect major activities of your daily living. You told us about difficulties in participating fully in work and school and maintaining stable housing, as well as experiences with the criminal justice system.

So you further discussed the impacts of stimulant use disorder on families and friends such as damage relationships and limiting the ability to care for children.

2.

2.1

We heard about your preferred approaches to managing your stimulant use disorder. You talked about the need for a broader perspective on treatment and recovery. Planning that goes beyond just acute medical care.

You mentioned the metrics model, contingency management, trauma-informed behavioral health effects, healthcare, and treatment of other underlying health conditions, including other substance use disorder.

You also discussed self-management, such as drinking coffee and participating in 12-step programs. And the role of pure relationships and support in helping you find a voice and seeking to improve overall care for -- stimulant use disorder.

And you emphasize the need for pharmacological treatment for stimulants that are

similar to what we already have for opiates.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

We heard the importance of language and the need to understand that stimulant use disorder must be part of a broader societal conversation about addiction.

You told us that the word stimulants means different things to different people. And that relapse should be, but often isn't, characterized as part of chronic condition rather than a sign of failure.

You discussed how characteristics, such as gender, race, sexual orientation and social economic status can impact experiences of stimulant use disorder and why they require a more intersectional approach to care.

And you spoke about frequent challenges with stigma, whether from healthcare providers or from individuals with other kinds of substance use disorder.

We heard about how COVID-19 has impacted substance use disorder, including broader

1 access to services via telehealth.

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

You also told us about distractions in switching in person care and support to virtual options, as well as challenges in filling prescriptions.

You also mentioned a potential silver lining, that people who were uncomfortable participating in person may be more comfortable participating in online support groups.

All of the insights you have shared at this patient-focused drug development meeting, a critical part of FDA's ongoing effort to advance drug development for stimulant use disorder.

I want to take a moment to tell you what else we've been doing to address stimulant use disorder as this meeting is part of our broader strategy that address this disease.

For instance, FDA is working closely with National Institute on Drug Abuse. And last year, we participated in two NIDA-led workshops. One on target identification for stimulant use disorder

2.1

deter non-oral abuse.

Page 218

interactions between opiates and methamphetamines, to
better understand the risk associated with -
In December of 2019, FDA held a public
workshop with Duke-Margolis Group to obtain input from
clinical and academic experts, as well as harm
reduction groups, about complexities of stimulant use
disorder and various new treatment development.

In two days, we'll have a public
advisory meeting to discuss a new drug application for
a potential ADHD amphetamine treatment that hasn't
been formulated with properties that are intended to

And off note, just last week, FDA

published a final guidance for industry on endpoints

for demonstrating effectiveness of drugs for treatment

of opiate use disorders. We are hoping to do more in

this space.

As you can see, we have had many discussions with FDA staff about how best to address substance use disorder. We look forward to continue

our work on stimulant use disorder within the agency and collaborating with other stakeholders.

2.

2.1

On behalf of FDA, I want to conclude by thanking everyone for participating in today's meeting. We are particularly grateful to the individuals with stimulant use disorder and the family members, advocates, caregivers who have attended and shared their perspectives, as well as panelists and audience members.

We recognize that speaking publicly about your experiences with stimulant use disorder may have been a difficult decision. We heard examples today about the ways that stimulant use disorder is stigmatized, perhaps more than some other types of substance use disorders. And how those -- added to it can make seeking care even more challenging.


FDA is committed to doing our part to destignatize stimulant use disorder so that individuals can receive the confident and compassionate care.

We also appreciate all of our entities

1	from the FDA and other federal agencies and the
2	press for listening this afternoon.
3	Finally, I would like to thank Robyn
4	Bent and Lyna Merzoug from the patient-focused drug
5	development staff for moderating and leading this
6	discussion. We couldn't have done it without you.
7	And I wanted to thank Admiral Giroir
8	for his opening remarks, as well as for all the FDA
9	panelists for the hard work in organizing and
10	facilitating this event. Have a wonderful evening.
11	Good night.
12	(Whereupon, the meeting concluded at
13	5:02 p.m.)
14	
15	
16	
17	
18	
19	
20	
21	

CERTIFICATE OF NOTARY PUBLIC

I, IRENE GRAY, the officer before whom the
foregoing proceedings were taken, do hereby certify
that any witness(es) in the foregoing proceedings,
prior to testifying, were duly sworn; that the
proceedings were recorded by me and thereafter reduced
to typewriting by a qualified transcriptionist; that
said digital audio recording of said proceedings are a
true and accurate record to the best of my knowledge,
skills, and ability; that I am neither counsel for,
related to, nor employed by any of the parties to the
action in which this was taken; and, further, that I
am not a relative or employee of any counsel or
attorney employed by the parties hereto, nor
financially or otherwise interested in the outcome of
this action.



IRENE GRAY

Notary Public in and for the

State of Maryland

CERTIFICATE OF TRANSCRIBER

I, JACOBEY RADTKE, do hereby certify that this transcript was prepared from the digital audio recording of the foregoing proceeding, that said transcript is a true and accurate record of the proceedings to the best of my knowledge, skills, and ability; that I am neither counsel for, related to, nor employed by any of the parties to the action in which this was taken; and, further, that I am not a relative or employee of any counsel or attorney employed by the parties hereto, nor financially or otherwise interested in the outcome of this action.

13

1

2

3

4

5

6

7

8

9

10

11

12

14

15

17

16

18

19

2.0

21

JACOBEY RADTKE

Public Meeting

October 6, 2020

[1 - access]

Page 1

1	1:55 52:13	30 20:2,3 50:3	221:10 222:7
	2	52:5 91:4 113:10	able 24:13 26:13
1 52:13 59:11		123:15 130:18	40:18 47:16 48:12
1,000 200:1	2 26:21 59:12	30s 135:5	48:14 49:4 51:13
1-800 77:20	111:2	320 179:9	51:13 76:3 77:4
1-800-527-1401	2,500 10:20	37 66:18	79:6 92:14 111:6
113:14	20 37:19 50:3	3:00 86:8	117:5 124:16
10 23:14 59:20	130:11 179:9,9	4	136:5,20 137:6,6
65:14 101:20	189:19 202:4		137:7,16,16
120:5 122:14	20/20 179:9	4 24:20 168:1	138:21 139:2,10
125:12 135:10	200 67:1	4.9 10:18	139:15,19 145:16
209:13	2005 29:16	40 108:1 126:11	146:6 158:3
100 48:10	2006 146:5	4140492 1:21	169:20 171:18,20
101 197:19	2007 8:20	43 130:6	177:4,9,21 179:11
11 26:21 67:8	2012 11:19 19:4	45 178:14	181:3,17 182:3
12 10:20 11:9	2013 12:2	5	184:4 185:9,11
91:21 92:4,5	2014 125:13	5 25:7,13,18 28:7	186:3 192:16
117:6 128:2 131:2	2015 126:7	209:13	193:21 195:20
132:15 142:4,5	2017 11:16,19	5,32 4:3	204:4 212:11
143:1 171:14	2018 125:9 126:7	5.5 11:2	abnormal 115:19
210:4 215:16	126:14	500 151:8	abscesses 67:14
12:30 1:6	2019 8:18 10:17	527-1401 77:21	absence 24:6
12th 8:13	12:3 218:4	5:00 75:6	absolutely 93:18
13 11:8 143:5	2020 1:5 11:9	5:02 220:13	195:12
14 12:3 66:21	201:20	6	abstinence 56:7
118:15	2030 8:6		129:18 169:6
14799 221:17	20910 1:10	6 1:5 65:14	187:9 206:14
15 4:5 110:21	20s 61:11 125:11	6,000 7:21	abstinent 65:1
189:20	135:8	60 107:21	abuse 9:16 23:21
160 74:14	213 4:7	7	25:1,2 44:16 62:2
16th 7:19	214 145:7	73 11:16	132:14 160:4
17 69:20 143:1	22 69:14 130:12	7th 38:21 112:14	164:7 178:7
144:16	23 4:6	8	194:21 204:21
17929 222:14	24 204:13	800-527-1401	217:19 218:13
18 70:15 130:8	25 19:6 52:5,12	52:14	abusing 64:1
144:16	130:9 189:17,18		academic 8:16
180 91:2	27 73:7	9	218:6
19 6:17 8:14 9:11	28 11:6 118:15	9 4:4	accept 75:15
12:8 36:11,14	204:13	90 91:3	210:18
133:19 190:8,10	280 179:10	a	accepted 28:16
203:7 205:19	2:50 33:12 110:15	ability 17:18	104:6 147:9
207:12 216:20	3	110:3 116:11	180:19
1994 24:20	3 111:3 167:21	127:3 164:15	access 46:5 47:16
1:50 52:13		188:8 215:3	87:5,19,20 104:19
		100.0 210.0	

[access - agitated] Page 2

104:20 122:7	activity 27:16	addition 8:10	advisor 8:3
127:14 133:12,20	acts 100:14	19:12 20:2 50:12	advisory 18:9
134:2,7 145:5,5	actual 176:14	107:17 117:8	218:10
148:10 156:15	acute 118:14,17	141:7 145:15	advocate 40:6
159:6 162:5	167:5 215:9	additional 93:14	53:7 77:2 115:8
190:20 191:18	adam 106:7,13	126:21 167:18	203:10
192:8 199:4	add 36:20 57:1	172:5 189:6 190:6	advocates 6:10
200:21 206:5	70:10 77:19 80:2	additionally 63:7	20:4 21:17 40:4,5
207:16 208:19	80:7 101:1 104:4	109:14	213:20 219:7
217:1	158:4 162:7	address 9:13 43:2	affect 132:17
accessible 201:3	190:15	57:20 66:13 93:15	214:11,18
accessing 124:9	added 25:16	147:2 168:14	affirm 157:13
199:5	219:15	193:10 217:15,17	afford 84:7 85:6
accompanied	adderall 6:7 30:11	218:20	afforded 71:6
162:14	49:13 60:16,18,21	addressed 42:10	afraid 70:18 86:5
accountability	61:13 84:8 90:21	193:21 194:5	129:12
104:21	91:2 159:18 178:3	addresses 65:4	afshar 2:7 4:6 6:2
accounts 90:4	204:5	addressing 10:8	23:3,5,6,8 32:18
accurate 221:9	addict 100:3 125:8	14:9,12 146:18	33:17 43:17,19,19
222:5	180:4	adds 99:2	afternoon 5:2,3
achieve 117:16	addicted 71:13	adequate 142:19	9:5 23:6 33:13
achieved 128:6	84:15	adhd 30:15 44:5	42:19 44:8,12
acknowledge	addiction 2:8,11	69:15,18 70:17	45:15 51:11 59:14
210:18	6:3 10:2 23:9	141:2 176:8 177:5	69:8 86:8 100:17
acknowledging	24:14 27:13 43:14	218:11	125:6 140:12
103:6	43:15,21 44:17	adjust 108:12	163:21 213:4
acquire 88:1	53:7,8 54:20 55:4	admiral 5:13,16	220:2
acquired 196:12	58:18 60:13 69:9	7:17,18 8:11,21	age 60:6 130:12
acquiring 65:19	71:2,7 72:6 81:18	9:3 220:7	143:1,1 144:5,15
68:1 88:10	91:7 96:1,2,5	admiral's 15:20	151:8
act 29:18 35:8	101:8 120:8 121:8	admire 14:6	aged 10:20
176:17	123:2,16,19 126:8	admit 125:20	agencies 13:11
acted 205:20	127:18 128:13	151:5	220:1
acting 8:17 44:3	129:14 135:4,9	admitting 151:16	agency 8:20 20:8
163:5	151:4,12 157:11	152:7	194:17 219:1
action 43:8 137:9	174:15 193:4,5,12	adults 92:12	agenda 5:11
221:12,16 222:8	216:5	advance 53:12,18	agent 147:19
222:12	addictive 10:15	217:12	aggravate 163:6
active 63:8 123:2	29:6 75:17,17	advanced 8:19	aggression 57:13
123:15	98:21 147:20	advancing 213:8 advantage 47:4	95:13
actively 49:16,20 activities 12:17	addicts 81:16 109:19 193:7	advantage 47:4 adverse 69:16	aggressive 28:5 agitated 75:3
26:17 56:16		advises 43:1	95:15
104:12 214:5,18	adding 109:15	auvises 45.1	73.13
104.12 214.3,18			

[ago - assaulted] Page 3

ago 29:15 70:16	altogether 189:18	162:14	112:20 117:9
73:4 114:21 117:3	amazing 63:15	anybody 75:21	131:7 172:12,13
176:4 187:10	165:16 203:13	80:1 81:9 83:20	182:17 183:2
205:18	212:9	93:6 107:6 109:2	185:19 215:6
agonist 28:21	ambulance 74:4	111:13 140:1	appropriate
160:2	ambushed 145:1	165:7 182:16	117:14 201:10
ahead 99:14 101:5	america 8:3	199:6 204:20	approved 17:5
102:6 125:5 149:6	173:10,20 174:18	205:15	18:3 180:11 181:2
149:14,14 150:21	america's 8:6	anymore 73:21	approves 44:5
163:20 168:7	american 147:11	74:17 76:7 171:9	arbor 70:2,2 84:5
172:17 175:19	americans 10:18	171:10	archived 7:14
178:20 179:19	amount 24:5 87:1	anyway 85:7	area 21:15 33:21
183:4,5 203:5	amphetamine	anyways 84:13	47:8,9 70:2 99:16
205:8 209:17	25:18 30:11	apnea 141:8	157:9 167:5
211:15 212:21	218:11	apologies 98:19	areas 19:9,19
aid 46:13 117:6	amy 3:6 134:18,21	182:12 209:15	88:10,19 167:14
147:19 166:17	140:7 184:8	apparently 179:18	armed 144:9,12
169:7 201:2,8	analogy 208:4	appetite 27:17	144:18 168:12
aims 12:20	analyst 44:21	28:1 30:5 95:15	arrest 124:17
air 88:13 164:5,6	anesthesiology 2:7	applauding 78:6	arrested 126:14
alarms 177:18,18	2:10 6:2 23:9	application 18:8	130:20
alcohol 59:19 65:7	43:15,21	45:20 47:20	arrythmia 29:14
120:14 121:1,2,9	anger 28:5	218:10	30:6,8 56:1
121:10,12 122:8,9	angry 132:19	applications 43:13	arson 136:17
123:9 130:7,11	ankylosing 141:3	apply 192:8	arthritis 70:15
131:11,14 154:21	ann 70:2,2 84:5	appointed 8:13	85:16
166:4 168:15	annual 180:8	appreciate 15:10	ash 7:20 8:3,10
202:7	anonymity 201:4	22:20 68:20 69:1	9:2 36:12
alive 135:4	anonymous 38:4	81:15 82:6 98:6	ashville 157:9
alleviates 198:4	39:8,18,18 45:21	104:3 112:15	asked 23:12 50:19
allies 202:6	128:2 211:18	113:21 119:8	72:2 95:6 108:19
allow 13:14	answer 40:18	161:3 175:13	129:5 150:2
155:17 187:12	46:11 109:2 152:4	198:18 199:11	160:12 181:16
allowed 18:15	186:17	203:8 212:8	197:5
70:16 128:16	answered 48:19	219:21	asking 48:2 52:7
145:10 197:3	answering 50:12	approach 14:19	65:2 108:9 125:7
212:3	answers 32:13	17:11 20:9 53:19	151:15 152:5
allowing 91:5 alter 13:10	46:3,11 49:4	118:15 131:20	aspect 66:11 93:16
	113:11	132:8,10,13	106:10 176:10 177:6
alternative 178:4	antagonist 29:1	138:20 156:13	
182:13 alternatives 147:1	antibody 13:9	158:1,8 216:15	aspects 42:9 176:13
147:14 148:6	anxiety 58:14 124:2 137:15	approached 94:19 approaches 6:15	assaulted 143:20
173:10	139:9 140:2	35:21 41:20	143:21
1/3.10	137.7 140.4	33.21 41.20	143.41

[assess - beliefs] Page 4

assess 32:14	attorney 221:14	101:14,15 102:1	basic 46:19 78:21
assessment 18:2	222:10	105:1 108:17	104:18,19 169:12
194:1,3	audience 23:10	109:6 110:13,21	169:17 191:12
assessments 17:18	168:6 213:7 219:9	111:4 125:1	196:3 206:19
assets 151:13	audio 158:20	134:12 138:1,3	basically 76:21
assigned 133:2	221:8 222:3	142:14 149:11	81:13 109:8 174:5
assist 194:6	auditory 28:3	153:4 155:20	179:5 180:5 210:2
assistance 184:12	authored 205:16	156:4 157:3	basis 21:8 64:4
assistant 5:14 7:19	avail 76:19	158:19 164:10	68:8 124:3 196:1
assisted 13:6	availability 60:12	168:6,19 169:20	basuco 173:21
131:6	87:21 88:12,21	170:17,18 171:1	battle 130:14
associate 5:17	available 18:21	171:17 177:7	battling 109:16
212:17	20:13 23:15 58:21	185:11 192:17	bear 100:12
associated 98:12	60:8 70:1,3 71:14	198:15,20,21	beat 171:19
99:2 124:9 174:14	84:5,6 88:17	203:3 210:9	beautiful 114:5
218:3	117:15 133:15	background 6:4	176:12
associations	147:14 148:6	15:14 16:13 34:2	beautifully 200:16
105:14	153:3 161:14,15	98:18 125:10	becoming 62:17
assumption 145:7	161:16 165:15	backseat 105:12	bed 177:18
asthma 56:8	181:20 191:10	backyard 102:10	beds 204:13
ativan 75:9	198:8 201:1	bad 10:11 98:17	beg 178:10
attached 94:6	average 10:20	98:19 116:1	began 19:3 70:5
106:12 122:10	66:21	125:20 176:20	70:10 84:14
attachment	avoid 24:7 61:14	208:1,4,11,15	121:13 143:17
166:19	91:6 150:10	ball 73:14	170:1 199:20
attack 30:6	avoiding 68:6	ballparking	202:5
attacks 55:15	185:13	189:19	beginning 91:4
attempt 70:19	awake 145:16	baltimore 88:11	133:19
115:21 160:7	aware 33:10 92:19	88:16	begun 200:9
attempted 136:16	191:14	ban 104:17,17	behalf 48:21 219:3
attempts 26:8	awareness 81:16	bank 90:4	behave 55:6
118:2	awful 84:19,20	barrier 139:21	behavior 28:5
attend 21:19	150:6	barriers 9:14	29:11 71:9 104:16
132:21	awol 145:9	124:9 129:16	105:15 143:7,13
attended 126:1	azar 10:9	138:10 148:8	147:20
128:11 180:7	b	155:15	behavioral 31:4
219:7	b 177:19	based 17:5 25:9	137:8 155:15
attendees 2:2	back 35:20 45:6	25:14 29:1 30:1	167:17 184:14,17
attending 26:16	56:15 60:17 61:3	32:7 65:18 87:20	185:20 215:11
attention 29:9	62:21 63:14,16	92:7 121:6 125:18	behaviors 54:19
117:2 167:20	68:19 74:9,10	131:20 133:5,12	58:7 63:18 96:7 belief 147:11
187:19	77:11 89:9,16	133:16,18 155:8	beliefs 147:13
attitudes 94:5	90:2,3,20 96:17	158:7 193:11 194:1	Delicis 14/.13
	98:5 100:21	134.1	

believe 95:20 96:1	186:10,20 187:14	bit 5:19 16:12	bought 67:6
110:15 116:12	190:17 192:10	19:2 22:17 33:5	boutique 184:21
118:13 135:5	194:13 198:13,19	34:2,8 44:20 47:1	box 77:19
209:11	199:17 202:18	47:21 48:12 52:10	boxes 72:18
ben 84:15	205:2 207:13,19	53:17,18 55:8	brady 165:10
beneficial 28:20	209:14 211:7	59:6 64:14 79:21	brain 10:6 31:8
65:5 137:1	212:7 220:4	80:20 83:1,21	55:5 76:10 96:6
benefit 19:16	best 31:21 35:17	84:2 86:18 89:14	197:2
118:14 139:12	42:4 48:7 73:9	93:2 97:16 99:7	brains 71:16
166:17 178:6	99:16 114:3 132:3	104:4 106:4,20	brandee 3:1 97:21
benefits 145:5	138:7 218:20	107:10,16,18	98:1 99:11 119:4
148:10 180:13	221:9 222:6	112:18 125:3,10	119:5 124:21
188:3,16 189:15	better 6:19 10:12	134:13,15 146:1	152:15,17 154:12
190:2	28:12 32:14 36:4	156:2 163:12	156:5
bent 1:4 2:3 4:3	36:4 50:21 57:11	173:17 175:10	brave 129:10
5:2,5 9:6 15:5,18	57:20 98:13 100:7	181:15 182:4	165:16
16:2 22:16 32:17	106:2 113:3	183:8 188:12	break 35:21 36:6
43:11,17 44:1,7	124:19 133:8	189:5 192:15	57:16 99:20 100:2
44:11,19 45:17	135:1,18 139:12	195:8 198:15	103:5 110:2,3,5
59:4,13,16 64:8	163:14 171:19	199:10,13 205:10	110:10,15 111:6
64:10,20 68:21	178:3 180:2	208:3 209:20	135:15 179:1
72:14 77:7 81:21	187:16 190:2	210:7	breakdown 93:14
82:12 86:13,20	202:12 208:16	bizarre 144:5	brendan 2:18 59:8
87:2 90:6,10	218:3	black 114:2,14	59:10,17 64:10
91:12 92:17 96:13	beyond 91:1 215:8	147:8	65:10 77:9 90:7
97:13 99:11	bias 115:12	blame 58:6 94:9	brett 2:4 5:13 7:17
100:18 101:18	biased 22:17	95:11	brief 16:6 23:12
103:14 105:18	biases 101:9,10	blessed 178:1	183:11
106:14 108:9	big 52:20 95:21	blind 179:10	briefly 5:12 182:8
109:21 111:4	98:5 122:18 139:3	blocking 193:18	182:9 188:14
113:18 118:21	146:10 147:11	blood 27:19	203:2 205:4
124:21 130:3	157:17,20 174:10	blue 182:14	bright 134:6
134:11 140:7	177:11,11 182:14	blurry 48:9	bring 32:5 51:17
148:12 149:18	185:21 196:5	board 8:12	99:6 168:5 205:11
150:18 152:14	203:11 208:1,4,11	body 141:6 196:3	bringing 8:8
154:11 155:18	208:15	197:9 198:8	187:19,20 196:6
156:20 158:17	bigger 16:11	bolivia 173:11	brings 8:21
160:20 162:6	48:12	boned 122:18	155:19 170:17,18
163:17 165:4	biggest 201:1	booked 171:6	182:20
168:2 170:4 172:4	billions 13:14,17	border 11:12	broader 42:8
172:20 175:8	bio 196:17	bored 115:12	159:7 205:10
176:1 178:15	biological 197:2	boston 73:2	209:7 215:7 216:4
179:1,14 180:1	bipolar 141:1	bottom 7:8 77:18	216:21 217:16
181:8 184:7	186:1	122:11	

broadly 192:8	113:20 122:18	care 8:21 9:15	cder 2:3,6,9
brother 73:9	135:9 140:2,15	26:13 39:13,15	ceasing 88:7
brought 69:2 74:5	142:17 149:10,11	53:4 56:14 67:12	celia 2:10 43:12
75:2,8 81:16	181:9 190:9 199:6	101:10 117:21	cell 36:17 46:1,6
120:7 155:1	200:2	118:14,16,17	46:17 171:5
214:11	called 5:10 8:5	127:8 137:6	cementing 145:19
bubble 144:6	38:17 69:12	138:20 142:11,19	center 5:7,18
buddhist 132:7,9	111:15 126:6	151:9 157:16	42:21 43:1 45:2
build 14:10 21:9	148:1 158:4	158:4 160:17	66:16 121:7
		190:21 191:1,2	130:13 136:8
34:11 36:21 59:1	173:20 184:13,13 185:5 203:17	· · · · · · · · · · · · · · · · · · ·	157:9 212:18
96:7 125:15		215:3,9,19 216:15	centered 9:1 14:19
169:19 171:20	caller 172:10	217:3 219:16,20 cared 78:16	128:8 191:17
173:15 174:9	179:17 203:5		
building 52:21	callers 172:9	career 62:5	centers 76:15
132:19	175:13	careful 86:1 195:2	130:17 136:6
builds 156:4	calling 7:9 113:14	caregivers 19:14	142:11 155:5
200:13	139:6 172:21	20:17 21:4,20	157:12 185:14
built 200:16 208:5	179:15,18	22:3,9 32:13	central 195:17
bulk 120:2	calls 38:11	213:20 219:7	196:8
bunch 96:12	calm 186:4	carolina 157:10	certain 88:19
165:11 171:15	calmed 137:18	157:14	152:1 194:9
buprenorphine	camera 46:6 149:4	carried 127:4	certainly 71:15
66:11 161:11,14	161:9	cartels 11:12	141:13 152:20,21
161:21 191:10	campbell 44:21	case 30:7 89:15	169:2,4 175:14
buried 73:3	cancer 56:1	115:16 117:1	191:6 195:4 197:1
bury 77:1	cannabis 142:9,13	133:2 159:20	202:20
business 184:20	142:17 146:4,10	196:13,14	certificate 221:1
205:19	146:14 147:12	cases 95:8 158:15	222:1
busy 123:6 128:19	148:3 162:18	194:21	certify 221:3
buttons 72:2	183:9	casual 104:10	222:2
c	capable 116:13	catch 107:1	challenge 48:13
c 2:1 4:1 5:1	capacity 12:15	categorized 24:21	challenges 9:12,18
177:19	19:11 118:9 124:6	26:1	31:9 47:20 54:4
caffeine 102:17	capital 117:14,18	category 28:8 48:5	72:17 151:4
104:5 123:13	208:10	48:6 58:5 71:3	155:15 161:5
café 184:19 185:5	captain 9:6 59:16	103:4 180:15	213:14 216:16
california 76:13	64:8	cause 30:7 122:12	217:4
146:3	capture 22:6	124:2 170:11	challenging 37:18
call 18:4 36:9	captured 17:13	caused 63:4	219:16
37:12 38:13 42:13	112:7	causes 71:6 141:5	chance 159:11
43:8 45:13 50:2	card 8:5	cautious 71:2	164:8,9
50:13 52:13 74:2	cardiac 30:5,7	cbt 167:13	change 25:18
77:17,20 107:14	cardiovascular	cdc 11:4 12:21	66:14 83:3,6
111:14,17 112:2	27:18		129:15 134:3

October 6, 2020 [change - come] Page 7

164:20 169:10,14	children 56:14	clinic 71:13	147:17,21 153:7
195:10	92:13 123:1 138:1	clinical 16:20 17:1	154:21 159:18
changed 24:18	155:6,6,7,17	17:21 20:12,12	160:15 166:14
35:18 54:20 83:19	215:4	31:11 32:8 44:21	173:19,19 175:7
87:3 144:10	chime 173:2	45:1 61:6 103:20	180:4 213:17
183:21	choice 81:19 86:3	218:6	214:8
changes 27:18	101:12,13 133:20	clinician 158:6	cocaine's 121:11
96:6 158:16	208:6	clock 88:12	cocoa 147:16
182:14 185:12	choices 62:13	close 20:16 37:17	code 46:7,9
197:2,2	182:11	205:7	177:16
changing 36:13,15	choose 48:6	closely 48:6 72:3	coffee 104:13,17
72:1 177:20	choosing 199:5	217:18	147:4,8 162:20
200:21 207:7	chose 62:19	closer 52:12	209:4 215:16
chaotic 152:20	christmas 53:1	closing 14:8 203:4	coffees 104:17
characteristic	136:13	211:12 212:20	147:15
153:16	chronic 10:6 56:8	213:5	cognitive 29:13
characteristics	56:12 104:11	closures 206:7	54:9 57:14 137:8
216:11	105:16 118:17	clown 176:18	167:8 181:5
characterized	145:21 167:2	clubhouse 184:13	185:20
216:8	187:3 216:9	cma 129:9 210:4	coke 68:2
charge 162:2	chronically 148:9	cna 91:21	cole 2:16 45:12
204:11	cigarettes 104:14	coast 65:16	collaborating
charged 136:17	162:21	coca 147:18 148:4	219:2
charges 126:15	circles 123:4,5	173:5,13,17,21	colleague 45:8,12
charity 130:12	circumvents 148:7	174:13,20 175:3	colleagues 42:16
133:7,16	city 98:5 126:4	cocaine 6:5 10:14	149:13 189:3,10
charles 3:5 130:4	136:2 209:2	11:2,6,8,17,19	189:13
130:5 134:11	clarifying 148:19	12:6,10 13:2,7,19	college 169:20
chase 61:20 62:9	157:4 159:1	25:11,19 27:14	color 115:12
71:20 89:10	clarity 182:5	29:3,5 30:1,21	columbia 173:11
chased 61:2,12	class 29:2 30:18	31:13 53:15,16	coma 28:6
chasing 71:21	176:17	54:1 55:13,16,19	combat 29:17
chat 7:7 36:19	classified 30:13	57:4 60:7,9,13	combination
check 127:19	clean 89:7	65:10,16 66:3	65:20 107:11
160:18 199:16	cleanly 156:5	67:1,4 69:14,19	142:2 166:15
checking 173:1	clear 10:3 60:10	70:1,7,10 72:6	191:16 196:20
chemical 17:2	115:17 116:15	73:11 79:3,11,15	201:16
chemicals 29:18	clearly 63:2 127:3	81:2 84:4,11,16	combined 13:20
chicago 210:1	176:13 188:5	84:16,21 85:1,6	25:19 31:16,18
child 49:14 73:3	click 72:2 77:19	87:12 95:10 103:1	66:3 67:2 143:17
77:1 123:2	clients 85:1 194:7	103:8 105:6,8	167:13
childhood 69:16	194:8	120:12 121:11,14	come 35:20 45:9
92:10	climbing 47:17	121:15,16,20	54:6,20 60:14
		124:8 141:14	61:16 63:12,14

	1		
64:6 70:8 76:4	108:18 109:4	compensatory	115:4 141:4 181:2
82:21 110:13	110:11 111:11,12	163:1	181:4 187:4 216:9
120:13 125:1	111:12,14,15	complaints 210:16	conditions 19:21
134:12 148:19	112:17 113:13	completed 130:18	141:9 147:3 167:2
149:4 162:13	157:1,6 165:18	completely 47:11	180:21 194:20
176:11 187:13	192:16 205:5	126:13 129:20	197:9 207:1 214:6
194:2 197:12	211:9,11 212:12	143:3 184:5 197:7	214:16 215:13
203:3 210:12	commissioned 8:1	199:14 209:9	conduct 12:21
comes 55:7,8	commissioner	complex 122:19	16:20 19:11 55:6
67:11 81:17 93:21	8:18	123:10 196:17	conducted 19:6
comfortable 40:3	commit 100:6	197:16	206:6
199:9 211:21	commitment 82:6	complexities	conference 180:7
217:8	213:8	218:7	197:18
coming 51:1 57:6	committed 10:8	compliant 143:8	confidence 29:10
59:19 79:10	14:9 82:9 142:15	143:12	confident 219:19
101:19 122:14	219:17	complicated 41:14	confirmed 200:1
164:4 177:7	committee 18:9	49:11	conflict 18:12
204:19	commonly 126:6	complications	confusing 102:13
command 164:9	communities	65:18	171:12
comment 38:21	173:12,15 174:9	complimentary	confusion 28:6
39:5,7 77:19 82:1	community 18:16	182:13	congregating
82:5 91:20 92:9	94:21 95:18 98:10	component 84:17	191:5
93:10 97:1,7	98:12 99:1 102:16	98:7 118:10	congress 13:16
99:13 101:4,16	102:20 114:10	124:14 193:21	29:17
102:8 105:19	118:1 137:12	203:12	connect 136:5
106:7 109:7,7	148:7 154:10	components 118:4	138:21 139:15,16
112:3 150:1,19	157:12 166:6	166:18,20 167:13	connected 137:7
156:1,7,9,19	174:7 175:5	200:13	137:11,15
157:21 158:9	191:10,17 195:14	compounding	connecting 138:7
161:1 192:20,20	201:7 202:3	207:10	157:11
193:3 211:17	205:18 207:10	computer 36:17	conscience 93:17
212:5	208:2,20 209:8	concepts 174:8	consequence
comment's 81:12	210:1	concern 209:7	94:18
comments 32:16	community's 82:9	concerning 133:4	consequences
36:9,18 37:13	211:4	concerns 41:15	43:4 54:4,15
38:8,10,14,16	commuter 74:17	205:19	125:14 126:21
39:6 42:13 45:9	compare 58:1	concerta 30:13	150:11
45:10,13 52:11	comparing 12:7	conclude 219:3	consider 14:4
72:12 77:17 78:3	compartmentali	concluded 220:12	50:12 52:11 76:11
81:8 82:6 91:14	152:11	concrete 132:3	113:13 132:8
91:17 92:16,20	compassion 57:9	197:11	154:17 188:4
96:18 97:12	94:2 96:7	condition 18:19	189:16 212:13
100:19 102:4	compassionate	18:19 20:13,15,19	considered 32:6
103:11 108:3,8,13	219:20	21:2 56:8,12 96:8	32:12 156:12

198:11	contributing	counsel 221:10,13	coworker 128:1
considering 31:19	154:15	222:7,10	crack 51:12 53:14
188:2 189:14	control 24:12 26:2	counseling 182:15	55:19 68:2 88:14
consistent 195:20	26:4 43:2 94:14	200:21	105:6 124:8
consisting 132:14	130:14 150:5	counselor 126:1	141:14 153:7
constant 61:20	184:4 190:1	127:16 133:3	crackhead 99:21
63:3 67:11	controllable	138:5	crap 208:12
constantly 177:19	163:12	countering 123:9	crash 75:10
consumer 104:18	controlled 42:21	country 71:12	170:13,14
104:19	43:3 212:17	84:4 118:13	craving 25:15
contact 89:1 144:1	conversation	couple 53:2 75:9	84:17 89:20
144:3,4	41:11 51:18 104:4	86:4 122:15	173:14 188:7
contain 23:13	106:15 142:12	139:10 169:8	cravings 54:5 66:1
contamination	216:4	210:14	66:14 70:9 84:21
153:6	conversations	coupled 123:1	87:4 121:15
contemplate	119:15	coupling 120:5	123:18 124:17
106:11	convinced 153:9	courage 14:6	131:11 146:14,19
context 17:21	convulsions 29:14	53:11	167:5 170:11,18
23:20,21 33:18	cooccurring 136:9	courageous 35:8	193:18 214:13
51:18 96:10	136:11 140:19	courageously	create 54:4,12
195:10 203:7	coordinate 12:17	157:18	139:19,20
contingence 51:8	coordinating	course 70:11	created 55:16
contingency	45:11	150:8,13 154:3	103:18 211:19
157:15 166:12	coordination 8:13	179:4 182:10	creates 37:1
215:11	cope 28:11,18	204:3	105:13
contingent 47:7,7	73:16 185:13	court 137:2,4	creating 55:20
continuation	coping 28:20	138:4 171:6	137:20
187:11	145:15 202:8	coverage 133:15	credit 210:8
continue 9:11	214:6	covered 131:3	crime 100:6,11
13:11 14:1,17	corner 7:8 75:7	covid 6:17 8:14	criminal 54:13
15:3 19:15,16	77:20 149:8	9:11,12 12:8	96:4 100:14 105:5
77:2 85:17 121:20	165:10 177:16	36:11,14 73:12	105:7 109:18
153:12 185:15	corps 8:1	133:19 134:13,14	120:9 214:21
187:6,6,7,8,9,12	correct 63:6	134:16 139:18	criminality 206:1
218:21	corrected 176:9	177:14 188:12,13	criminalization
continued 66:15	correctly 159:16	189:5,5 190:8,10	100:10 109:16
66:15 67:10 70:20	160:19	190:19 191:6,8,17	criminals 109:19
continues 9:18	corresponds	192:18 198:16,16	crisis 9:17,18 10:7
130:1	24:14 27:12	199:4,11 203:3,7	97:9 122:2,2
continuing 12:21	cost 65:18 66:5	203:15 204:6	124:12
26:10	133:7	205:12,19 207:12	criteria 25:1,4
continuity 142:11	costing 162:2	208:1,11 209:10	27:11
contract 119:21	couch 139:5	211:19 216:20	criterion 25:17

critical 8:21 9:14	d	218:9	defense 208:9,15
14:14 17:17	d 5:1	dbt 167:13	defensive 8:19
161:13 166:9,21	d.c. 50:20,20	dcyf 144:14	deficit 163:1
167:13 217:12	88:11	168:17	define 17:10 78:15
crossing 51:4	dad 53:14	dd 145:7	defining 78:14
crummy 85:2	dad's 59:7	dead 154:1	153:16 154:8
crying 139:5	daily 6:12 18:20	deal 9:11 65:5	definitely 45:16
crystal 6:6 57:3	20:15 35:15 37:16	73:15 89:11 124:3	99:2 144:9 152:6
65:10,14 66:3	41:20 52:2 61:19	128:15 170:10,12	154:17 157:20
67:1,3 68:2 79:3	64:4 68:8 82:18	178:9	212:5
81:5 87:9 88:16	83:12 88:5 90:4	dealing 68:6,8	definition 23:17
92:5 95:10 103:1	92:2 104:10 124:3	124:11 126:12	definitions 23:17
103:8 125:8,9,11	126:8,11 128:11	140:20 177:15	degree 23:10
127:18 128:2	131:14 196:3	dear 67:15	154:4 169:21
158:3 213:17	214:18	death 29:15 74:15	delay 37:19 47:1
cue 172:7	damage 55:9	121:2 206:11	191:2 192:15
cultivation 175:4	67:10 97:10 215:2	207:2	delivery 159:8
cultural 116:18	dangerous 11:14	deaths 9:13 11:5,7	demanded 125:17
culture 101:8	26:10	11:9,17,19 30:19	demographic
174:3 177:6	dangers 74:20	decade 71:11	46:19
cup 147:5	132:18	decades 53:2	demographics
curb 123:18	data 10:17 11:4,18	198:9	50:20 51:5
curled 139:5	12:16 100:12	decay 202:17	demonized 71:12
current 6:15 21:3	date 19:20	december 38:20	115:1
35:21 80:3 83:17	daughters 114:5	112:14 218:4	demonstrating
86:16 93:20	david 3:7 172:11	decided 66:19	218:16
101:10 112:20	172:14,18,21	67:8 136:14,14	denial 106:10 129:15
154:9 158:1,7 170:1	175:9	deciding 209:1 decision 18:1 42:5	dental 29:12 63:4
	dawn 51:12	219:12	95:15 191:1
currently 18:20 20:13 24:15 31:5	day 7:5 10:20	decisions 17:4	deny 104:18
80:4,12,14,19	35:16,16 36:16	33:2 131:19 132:3	department 2:4
82:15,18 83:11	60:21 61:1 67:1	133:4	7:20 12:13,18
106:17 177:13	83:13 85:10,11	declaration 12:9	departments
cursor 192:11	86:5,7 88:20 91:3	declared 10:9	157:12
curveball 106:21	91:4,6 92:3,3	declined 125:21	depend 133:9
custody 130:14	118:16 120:4,5	decrease 30:4	dependence 24:8
cut 26:8 175:11	128:4 143:5 156:2	189:18	24:9,11 25:1,4
178:13	185:18 196:1,1	decreased 24:10	27:13 94:14
cycle 68:16 89:9	197:8,8 200:17	27:17 188:7	dependent 70:11
126:9	203:21 204:17,17 days 35:17,18	deep 197:14	70:19 86:2,6
	91:4 102:11 117:3	deeper 119:3	depending 83:8
	121:17 127:1	148:21	110:12 141:11
	130:18 210:4		
	130.18 210:4		

deployed 145:3	detoxes 75:18	difference 82:10	dina 91:20 92:6
168:18	detrimental	105:5 131:16	direct 59:20 124:6
deploying 191:12	194:11	differences 29:6	directed 27:6
deployment	detroit 70:2	94:4 95:14 117:2	81:12
168:20	develop 13:5	different 13:4	direction 68:15
depressed 28:19	16:19 22:5 27:7	19:19 20:8 21:6	76:11 177:1
depression 68:1,9	58:16 213:15	21:11 25:8,14	directly 20:18
69:17 70:20	developed 32:21	28:10,14 30:1,2	21:20 22:2 62:13
109:12 124:2	160:7	31:4,14,18,20	63:17
194:20	developer 40:21	41:8 58:8 66:21	director 5:6,17
depressive 68:4	developers 21:18	71:8,19 73:13	8:19 43:1 44:3
describe 55:4	37:5	79:2 83:7 84:21	212:17
102:19	developing 8:5	89:21 94:4,5,20	disability 139:10
described 22:7	58:17 156:13	117:1 123:19	disagree 116:4
41:18 150:4	160:12	128:16 137:7,12	disagreement 10:5
208:11	development 1:1	141:16 142:7	discharge 168:13
describes 48:8	5:4,6,10,20 15:15	153:2 162:15	168:18
deserve 57:10	16:6,8,14,18,20	175:4 177:6 193:6	discharged 144:12
136:15	17:4,6,9,10,14	193:13,14 196:13	145:8
deserves 174:12	19:3 20:7 21:14	207:2,16 216:7,7	discharging
design 191:21	22:20 31:10 34:1	differentiate	144:17
designing 159:12	42:5 43:4 66:17	196:9	disclosure 168:13
desirable 29:8	68:10 78:7 111:20	differently 89:14	disclosures 144:13
30:3	167:11 213:8	95:16 129:3	discomfort 141:6
desire 25:16 66:14	217:11,13 218:8	differing 41:8	146:15
76:6 89:20	220:5	difficult 54:2,16	discriminated
desired 24:3 92:14	devices 31:7	56:4,18 77:12	81:16
desperate 128:10	dexedrine 30:12	124:7 141:7	discrimination
desperately 61:14	dextroampheta	158:16 159:5	57:7 105:2 205:21
61:14	30:11	190:20 201:14	discuss 31:12
despite 26:10,15	diabetes 55:21	202:9 211:19	33:20 218:10
destigmatize	diagnosed 12:11	219:12	discussed 215:1
219:18	26:20 27:1,11	difficulties 214:19	215:15 216:11
detecting 31:21	63:10 136:20	difficulty 49:7	discussing 37:14
detects 32:2	141:3,8 214:5	165:14 200:9	174:6 205:18
deter 218:13	diagnoses 136:21	dig 94:1 148:20	discussion 6:8
determinants	186:1	digital 46:9 221:8	20:20 21:9 36:8
105:3 141:15	diagnosis 25:8,13	222:3	36:11 37:10 41:12
153:15 169:17	25:20 27:4 140:21	dimensional	41:19 42:5,7
196:18 206:4	diagnostic 24:18	141:13	46:13 50:17 64:15
detox 75:15,15	dichotomy 105:14	dimensions	69:3 93:1 105:21
76:3 121:1 122:10	die 85:15 122:10	167:10	113:4,8 175:7
158:3	139:7	diminish 71:5	176:3 188:10,11
			220:6
		1	

discussions 5:8	152:21 156:14	distinction 161:10	double 61:1
18:7 22:1 34:21	157:15,17 159:17	distracted 68:5	downer 123:8
218:20	159:21 160:6,8	distractions 217:2	downhill 84:14
disease 10:6 19:6	163:7 166:3,4,4,8	distress 24:13	downward 206:19
19:9,19 21:15	166:14 168:16	145:15 198:5	dozen 130:17
22:4 43:9 56:1	170:8 173:3,4	distressful 207:8	dr 2:4,6,7,9,10,12
75:21 81:17,19	176:8 180:8,12,18	distribution	2:13,14 4:4,5,6,7
106:10 121:7	184:6 187:3 192:1	126:15 161:10,11	5:17 6:2 9:5 15:13
123:10 125:19	194:4 196:12	dive 119:3	15:16,17,19 16:4
128:15 129:6,16	202:1 203:6	diversity 165:7	22:16 23:2,5,6
164:16 211:2	204:21 213:9,9,13	188:6	32:18 34:11 42:18
217:17	213:21 214:11,17	division 2:7,10,12	42:19 43:11,12,17
diseases 95:5	215:2,6,14,19	2:13,14 6:2 23:8	43:19 44:1,2,7,8,9
214:16	216:3,14,19,21	32:20 43:14,20	44:11,12,20 93:4
disorder 1:2 5:5	217:13,16,21	44:3,4,10,14 45:2	93:8,9 149:3,7,16
6:5,9,13,16,18 7:5	218:8,21 219:1,6	159:10	149:19 155:21
10:6 12:12 13:6	219:11,13,18	divisions 16:21	157:3 158:19
14:13 15:10 23:5	disordered 196:9	divorce 130:14	159:2 160:21
23:12,18 24:16	196:10	docket 38:18,20	163:18,19,20,21
25:7,10,10,19,19	disorders 8:10	39:7,9 102:5	172:2,6 192:12
25:20 26:1,20	9:13 10:4 11:14	111:16 112:13	194:14,15 198:12
27:1,9,11 30:14	14:9,11 15:9	doctor 60:15 62:1	212:16 213:1
31:1 32:21 34:15	24:19,21 25:13	119:19,19 143:7	dramatic 54:10
35:14,16 36:1,12	28:8 95:18 105:17	178:1	dream 166:6,8
37:7,8 40:11	109:15,17 117:12	doctor's 191:3	dreams 27:21
41:17,19 42:9	122:6 140:20	doctors 33:16	179:12
43:5 48:20 50:11	159:14 181:3	120:1 197:19	drilldown 160:14
52:3,18 53:1,3,14	218:17 219:15	documentation	drink 162:20
54:18,21 57:2	disparities 8:8	145:8	drinking 176:20
58:9,17 60:3,4	dispel 116:9	dogs 102:9	215:16
65:4 66:13 71:4	dispensaries	doing 9:8 32:9	driven 11:20
75:5 76:1 77:3,14	201:13	66:7 73:13 74:18	driver 105:12
82:7 92:11 93:12	dispensary 146:7	93:20 142:4 147:6	drives 87:3
93:13 94:7,8,10	disposition 13:10	179:12 190:6	driving 65:15
95:4 98:8,17 99:3	disrespectful	197:6,11 217:15	196:5,8 212:19
99:4 100:4,6,11	186:15	219:17	dropped 149:10
100:13 102:12,19	disrupted 202:15	dollars 13:14,18	drug 1:1 5:4,6,7
104:8 109:17	disrupting 200:10	66:2	5:10,18,20 11:12
112:21 114:19	disruption 200:3	door 74:9	11:12 12:2,7
115:3,12 119:13	disruptions 200:6	doors 145:2	15:15 16:6,8,18
120:8 122:1,4,8,8	disruptive 201:5	dopamine 10:16	17:4,5,9,10,14,14
122:9,13 130:7,8	distanced 209:5	71:15 132:18	19:2 20:7 21:14
135:7 137:21	distant 62:17	dose 143:8 178:5	21:17 23:19,21
140:3 141:2		183:13	24:1,7,7,9,12 26:2

26:6,18 30:18	dutchess 191:11	167:16 208:2	emotional 61:15
32:3,7 43:14	duty 184:19	effective 31:6	71:7 186:2,5
44:15,16 45:3	dvt 137:8	115:5 116:17	193:8
61:20 62:6,13	dysphoric 27:20	133:17 157:16	empathy 57:9
70:12,19 78:7	dysregulated	162:3,19 169:1,2	94:1 96:7
84:19 88:13 95:3	196:4 197:7	174:15 189:20	emphasize 111:10
98:13,13,15,15	e	195:5 213:15	155:3 215:20
104:15 105:9		effectively 12:17	employed 145:5
106:18 111:20	e 2:1,1 4:1 5:1,1 ear 40:6	146:18	221:11,14 222:8
119:14,16,17	ear 40:0 earlier 12:1 50:19	effectiveness	222:11
121:19 126:14	92:8 93:10 95:6	16:16 218:16	employee 185:15
127:16 128:6	107:10 116:20	effects 6:12 24:2	221:13 222:10
129:19 131:14,19	119:12 145:3	26:3,7,18 29:7,8	employers 114:10
139:3 142:17	150:7 151:19	30:3 35:15 41:13	employment 62:8
143:13,15,16	150:7 151:19	41:20 52:2 53:21	146:7 206:5,10
153:8 154:6	177:10 203:17	54:3,3,8 55:12	empower 132:2
160:12 162:2	208:11	64:5 81:20 124:2	185:2,9
191:14 212:18	early 60:6 61:11	163:2,2 167:6	empowerment
213:8 217:11,12	63:5,10 97:11	174:20 207:9	37:3
217:19 218:1,1,10	108:4 110:19	208:13 209:10	empowers 131:18
220:4	127:1 140:17,18	214:12 215:12	empty 39:18 90:4
drugs 11:15 16:17	142:14 143:17	efficacy 193:9	enabled 114:6
16:19,21 18:3	150:4,12 152:5	effort 14:1 19:3	115:7
29:3 42:21 43:13	166:8 168:15	217:12	encounter 137:2
44:5 59:19 65:20	176:6 204:17	efforts 5:21 8:14	encountered
66:7 73:8 74:15	206:13 210:15	9:12 12:14,20	128:5 146:4 148:8
87:20 89:18 99:4	easier 48:16 89:13	13:20 53:3 71:2	encourage 21:17
107:5,17 126:12	133:21	111:21	38:13 39:4 198:1
130:10 132:17	easily 185:17	eight 126:10	205:15
140:19 142:1,10	easing 188:12	either 7:7 53:9	ended 55:20 92:3
180:11,14 181:6	east 65:16	77:19 81:3 122:7	126:4 128:12
192:9 195:4,5	eastern 110:15	139:7 155:5	176:21
218:16	easy 196:2	184:18	endpoints 218:15
dry 67:11	economic 133:5	elective 191:6	ends 95:4
dsm 24:19 25:7,12	206:20 216:13	electronically	energy 28:12 30:4
25:18 28:7	economical 31:3	111:13	60:11 61:7 62:4,6
due 25:3 29:16	ecstasy 67:3 87:9	elicit 10:1	66:6 88:9
69:16 106:11	120:13	elizabeth 197:20	enforcement
153:6 206:18	educating 81:19	embarrassed	114:11
207:11	education 96:1	56:10 126:18	engage 94:2 150:9
duke 218:5	109:10 131:8	emergency 10:10	engagement 15:2
duly 221:5	132:14 157:9	12:8	45:1 153:14
duration 145:21	effect 24:4,4 147:2	emerging 195:13	166:20 191:19
163:11	148:1 163:10		

engages 118:17	104:5 122:5	excited 51:21	24:13 34:6 35:7
engineers 17:2	essential 169:14	exciting 13:8	36:2 40:8 41:9
enhance 28:11,13	essentially 204:10	executive 8:12	52:4,6,8,17 53:11
enhanced 114:4	204:14	exercise 70:21	53:17 64:11,17
enhancement	established 12:19	99:18	68:18 69:16 77:8
58:15	19:4,7	exhaustion 61:15	77:10,21 78:3,17
enjoy 187:13	esteem 193:8	61:16	79:7 80:10 82:10
enjoyed 137:14	estimate 49:19	existing 180:14	110:20 112:5,21
enlightening	etcetera 102:11	192:2	113:5,7,16 125:4
159:4 164:2	euphoria 27:17	expand 13:11	143:3 148:15
enroll 31:10	29:8 30:5 61:12	expanded 12:13	150:6 153:5 164:2
enrolled 129:7	evaluate 16:16	133:21	165:17 168:12,17
ensure 13:21	evaluation 5:7,19	expect 28:17	175:18 189:5
17:11	16:14 17:14 45:3	119:8 133:8	203:3,6 214:21
ensuring 42:1	125:18 212:18	expected 133:6	216:13 219:11
enter 46:9 150:10	eve 136:13	expensive 70:13	experiencing 24:4
entered 120:15	evening 220:10	experience 14:3	24:5 26:10 157:16
144:15	event 1:9 69:7	14:14 21:5,10	195:19 207:11
entire 73:15 84:12	213:10 220:10	23:11 24:1,10	experiment 70:6
114:6,21 145:21	events 153:21	27:8 34:15 38:7	experimentation
173:8	eventually 62:1	39:15 40:10,10	183:11,15,19
entirely 67:6	87:12,16 88:1,4	48:8 50:10 52:10	experimenting
entities 219:21	89:6 90:3 117:5	59:7,7,9 60:2 71:1	65:7
entitled 148:10	123:3 160:17	72:20 78:12 84:20	expertise 34:16
entitlement	177:2	90:18 92:2 93:19	72:10
155:11	everybody 5:3	97:6,6 105:13	expertly 12:20
entourage 148:1	20:21 47:14 59:15	119:5,21 127:17	experts 34:16 35:2
environment	79:5 92:18 136:4	140:9,10,16 142:6	35:3,7 36:5 174:1
117:20 143:2,19	140:13 198:3	143:18 144:6	180:9 218:6
145:16 169:16	211:14	152:11 153:20	explain 6:19 57:12
185:8	evidence 14:18	158:1,12,14 164:7	103:5 183:21
ephedrine 29:18	17:6 18:2 198:7	164:14,19 170:19	explanation
epidemic 8:7	evolve 9:19	177:12 179:16	173:17
29:17 58:1	exact 11:10	180:17 184:2	exponential
epidemiologist	exactly 50:4 109:9	185:9 190:19	124:10
44:13	171:16 184:1	194:12 195:10,15	exposed 67:19
epidemiology 2:14	examiner's 207:3	195:18 196:8	exposing 89:17
44:14	example 32:1	197:1 203:13	expressed 41:2
epiphany 171:7	117:18 121:16	205:10,12 208:18	extend 14:15
equal 100:13	examples 26:4	210:16	extensive 18:12
error 170:21	219:12	experienced 21:1	extent 93:1
es 221:4	excellent 170:4	205:14	external 98:10
especially 34:3	exchange 177:3	experiences 7:4,7	externally 19:8,12
43:6 93:12 97:8		17:12 20:18,18,21	20:3

[extreme - first] Page 15

extreme 62:2 63:4	false 105:13,14	219:17 220:1,8	fields 35:2
extremely 65:5	familiar 24:14	fda's 5:20 16:13	fight 164:15
74:13 109:11	46:19	16:14 17:17 19:6	figure 127:2 151:9
124:7,12 127:6	families 53:8	19:10 213:7	171:13 186:4
207:8	57:17 59:3 102:14	217:12	197:6,8,13 203:21
eye 45:9 89:1	102:21 155:6,17	fear 155:8 208:16	figured 114:16
110:11	199:21 201:19	feature 7:7 36:19	figuring 121:15
eyes 179:8	215:2	features 154:9	filling 217:4
f	family 19:14 39:6	february 11:9	final 72:19 179:17
f 3:4	40:2,11 42:11	fed 141:9	211:9,11,17
face 9:11,14	43:7 48:20 53:6	federal 8:16 15:2	218:15
108:14,14 126:21	54:11 62:16 72:21	20:8 38:18 111:16	finally 36:10
184:5	78:13,14 96:3	146:6 212:14	66:18,18 70:16
faced 9:18	126:13 136:7	220:1	141:3,8 171:2
facet 114:4	146:2 165:13	feedback 47:15	220:3
facilitate 43:4	175:19 176:4	78:9 140:14	finances 87:21
139:20	179:18 180:4	175:14	financial 117:19
facilitated 21:8	185:8 202:5	feel 37:3 40:3	145:14
facilitating 220:10	213:19 219:6	56:10 57:21 58:5	financially 221:15
facilitator 5:8	fancy 57:7	76:2 86:7 92:14	222:11
134:4	far 61:19 84:16	94:6,16 95:6,17	find 55:1 58:21
facilities 155:16	165:18 166:10	97:19 101:9,12	62:3,6 68:15
164:6	203:15 204:17	103:13 112:1,2	76:20 91:16 92:10
facility 132:16	farchione 2:12	138:17,20 147:13	102:10 117:13
136:10,19 138:11	44:1,2,3,10	153:14 184:4,15	123:20 127:17
facing 130:14	farther 141:14	191:4	136:7 143:15
fact 63:11 67:18	father 55:18 123:3	feeling 61:12 85:9	163:10 178:6
68:10 81:15 115:4	173:7	122:16 170:13,15	192:5 215:18
115:9 123:1	fatigue 27:21	feels 57:4	finding 65:3 90:1
131:18 162:2	favorite 85:4	feet 101:14,15	176:21 203:13
177:21	89:18 160:1	fellow 35:6	fine 182:5
factor 154:16	fda 2:3,6,9 5:4,8,9	felony 137:3	finish 36:10
factors 133:5	8:17 13:20 14:21	felt 68:3 73:20	178:17,20
206:10	15:14,16 16:7,19	75:11,11 87:11	finished 174:19
failing 96:9	23:15 32:19 33:1	123:5 128:12	fire 136:16
failure 30:8	33:21 37:4 38:20	143:9 145:17	firmly 95:20 96:1
116:10 155:11	40:13 42:3,16,16	155:11 177:8	first 6:11,20 8:18
216:10	43:1,16 44:4 45:6	fentanyl 11:15,21	23:16 29:5 33:7
faint 180:2	52:20 59:16 64:7	12:4,10 73:5	35:10,13 46:20
fairly 60:6 162:3	93:3,15 111:21	153:6 191:13	50:17 51:20 53:20
faithfully 22:6	119:1 140:14	fertile 143:10	59:5,15 63:11
fall 196:2	148:18 149:12	field 35:3 69:9	73:10 79:2,11
fallen 21:7	189:3,9,10 217:18	71:11 77:14	98:1 110:18 113:8
	218:4,14,20 219:3		120:21 125:10,12

Public Meeting October 6, 2020

[first - gained] Page 16

128:3,4 129:8,11	focuses 188:7	formats 175:5	free 97:19 130:10
130:11 135:17	focusing 52:21	formed 144:7	freely 159:21
138:11 142:5	68:11 71:2 94:13	former 127:21	161:13
144:19 146:4	fold 12:3,6	forms 13:7 93:21	freer 177:6
149:19 153:4	folks 103:10 147:7	180:19 181:5	frequency 83:3,5
159:15 170:16	157:16 165:13	formulated	83:7,14,19 87:4
171:14,17 178:1	166:11 195:14	218:12	90:15,19
199:2	200:5 201:5	fortitude 116:7	frequent 216:16
firsthand 21:5	follow 15:20 21:16	fortunate 13:5	frequently 82:16
60:2 214:1	40:15 45:7 93:6,7	135:3 173:4	84:6
fit 17:9 48:5 58:13	118:16 119:2	fortunately 169:8	friend 67:16 73:9
117:10,13 118:1	150:1	forum 15:1 53:7	128:1 169:9
133:9 138:12	followed 20:14	forward 22:12	friendly 163:12
198:3 212:1	21:2,7	32:16 45:16 50:14	friends 39:3 54:12
fits 118:11 132:13	following 92:15	57:6 77:15 102:2	60:7 62:17 126:13
147:12	181:12 188:3	112:11 119:3	127:7,8,13,16
fitting 117:11	189:15	127:14 146:5	128:12 201:18
five 52:3 56:6 65:1	follows 21:9	218:21	202:6 215:2
204:11	force 12:19 89:8	found 12:3 19:8	front 74:16
fixed 158:20	143:6 164:5,6	59:19 66:1 67:18	frontline 204:10
flaw 10:7	196:5 212:19	68:13 75:6 76:13	frustrating 124:12
flexibilities 13:12	forced 143:4	76:15 94:21	201:11
flexibility 13:17	206:14	117:10,21 121:21	frustration 201:1
flipped 34:18	forces 144:9,13,18	125:16 128:13,15	fuel 128:13
floor 9:4 177:17	168:12	129:14,18 144:14	fulfill 42:4
fly 108:12 179:11	foregoing 221:3,4	144:17,21 145:3	full 5:11 89:10
focus 6:12,14,17	222:4	146:5 154:1	104:12 105:15
10:13 13:18 20:14	foreign 177:3	162:18 171:17	118:9 143:3 174:2
21:19 35:13,21	foremost 53:20	176:5 178:2,5	fully 7:3 94:3
41:12 42:2 52:1	forever 112:8	foundation 137:20	144:12 214:19
60:19 66:6 68:18	177:20	169:18	fun 99:18
112:20 128:16	forget 179:9	foundations 138:7	function 190:1
139:11 158:5	forgets 185:17	founded 169:9	functional 32:8
161:3,7 193:19	forgetting 189:8	founder 53:6	147:3
197:10 214:5	forgivable 133:6	four 26:1 27:11	fundamentally
focused 1:1 5:4,6	forgive 54:18	50:6 73:4 74:3	183:21 191:4
5:10,20 7:3 15:14	forgiveness 55:2	95:1 123:1 142:21	further 163:19
16:6,7 17:9,10	form 39:17 173:21	146:1 200:5,8	215:1 221:12
19:2 20:7 21:14	174:14	204:12 210:4	222:9
41:19 62:5 78:7	formal 153:14	fractures 178:11	future 36:3 113:2
88:9 94:9 128:2	format 6:19 20:10	frame 117:17	g
173:9 202:11	21:16 90:13 174:3	118:12	g 5:1
217:11 220:4	210:13	framework 93:15	gained 65:9 135:8
		99:5	135:8
			155.0

[gainful - great]

Page 17

gainful 146:7	107:1,14 108:20	209:3,16,17 211:3	212:16
galipeau 3:3 104:2	110:17 158:21	211:15 212:21	gong 210:9
140:12 152:18	163:1 172:15	goal 10:11 32:4	good 5:2,2 9:5
162:9 168:9 183:7	181:21,21 185:11	goals 132:5	10:12 20:19 21:8
190:16,18 195:12	189:12 190:4	goes 76:2 110:12	23:6 42:19 44:8
205:9 207:14	210:7	203:15 215:8	44:12 45:14 49:3
gateway 120:16	given 41:10	going 5:12,12 7:15	50:9 51:5 53:21
120:17 154:6	129:19 177:9	7:16 15:20 16:5	59:14 69:8 83:13
gay 127:18 128:13	178:12	22:14 33:7,10,11	83:16 86:15
151:7 152:10	gives 19:1,17	33:20 35:7,13,21	103:15,21 105:19
171:15	50:21 51:4 64:2	36:6,10 37:18	111:6 113:17
gender 144:5	giving 16:12 34:20	40:5,9 41:12	114:9,12 115:2
154:15 216:12	50:13 157:17	42:18 45:5 46:16	122:16 125:6
general 23:17	169:17	46:18 47:2 48:18	126:15 127:11
24:15 25:21 104:8	glasses 177:5	49:3 51:16 59:8,9	129:13 139:12
118:13 141:5	global 134:6 170:3	63:2 64:12,13,16	140:6,12 147:21
174:1	go 23:16 34:19	65:11 69:2,5	152:3 160:14
generally 180:21	38:1 39:10,21	72:19,20 76:11	163:21 172:7
generation 114:21	46:8 51:16 61:5	77:1,11 78:8,19	188:6 192:20
genetic 141:4	62:3,6 66:2 73:18	78:20 82:21 85:3	198:8 220:11
gentleman 69:21	74:4,13,13 76:18	85:5,6,7 93:2,3	gorman 197:20
158:10 181:9,16	77:13 85:5,14,18	97:16,21 99:5,12	gotten 81:11 85:16
gentlemen 69:19	86:5,6 89:1 91:21	99:15,17 100:19	133:21 135:6
geographic 126:6	92:5 98:5 99:14	101:21 102:2,18	145:1 151:18
getting 26:6 41:17	99:16 101:2,5,21	105:20 106:3,16	203:19
47:12 49:5 56:15	102:6 104:13	110:10 112:19	government 8:16
89:9,10 91:2	107:3 108:17	113:9,15,15 119:2	14:18 15:2 21:18
94:14 120:19	110:10,15 113:21	119:4,5 122:3	grab 111:7 164:20
127:5 135:10	125:5 129:10	123:12 125:1,3,4	grades 176:16
139:11 168:18	133:1 139:8 149:6	130:4 134:18	gradually 92:2
174:5 180:2	149:14,14 150:20	139:7,14 140:9,10	grasp 89:10
192:16 193:19	150:21 155:20	142:6,14 149:11	grateful 51:12
206:16	159:12 160:12	152:16 156:4	53:8 72:9,10,11
girlfriend 154:1	163:20 164:10	165:5 168:4 171:1	130:1 135:3 219:5
giroir 2:4 4:4 5:14	165:5 168:7,7	172:6,9,10 175:16	gratitude 14:15
7:17,18 8:11,21	169:20 172:7,17	175:17 176:21	64:7
9:3,5 220:7	174:21 175:16,17	177:16,18,18	gray 1:20 221:2
giroir's 5:16	175:19 176:19	178:13,16 179:16	221:18
give 15:21 16:5	178:20 179:4,19	181:18 182:1	great 9:7,20 44:19
20:6 33:18 38:4	181:13,17 182:6	192:14 196:15	45:17 47:13,18,18
47:2,14 49:6,19	183:4,5 184:15	198:20,21,21	50:1,9 51:15
52:13 74:7,8,9	185:7 191:3	203:2,21 204:1,20	79:13 80:18 81:21
75:19 79:5,13	197:16 203:1,5	207:20 209:12	82:1,12 86:20
80:17,19 82:18	204:4 205:8 209:1	210:4 211:8,10	92:17 97:4,13

[great - heart] Page 18

99:11 100:18	guess 67:18 85:20	199:15	211:4,5 214:6,11
106:15 109:21,21	88:2,6 149:10	hard 15:3 54:6	214:15,16,16
118:21 119:7	150:3 182:20	56:19 72:1,7	215:12,13
138:1 149:14	guessing 83:13	81:17 95:12 97:9	healthcare 21:18
151:1 152:14,14	guidance 218:15	102:10 159:5	40:21 42:1 96:4
154:11 155:18	guided 183:12	165:10 166:1	109:11 117:20
156:20 158:17	guilt 155:12	197:10,16 201:6	133:8 159:8 161:4
160:20 162:8	guise 115:2	203:20 211:6	166:11 167:11
163:17 168:2	guy 116:2 204:14	220:9	215:12 216:17
172:21 173:2	guys 47:16 48:14	harder 55:8 166:1	healthier 8:3
178:4 179:14	50:11 60:1 78:1	harm 69:10,12	healthy 8:6 63:16
181:18 184:7	98:3 104:3 108:12	158:5 169:8 218:6	166:19 202:2
186:10 189:2	110:21 111:1	harsh 70:8	hear 5:17 15:21
192:10 193:1	113:20 148:10	hat 40:10	16:1,3 20:1 21:9
198:19 199:17,17	149:7 164:16	hate 85:3,6	21:20 22:2 32:19
202:18 211:7	165:1 182:1	hats 40:7,8	34:17 37:20 40:1
212:7	h	he'll 5:14	52:9 53:4 64:19
greater 19:10 57:4	habit 127:2	head 88:18 100:2	71:17 72:20 80:21
118:4 134:2	haldol 74:7	100:16	91:10 111:11,14
greatly 19:13,16	half 142:21 178:12	heal 195:17	116:3 130:4
green 182:15	hallucinate 73:18	healing 185:15	149:17 150:15
grew 60:3,5 151:7	hallucinations	207:16	159:5,20 165:6
griesel 3:6 134:20	28:4	health 2:4 5:14	172:19 175:21
184:9	hallucinogens	6:12 7:19,20 8:1,2	176:1 178:18
grinding 63:3	65:8	8:5,8,12,14 9:17	179:21 183:5
grisel 134:21	hampton 205:17	10:7,10 16:15	186:16 190:13
ground 56:9 143:6	hand 28:18 76:2,2	24:19 31:3 35:15	192:20 194:15
143:10	handed 132:20	41:13 43:4 52:2	198:15
grounded 14:17	handle 38:11	54:8 55:20 56:8	heard 14:7 22:6
group 30:9 43:1	197:4	56:12 63:1,8,13	35:1 37:4 78:2
70:6 126:2 127:13	handoff 194:7	63:19 64:3 67:5	79:7 80:9 84:7
128:5 131:1 137:8	hands 9:1 160:2	70:13 96:8 105:16	93:7 110:8 125:15
139:21 142:16	happen 37:7 56:12	126:12 127:15	160:3,3 164:14
144:5 162:4	60:20 62:7 175:5	136:19,21 137:3	165:20 167:16
166:17 169:10,11	happened 55:1	139:11 140:19,20	200:18 202:3
218:5	136:13 153:10	141:15 153:16	213:6,15,19 214:2
grouped 46:4	171:8 184:1	155:16 157:9,12	214:10,17 215:5
groups 24:21 26:1	happening 161:21	157:12 158:7	216:2,20 219:12
43:8 117:1,6	happens 115:21	167:2,6 169:17	hearing 6:1 7:3
137:12,17 139:18	117:17 161:10	170:3 174:14	22:12,12 90:16
181:4 185:6 201:2	162:2	184:14,18 193:4,9	135:19 157:13
201:8 217:9 218:7	happy 86:19 92:20	193:21 194:3,7,20	heart 27:18 30:6
growing 88:3	109:6 114:8	196:4,17,18	55:15,17 56:1
176:6,14	171:16 183:5	200:14 206:4	67:17 167:9

heartbreaking	190:12 192:12	hit 157:6 206:8	horizon 197:18
156:18	193:5,17 194:2	211:5	hormones 176:15
heartrate 74:13	202:19	hiv 8:6 63:9	horrible 135:15
heathy 56:19	helping 54:18	hocking 85:4	195:19 196:4
heavily 143:2	195:17 215:18	hold 22:18 47:6	horrific 208:13
heavy 110:9	helps 17:15 42:8	164:20	hospital 74:5 75:2
held 142:3 146:2	185:18	holding 171:5	75:8,8,9,12 85:14
174:17 195:17	hereto 221:14	holistic 15:3	85:18 138:18
218:4	222:11	118:17 187:7	139:8
helicopter 179:11	heroin 53:15	home 26:14	hospitalization
hello 45:14 64:18	55:14 67:2 70:10	130:15 136:13	191:7
73:1 111:4 130:5	71:12,14 72:5	140:3 142:16	hospitalizations
179:21	88:15,16 135:12	homeless 144:15	67:14
help 10:12 14:3	135:14	144:18 148:9	hospitalized 70:14
15:4 17:11 32:14	heterogeneity	homelessness	85:12
34:9 37:12 43:8	31:19	144:21 145:21	hospitals 138:15
54:14,17 57:6	hey 149:7	158:11,15	host 206:10
58:20 60:19 65:21	hhs 12:13,20	honest 123:13	hosting 140:14
66:13 68:15 73:17	13:11,21 14:8	127:12	hours 65:14
74:3 75:10 77:14	hi 43:12,19 44:2,8	honestly 59:20	145:17
80:16 96:8 106:1	44:12 73:1 81:10	171:4 181:20	house 74:2 99:21
107:14 126:19	84:1 134:20	190:20	208:5,16
127:9,14 129:5,17	149:16 159:2	honor 15:20 33:14	household 10:17
132:4 135:1,6	194:15	59:21	housekeeping 7:2
136:7 139:14	hid 152:9	honorably 144:12	housing 15:1
146:14 150:2	hidden 152:12	honored 44:17	117:18 146:8
151:13,15 152:6	hide 126:20 152:8	134:21	169:15 214:20
153:2,13 154:17	high 60:6 61:4,11	hope 16:10 34:2	hub 157:10
164:12 165:2	69:20 74:13,16	36:8 37:9 40:2	hue 176:12
189:21	172:16 198:10	48:13,15 50:11	huge 55:19 110:17
helped 127:17	higher 201:15	64:2 68:17 111:5	123:13 129:16
128:13,14 150:9	highlight 213:7	129:19 135:1	152:7 155:8
151:11 163:13	highly 29:6	171:18 186:11	185:13 203:10
203:13	highspeed 208:20	194:15	hulsey 2:17 52:19
helpful 28:17	highway 74:20	hoped 110:7	53:5 93:18 102:7
32:18 33:17 36:14	hijacker 55:3	hopefully 15:21	165:12 199:15,19
37:21 47:19 50:7	hijacker's 55:7	16:1 47:16 48:16	human 2:4 7:20
51:2 79:16 81:6	hijacks 55:4	64:18 134:16	8:14 75:4 105:15
83:4 86:14 90:7	hindsight 129:2	149:8	142:11 144:1
91:12 96:14 102:5	hiring 97:3,5	hopes 53:18 126:5	145:11
103:5 112:6	histories 206:1,2	hoping 72:15 76:4	humane 75:12
132:11,12 149:21	history 142:4	124:19 139:13	hump 98:20
159:4,13 164:21	153:19	218:17	hundreds 66:2
181:16 188:10			

hungry 132:18	impacted 10:1	incarcerated	indiana 151:7
hurt 54:11	36:11 53:6,8	66:20 89:8 147:6	indicating 180:13
hurts 57:5	62:13 126:8	147:7	indicator 100:21
husband 138:2	216:21	incarceration	indigenous 147:18
hustle 119:19,20	impacting 109:14	66:9 109:15	174:17
hydrochloride	impacts 6:13	169:19 206:14,17	indirect 120:20
173:19	20:15 35:16 41:20	incarcerations	individual 14:13
hyperthermia	52:2 61:19 63:1,8	89:5	23:19 24:10,12
29:14	63:13,19 64:4	include 27:14,20	27:4 32:9 39:6
i	105:2 134:16	28:2 29:3,14 31:4	46:2 118:5 157:8
idea 47:12 48:3	190:8,10 198:16	49:14 92:21	193:14 196:16
50:21 51:5 114:11	214:15 215:1	104:11 212:14	individuals 6:8,14
120:10 126:17	impaired 110:5	included 103:13	14:20 28:9 32:6
172:16 176:7	impairment 26:12	111:17 117:6	40:2,5 42:1 48:20
189:13 206:3	imperative 14:12	175:14	57:2 95:2 102:14
ideal 36:3 113:2	imply 195:3	includes 30:10	102:20 106:10
188:15	importance 8:9	117:21 142:3,4,4	124:6 139:1
ideas 68:18	132:19 216:2	194:3	156:12 165:16
ideation 28:4	important 13:13	including 13:2,9	166:11,16 184:16
identification	14:2 16:17 18:1	15:9 25:5 30:6,17	200:11,18 201:21
217:21	22:18 27:2 32:13	30:20 31:8 103:9	202:6 213:16,20
	38:6,7 39:14,21	118:7 138:14	214:3 216:18
identify 48:6 72:3 72:8 102:21	41:18,21 58:9	200:12 214:8	219:6,19
103:10 141:20,21	92:10 96:10	215:13 216:21	industry 218:15
142:10 195:14	101:17 102:18	incoming 110:11	infection 29:10
ii 30:13	109:11 114:18	incorporated	infections 67:13
	117:11,13 137:5	17:13	68:9
illicit 30:18 106:18 107:5	137:21 138:21,21	incorporating	infectious 214:16
	139:4 166:5,17,21	22:19	inflammation
illness 53:12,19	167:2 178:20	increase 11:7,8,11	141:5
57:8,19 59:3 115:15 135:16	183:10 185:10	12:3,6 15:1 27:16	inform 12:20
150:13 167:15	186:6 187:15,21	29:9 30:4	17:20
201:19 209:10	188:21 191:20	increased 28:1	information 23:13
imagined 92:4	193:10 198:7	29:16 30:21 57:13	33:1 34:8 39:11
immediately	importantly 115:5	85:19 126:8 134:7	39:13,16 42:13,14
155:13,13 197:3	128:18 155:2	202:4 206:20,21	83:16 86:15,18
impact 6:17 18:19	improve 8:7 28:20	increases 11:11,18	90:7 91:13 96:15
21:2 37:16 54:10	215:19	12:9 207:1	103:17 109:13
55:19 72:7 93:11	improved 94:12	increasing 11:4	116:7
105:1 167:8 172:1	improvement 32:8	191:18,19,19	informative 47:10
188:13 199:3,11	169:11 170:3	214:5	informed 138:20
200:7 204:18	improving 169:16	incredible 197:21	154:7 215:11
	incapacitation	incredibly 96:10	infrequent 104:9
206:9 213:13,21	89:6		
216:13			

ingmar 197:20	intended 26:5	intersectionality	irritability 28:5
inhaler 56:10	218:12	116:19	island 206:15
initially 29:8 84:2	intense 54:5	intervene 63:21	isolate 61:8 211:4
87:7 122:21	162:14 214:13	166:8	isolated 126:13
initiated 10:21	intensified 125:14	intervention	127:6
initiative 5:9 16:7	intensity 162:20	133:14 146:3	isolation 117:12
19:3	intensive 131:1	150:4	128:12 211:2
initiatives 5:18	intention 89:9	interventions	issue 41:14 93:15
43:2	intentional 23:18	130:21	122:5,19 159:7,7
inject 70:5 85:17	34:13	intoxication 28:2	160:3,3,5 173:6
injecting 84:14	interaction 209:11	intravenous	194:5
126:11	interactions 218:2	159:18	issues 41:21 42:8
injection 29:11	interactive 52:7	intricate 196:6	44:15 55:17,21
69:13 70:6,12	interactivity	introduce 7:17	63:4 68:8 70:20
injections 70:11	163:7	22:15 40:14 42:17	75:14 119:17
innovative 174:1	interagency 12:19	45:8	155:14 158:20
inpatient 127:5	interest 18:12	introduced 60:5	183:18 193:11
130:21 137:9	110:1 167:4 195:1	60:15 63:12	214:15
138:14 139:4	interested 40:21	114:14,17 127:21	it'll 135:1
input 13:21 14:1	86:17 113:12	128:1	iv 67:4,13
14:13 18:6 19:13	156:11 205:15	introduction 9:7	izquierdo 3:1 98:4
22:8 42:3 104:3	209:21 221:15	60:9 62:12 65:9	119:6 154:13
175:6 218:5	222:12	144:19	j
175:6 218:5 inside 50:20	interesting 39:1	invasive 31:8	
		invasive 31:8 invisibility 97:11	jacobey 222:2,15
inside 50:20	interesting 39:1	invasive 31:8	jacobey 222:2,15 jail 120:15,20
inside 50:20 129:12	interesting 39:1 71:17 91:10	invasive 31:8 invisibility 97:11 invitation 36:21 37:10	jacobey 222:2,15 jail 120:15,20 121:5 136:17
inside 50:20 129:12 insight 205:13	interesting 39:1 71:17 91:10 174:12 175:6	invasive 31:8 invisibility 97:11 invitation 36:21	jacobey 222:2,15 jail 120:15,20 121:5 136:17 155:1
inside 50:20 129:12 insight 205:13 212:11 insightful 96:14 213:4	interesting 39:1 71:17 91:10 174:12 175:6 194:18 202:20	invasive 31:8 invisibility 97:11 invitation 36:21 37:10	jacobey 222:2,15 jail 120:15,20 121:5 136:17 155:1 jama 12:7
inside 50:20 129:12 insight 205:13 212:11 insightful 96:14	interesting 39:1 71:17 91:10 174:12 175:6 194:18 202:20 213:4	invasive 31:8 invisibility 97:11 invitation 36:21 37:10 invite 15:12 113:16 inviting 52:15	jacobey 222:2,15 jail 120:15,20 121:5 136:17 155:1 jama 12:7 jamie 109:8,20
inside 50:20 129:12 insight 205:13 212:11 insightful 96:14 213:4 insights 217:10 insomnia 56:18	interesting 39:1 71:17 91:10 174:12 175:6 194:18 202:20 213:4 intermittently 146:17 internal 98:11	invasive 31:8 invisibility 97:11 invitation 36:21 37:10 invite 15:12 113:16 inviting 52:15 69:8 148:11	jacobey 222:2,15 jail 120:15,20 121:5 136:17 155:1 jama 12:7 jamie 109:8,20 jana 2:14 44:13
inside 50:20 129:12 insight 205:13 212:11 insightful 96:14 213:4 insights 217:10 insomnia 56:18 instance 11:16	interesting 39:1 71:17 91:10 174:12 175:6 194:18 202:20 213:4 intermittently 146:17 internal 98:11 106:9 197:9,15	invasive 31:8 invisibility 97:11 invitation 36:21 37:10 invite 15:12 113:16 inviting 52:15 69:8 148:11 involve 44:16	jacobey 222:2,15 jail 120:15,20 121:5 136:17 155:1 jama 12:7 jamie 109:8,20 jana 2:14 44:13 149:16
inside 50:20 129:12 insight 205:13 212:11 insightful 96:14 213:4 insights 217:10 insomnia 56:18 instance 11:16 217:18	interesting 39:1 71:17 91:10 174:12 175:6 194:18 202:20 213:4 intermittently 146:17 internal 98:11 106:9 197:9,15 internally 98:9	invasive 31:8 invisibility 97:11 invitation 36:21 37:10 invite 15:12 113:16 inviting 52:15 69:8 148:11 involve 44:16 involved 11:17,17	jacobey 222:2,15 jail 120:15,20 121:5 136:17 155:1 jama 12:7 jamie 109:8,20 jana 2:14 44:13 149:16 javier 2:13 44:9
inside 50:20 129:12 insight 205:13 212:11 insightful 96:14 213:4 insights 217:10 insomnia 56:18 instance 11:16 217:18 instant 60:10	interesting 39:1 71:17 91:10 174:12 175:6 194:18 202:20 213:4 intermittently 146:17 internal 98:11 106:9 197:9,15 internally 98:9 103:16	invasive 31:8 invisibility 97:11 invitation 36:21 37:10 invite 15:12 113:16 inviting 52:15 69:8 148:11 involve 44:16 involved 11:17,17 11:19 18:10 65:12	jacobey 222:2,15 jail 120:15,20 121:5 136:17 155:1 jama 12:7 jamie 109:8,20 jana 2:14 44:13 149:16 javier 2:13 44:9 168:10
inside 50:20 129:12 insight 205:13 212:11 insightful 96:14 213:4 insights 217:10 insomnia 56:18 instance 11:16 217:18 instant 60:10 institute 217:19	interesting 39:1 71:17 91:10 174:12 175:6 194:18 202:20 213:4 intermittently 146:17 internal 98:11 106:9 197:9,15 internally 98:9 103:16 internet 36:9	invasive 31:8 invisibility 97:11 invitation 36:21 37:10 invite 15:12 113:16 inviting 52:15 69:8 148:11 involve 44:16 involved 11:17,17 11:19 18:10 65:12 128:19 142:5	jacobey 222:2,15 jail 120:15,20 121:5 136:17 155:1 jama 12:7 jamie 109:8,20 jana 2:14 44:13 149:16 javier 2:13 44:9 168:10 jay 97:1
inside 50:20 129:12 insight 205:13 212:11 insightful 96:14 213:4 insights 217:10 insomnia 56:18 instance 11:16 217:18 instant 60:10 institute 217:19 institutionalized	interesting 39:1 71:17 91:10 174:12 175:6 194:18 202:20 213:4 intermittently 146:17 internal 98:11 106:9 197:9,15 internally 98:9 103:16 internet 36:9 45:10 173:1	invasive 31:8 invisibility 97:11 invitation 36:21 37:10 invite 15:12 113:16 inviting 52:15 69:8 148:11 involve 44:16 involved 11:17,17 11:19 18:10 65:12 128:19 142:5 143:18	jacobey 222:2,15 jail 120:15,20 121:5 136:17 155:1 jama 12:7 jamie 109:8,20 jana 2:14 44:13 149:16 javier 2:13 44:9 168:10 jay 97:1 jennifer 82:5,11
inside 50:20 129:12 insight 205:13 212:11 insightful 96:14 213:4 insights 217:10 insomnia 56:18 instance 11:16 217:18 instant 60:10 institute 217:19 institutionalized 142:21 205:20	interesting 39:1 71:17 91:10 174:12 175:6 194:18 202:20 213:4 intermittently 146:17 internal 98:11 106:9 197:9,15 internally 98:9 103:16 internet 36:9 45:10 173:1 208:20	invasive 31:8 invisibility 97:11 invitation 36:21 37:10 invite 15:12 113:16 inviting 52:15 69:8 148:11 involve 44:16 involved 11:17,17 11:19 18:10 65:12 128:19 142:5 143:18 involvement 54:13	jacobey 222:2,15 jail 120:15,20 121:5 136:17 155:1 jama 12:7 jamie 109:8,20 jana 2:14 44:13 149:16 javier 2:13 44:9 168:10 jay 97:1 jennifer 82:5,11 jess 169:9
inside 50:20 129:12 insight 205:13 212:11 insightful 96:14 213:4 insights 217:10 insomnia 56:18 instance 11:16 217:18 instant 60:10 institute 217:19 institutionalized 142:21 205:20 institutions 8:17	interesting 39:1 71:17 91:10 174:12 175:6 194:18 202:20 213:4 intermittently 146:17 internal 98:11 106:9 197:9,15 internally 98:9 103:16 internet 36:9 45:10 173:1 208:20 interpreting 90:11	invasive 31:8 invisibility 97:11 invitation 36:21 37:10 invite 15:12 113:16 inviting 52:15 69:8 148:11 involve 44:16 involved 11:17,17 11:19 18:10 65:12 128:19 142:5 143:18 involvement 54:13 involving 20:20	jacobey 222:2,15 jail 120:15,20 121:5 136:17 155:1 jama 12:7 jamie 109:8,20 jana 2:14 44:13 149:16 javier 2:13 44:9 168:10 jay 97:1 jennifer 82:5,11
inside 50:20 129:12 insight 205:13 212:11 insightful 96:14 213:4 insights 217:10 insomnia 56:18 instance 11:16 217:18 instant 60:10 institute 217:19 institutionalized 142:21 205:20 institutions 8:17 66:21 142:16	interesting 39:1 71:17 91:10 174:12 175:6 194:18 202:20 213:4 intermittently 146:17 internal 98:11 106:9 197:9,15 internally 98:9 103:16 internet 36:9 45:10 173:1 208:20 interpreting 90:11 101:4 149:5	invasive 31:8 invisibility 97:11 invitation 36:21 37:10 invite 15:12 113:16 inviting 52:15 69:8 148:11 involve 44:16 involved 11:17,17 11:19 18:10 65:12 128:19 142:5 143:18 involvement 54:13 involving 20:20 25:11 30:20 154:3	jacobey 222:2,15 jail 120:15,20 121:5 136:17 155:1 jama 12:7 jamie 109:8,20 jana 2:14 44:13 149:16 javier 2:13 44:9 168:10 jay 97:1 jennifer 82:5,11 jess 169:9 jessica 2:17 52:16 53:5 59:5 77:9
inside 50:20 129:12 insight 205:13 212:11 insightful 96:14 213:4 insights 217:10 insomnia 56:18 instance 11:16 217:18 instant 60:10 institute 217:19 institutionalized 142:21 205:20 institutions 8:17 66:21 142:16 insulated 144:6	interesting 39:1 71:17 91:10 174:12 175:6 194:18 202:20 213:4 intermittently 146:17 internal 98:11 106:9 197:9,15 internally 98:9 103:16 internet 36:9 45:10 173:1 208:20 interpreting 90:11 101:4 149:5 intersection	invasive 31:8 invisibility 97:11 invitation 36:21 37:10 invite 15:12 113:16 inviting 52:15 69:8 148:11 involve 44:16 involved 11:17,17 11:19 18:10 65:12 128:19 142:5 143:18 involvement 54:13 involving 20:20 25:11 30:20 154:3 iop 125:18 129:7	jacobey 222:2,15 jail 120:15,20 121:5 136:17 155:1 jama 12:7 jamie 109:8,20 jana 2:14 44:13 149:16 javier 2:13 44:9 168:10 jay 97:1 jennifer 82:5,11 jess 169:9 jessica 2:17 52:16
inside 50:20 129:12 insight 205:13 212:11 insightful 96:14 213:4 insights 217:10 insomnia 56:18 instance 11:16 217:18 instant 60:10 institute 217:19 institutionalized 142:21 205:20 institutions 8:17 66:21 142:16 insulated 144:6 insurance 76:17	interesting 39:1 71:17 91:10 174:12 175:6 194:18 202:20 213:4 intermittently 146:17 internal 98:11 106:9 197:9,15 internally 98:9 103:16 internet 36:9 45:10 173:1 208:20 interpreting 90:11 101:4 149:5 intersection 162:17	invasive 31:8 invisibility 97:11 invitation 36:21 37:10 invite 15:12 113:16 inviting 52:15 69:8 148:11 involve 44:16 involved 11:17,17 11:19 18:10 65:12 128:19 142:5 143:18 involvement 54:13 involvement 54:13 involving 20:20 25:11 30:20 154:3 iop 125:18 129:7 210:14	jacobey 222:2,15 jail 120:15,20 121:5 136:17 155:1 jama 12:7 jamie 109:8,20 jana 2:14 44:13 149:16 javier 2:13 44:9 168:10 jay 97:1 jennifer 82:5,11 jess 169:9 jessica 2:17 52:16 53:5 59:5 77:9 81:11,13 93:8,9
inside 50:20 129:12 insight 205:13 212:11 insightful 96:14 213:4 insights 217:10 insomnia 56:18 instance 11:16 217:18 instant 60:10 institute 217:19 institutionalized 142:21 205:20 institutions 8:17 66:21 142:16 insulated 144:6 insurance 76:17 127:15 131:4	interesting 39:1 71:17 91:10 174:12 175:6 194:18 202:20 213:4 intermittently 146:17 internal 98:11 106:9 197:9,15 internally 98:9 103:16 internet 36:9 45:10 173:1 208:20 interpreting 90:11 101:4 149:5 intersection 162:17 intersectional	invasive 31:8 invisibility 97:11 invitation 36:21 37:10 invite 15:12 113:16 inviting 52:15 69:8 148:11 involve 44:16 involved 11:17,17 11:19 18:10 65:12 128:19 142:5 143:18 involvement 54:13 involving 20:20 25:11 30:20 154:3 iop 125:18 129:7 210:14 iraq 145:1	jacobey 222:2,15 jail 120:15,20 121:5 136:17 155:1 jama 12:7 jamie 109:8,20 jana 2:14 44:13 149:16 javier 2:13 44:9 168:10 jay 97:1 jennifer 82:5,11 jess 169:9 jessica 2:17 52:16 53:5 59:5 77:9 81:11,13 93:8,9 96:13 100:20
inside 50:20 129:12 insight 205:13 212:11 insightful 96:14 213:4 insights 217:10 insomnia 56:18 instance 11:16 217:18 instant 60:10 institute 217:19 institutionalized 142:21 205:20 institutions 8:17 66:21 142:16 insulated 144:6 insurance 76:17	interesting 39:1 71:17 91:10 174:12 175:6 194:18 202:20 213:4 intermittently 146:17 internal 98:11 106:9 197:9,15 internally 98:9 103:16 internet 36:9 45:10 173:1 208:20 interpreting 90:11 101:4 149:5 intersection 162:17	invasive 31:8 invisibility 97:11 invitation 36:21 37:10 invite 15:12 113:16 inviting 52:15 69:8 148:11 involve 44:16 involved 11:17,17 11:19 18:10 65:12 128:19 142:5 143:18 involvement 54:13 involvement 54:13 involving 20:20 25:11 30:20 154:3 iop 125:18 129:7 210:14	jacobey 222:2,15 jail 120:15,20 121:5 136:17 155:1 jama 12:7 jamie 109:8,20 jana 2:14 44:13 149:16 javier 2:13 44:9 168:10 jay 97:1 jennifer 82:5,11 jess 169:9 jessica 2:17 52:16 53:5 59:5 77:9 81:11,13 93:8,9 96:13 100:20 101:3,7 102:1,6

202:19	keeping 45:9	92:21 93:7 96:17	135:13 136:1
jewelry 85:5	152:12 201:12	97:14 100:15	knocks 208:12
job 1:21 83:13	202:14	101:19 102:1	know 9:9 11:10
119:7 126:9,12	keeps 57:5,6 95:7	103:15,17,18	27:2 35:3 36:13
170:1 184:19	kept 126:2 128:18	105:12 106:1,2	37:2 40:7 41:13
185:7 187:16	kevin 3:4 125:4,5	107:1,10,14 108:4	47:5 48:14 49:16
jobs 128:16	125:6,7 130:3	108:11,12,15,16	50:1,7,19 51:2,3,3
201:18	150:1,14,17,18,20	108:17,20 109:2,3	53:20 58:1 63:17
joey 73:10,11,12	150:21 151:1	110:2,6,11,19	65:17 66:6,12,19
73:20 74:17	168:3,8 170:5,6	111:8 112:4,16	67:2,10,17,21
joined 44:20	205:4 209:16,18	113:11 117:7	68:5,11 71:18
joining 5:3 9:3	211:8	119:3 125:2	73:15,16,16 74:12
22:11 23:7 45:15	key 34:3 96:2	134:12,15 136:4	74:18,19 75:16
47:12 51:9 53:9	114:8,9 118:9	137:4 141:4,5	76:2,21 79:16
60:1 69:6 78:9	154:8	143:16 144:19	83:17 84:15 85:2
201:5	keyed 176:3	145:6,19 147:20	85:3,4,4,12,14
jonathan 158:10	kick 160:21	148:13,17 151:13	86:8,10,11 87:6,7
jotting 42:15	kicked 130:15	155:21 156:2,6	87:8,10,12,14,19
journey 113:9	136:12 138:11	157:6 158:18	88:2,5,8,18,19,20
119:10 142:14	164:10 165:21	159:19 160:21	89:7,16,21 93:18
146:21 152:19	kickoff 34:5	162:10,17 164:20	93:21 94:2 98:20
153:1 170:8 186:9	kid 151:7 176:15	165:6,8 168:5	101:18 103:15,19
judging 138:16	176:20	169:12,13,15	104:7,18,19 105:8
judgmental	kids 135:21 155:4	170:13,17 171:20	105:12 108:3
138:19	155:9,14 177:8	172:15 174:1	110:5 112:10,14
juicy 122:18	kill 139:7	178:16 181:15	113:7 118:5 119:1
jump 33:9 74:16	kind 9:7 19:10	182:8,9,12 183:1	119:13,18,20
109:6 155:21	21:12 22:21 23:4	183:12 184:15,21	120:11 121:1,21
156:4	34:7,9,11,18,19	186:5,16 187:18	123:4,21 124:1,13
jumped 110:19	35:5,9,17 36:21	188:7,10,11,13,19	124:18 129:4
jumping 181:14	37:1 40:6,7,9 41:1	189:1,2,7,13	138:16 139:1
justice 54:13 96:4	41:11 46:16 47:2	190:7,9 191:6	140:14 141:1
105:5,7 109:18	47:10 49:10 50:21	192:11,16,17	142:15,15,16
115:8,9 120:9	51:5,17,21 59:6	195:17 198:14,20	143:5 144:12,14
214:21	65:11,13,17 66:4	199:2,10,12 203:4	144:17 146:12,20
justify 115:21	66:14,15 67:8,12	203:5 208:3	147:1,5,10,13,15
k	67:18,19,21 68:3	209:20 211:10	151:2,3,6,8,10,11
keep 37:21 39:8	68:4 69:3 72:15	212:8,19	151:12,17,17,20
39:15 41:11 90:16	72:16 78:1,8,19	kinds 17:18 19:9	151:21 152:1,6,10
110:11 129:1	78:21 79:6 80:3	196:19 197:10	153:21 154:3,14
159:3 185:16	80:10,15,16 82:13	216:18	154:18 156:3
196:5 202:13	83:3,4,18 87:3,5,7	knees 120:7 155:1	162:11,13,18,21
207:6	87:15 88:21 89:16	knew 62:10 120:1	162:21 163:1,18
	89:19,21 91:18	121:16 129:4	165:15 166:13,21

167:1 168:11,15	156:16	134:15 186:3	74:21 103:21
169:9 170:6,8,15	lacked 116:18	213:13	114:3,4 123:14
170:17,18,20,21	lady 156:10	learned 97:5	130:13 140:18
170:21 171:2,2,6	lag 47:21 80:21	110:8 121:7	141:10,12,18
171:7,7,14,19	108:13	143:11 146:11	142:15 143:1,10
172:14 173:2,9	laid 91:8	151:8 191:20	144:6,10 145:13
174:6,13,19,21	lake 171:5	learning 185:13	151:14 163:14
175:7 176:6,15,18	language 103:9	leave 39:18 99:5	168:19 170:3
176:18,20 177:2,6	216:2	leaves 173:6,13	173:8 176:6 177:7
177:7,11,14,16,17	laptop 46:1	174:20	184:4 187:13
177:17,19 178:9	large 19:21 47:6,7	leaving 126:5	196:21 200:17
178:11,12 180:15	104:16 112:9	lecture 133:10	203:12
180:15,19 181:1,6	133:7 162:4 209:8	lectures 132:17	lifelong 196:12
183:8 184:18	largely 147:16	led 5:4 19:8 20:3	lifespan 8:4
185:1 188:11	148:3 153:20	62:13 63:18 66:4	lifestyle 163:14
190:7,18 191:2,9	larger 177:10	67:5,13 70:12	182:14 185:12
191:12 193:10	largest 164:6	145:19 168:13,16	197:4
194:16 195:5,9	laser 179:8	173:8 185:4	lifetime 193:17
196:16 197:6,10	lasik 176:9	217:20	lift 115:7
197:11,19 198:1,9	lasting 29:7	led's 19:12	limit 88:12 89:3
199:6,7,9,13	lasts 54:7 174:16	left 55:10 63:4	limited 18:6 78:11
200:2,10 201:4,19	late 51:11 67:20	67:7 101:20	87:18 127:3
202:11 204:2,7,12	125:11 204:18	legal 31:2 104:6	161:19 163:11
204:20,20 205:11	laughing 129:13	126:19 130:16	164:7,12
206:3,6,18 207:5	launch 95:21	legally 145:10	limiting 215:3
207:6 208:4	113:6,15	148:9 179:10	limits 89:6
209:19,21 210:2,2	launchpad 20:20	lending 40:3	line 141:14 156:21
210:6,9,10,12,13	law 114:10	length 200:19	lines 204:6
210:15,17,20	layered 160:10	214:8	lining 211:20
211:1,1,2,3,5,18	layering 167:16	lens 205:10	217:7
knowing 63:20	167:19	lessons 191:20	linkages 153:15
140:4	lead 8:13 42:20	letting 68:20 77:6	153:17
knowledge 221:9	43:13 66:8 177:10	level 84:18 85:1	liquor 201:12
222:6	197:3	172:16	lisa 101:16 102:7
known 205:17	leadership 8:15	leveling 115:20	lisa's 101:7
knows 170:6	leading 8:3 13:4	levels 132:18	list 2:2 55:5 95:8
l	90:1 94:13 126:11	liabilities 151:14	132:20 197:12
1 2:20	213:2 220:5	liability 122:9	listed 20:3
label 180:13,21	leads 7:21 90:13	licit 147:1 148:5	listen 34:21 40:13
181:7	181:10	life 18:20 35:17,17	41:9
labeled 109:19	leaf 173:17 174:2	35:17 55:9 56:13	listening 21:21
labs 29:16	174:3,4,13 175:3	61:20 62:16 63:2	40:16 41:1 82:9
lack 60:12 129:15	learn 43:9 53:3	63:19 69:14 72:1	90:9,14 166:16
142:18 146:6	54:18 55:1 101:15	72:7 73:15,20	220:2

literacy 96:2	lives 8:3,7 77:5	107:8,15,19	98:21 105:9 110:8
literally 13:14	114:7 150:4	114:21 116:21	110:9 115:19
87:18 121:4	171:17	124:15 142:6	116:11 127:4
144:18 145:2	living 6:9 41:16	165:11 167:10	128:21 129:2,5
154:2 183:16	114:2,3 115:4	169:4 174:13	147:1,6 148:8,13
206:7	130:15 177:3	188:15,17 192:9	148:14 150:4
little 5:19 15:14	197:15 214:18	198:1,7 218:21	151:3 152:4,6,11
16:12 19:2 33:5	liz 92:9	looked 147:17	155:4 157:6 159:2
34:2,8 35:20	local 47:8	150:12	163:4 165:19
37:18 44:20 47:1	location 136:4	looking 32:15	170:20 182:11
47:21 48:9,12	lockdown 210:2	45:16 60:17 61:3	186:2 189:1 192:7
53:17,18 55:7	211:3	62:21 63:14,16	194:17,18 195:18
59:6 64:14 67:19	locked 115:1	71:16 83:9 105:3	197:14,20 200:2,3
72:18 79:21 80:20	192:11	107:19,21 111:20	200:9 206:15
83:1,21 84:2	logistics 7:1,1	114:15 118:10	209:19 210:10
86:17 89:14 93:2	lonely 132:19	132:4 168:19	211:5
97:16 99:7 104:4	long 31:12 32:9	206:15	lots 94:8
106:4,20 107:9,16	49:9,12,16 54:3	looks 46:21 47:17	love 98:5 107:13
107:18 110:4,4	55:11,21 59:17	50:1,4 51:7,9	150:15 195:13
112:18 122:18	63:19 64:5 65:19	79:10,13,16 80:14	loved 6:9 34:14
125:3,10 134:13	70:15 84:13 87:14	81:1,3 82:3 83:5	36:12 39:3 48:21
134:15 146:1	92:3 112:9 114:2	83:11 98:4 149:9	49:2,9 52:17
148:20 149:8	114:14,20 115:6	149:10 152:15	53:17 78:2,14,15
156:2 158:13	119:11 122:14	182:16,19 191:21	79:1 80:12,14
163:12 165:3	128:6 129:18	197:13	82:15 93:19
172:11 175:10	130:6 132:17	lose 56:9 62:8	106:17 107:17
176:4 180:1	141:21 142:8	123:2 155:9,13	181:11
181:15 182:4	145:16 151:10,17	losing 73:8 95:14	loving 94:6
183:8 188:12	152:8 163:2 167:6	loss 26:1,4 29:12	low 133:7 139:21
189:5 192:15	174:16 187:10	62:3 119:16,17	141:16 148:5,5
195:8 198:15	193:16,19 200:12	206:9	153:17 154:8
199:10,13 200:1	200:19 204:6	losses 207:11	162:19 183:13
205:10 208:3	longer 29:7 49:15	lost 24:12 53:16	192:8 193:8
209:20 210:7	54:7 68:15 81:3	55:13 67:7,15	lumping 159:17
live 7:12 35:4,14	121:10 126:19	68:3 126:11	lunch 185:6
39:14 46:21 50:19	163:5 206:18	144:19 195:1	lung 55:21
60:2 72:5 73:2	214:14	201:18,18	lungs 55:19 167:9
84:3 112:7,8	longitudinal	lot 26:5 34:20 40:4	luxury 71:6
127:16 136:15	118:18	47:5 54:4 55:20	lyna 1:4 2:15 45:8
171:9,10 210:1	longstanding	64:2,12,14 65:12	45:13 81:7,21
lived 34:6,15	170:2	68:10,15 76:12,15	91:15 92:17 96:16
40:10 69:21 78:12	look 22:12 29:4	77:8,12 79:14	99:14 100:19
88:10 97:6 185:8	47:19 49:5 51:6	80:18 81:3 84:20	101:2,5,18 106:5
	95:16 99:8 105:15	86:14 88:13 97:9	106:14 108:2,6

[lyna - meeting] Page 25

109:3,21 156:1,6	mania 60:11 61:1	83:10 84:18 90:10	medicated 143:2
158:18 192:15,20	manifest 123:18	90:11,16 96:19	medicating 146:12
211:10,15 212:8	124:19	101:4 105:3	medication 13:6
220:4	manifests 123:19	116:20 123:21	27:5,7 31:9 53:2
m	manipulate	124:10 149:5	61:17 63:21 70:17
	121:18	153:4 162:9 170:7	118:11 131:6
m 70:2	manual 24:19	179:4 183:7	159:13 161:6,18
maintain 131:14	manufacturing	186:15 188:6	170:12 176:7
maintaining 132:5	104:21	189:1 190:16	203:20 204:15
214:20	march 8:13	191:8 196:11	medications 27:6
maintenance	margolis 218:5	199:1 204:21	31:7 57:19 58:3
183:9	marijuana 65:8	206:7 209:16	75:18 143:6
major 63:8 97:2	mark 73:4,6	212:12	156:13 162:16
154:2 159:7	market 163:4	meaner 55:8	163:3,4,9 166:2,3
214:18	191:13 207:1	meaning 85:15	167:3 170:10
majority 50:5	marketing 17:5	meaningful 42:10	181:1 182:16
83:11 97:5	18:3	145:6 169:2 188:4	medicine 2:8,8,11
makers 37:6	markets 88:13	189:16 206:5	2:11 6:3,3 23:9,9
making 18:1	104:17	meaningfully	43:15,15,21,21
40:18 42:5 82:9	marks 127:7	17:13	147:12,18 148:2
175:4 191:9,15	marriage 114:8	means 40:13	medicines 32:20
192:4 213:4	marta 2:9 42:20	59:18 78:15 88:1	meditation 131:15
man 114:2,14	212:16	114:3 216:7	137:16 183:13
128:13 152:10	maryam 2:7 6:2	meant 46:12,13	203:11
manage 54:6 56:2	23:2,7 43:19	112:20 126:19	meditations
56:19 69:15 70:20	maryland 1:10	measure 31:11,12	132:10
116:11 131:11	121:6 221:20	208:7	meet 33:15 133:4
143:12 146:14	mass 73:2	mechanism 18:5	153:18 191:21
160:7 163:13	math 107:20	145:14	209:4
165:10 167:7	130:9	mechanisms 202:8	meeting 1:1 5:4,9
181:4,12 187:2	matrix 166:12	media 59:11,12	6:19 7:2,8,10,11
manageable 197:4	matter 6:13 14:2	111:2,3 167:21	7:13 13:20 14:21
managed 162:11 162:15	37:2 63:11 88:20	168:1 194:18	16:7,8 20:9,21
	115:9 129:6 162:3	medical 16:13	33:5,16,19 34:10
management 41:20 105:16	199:8	17:1 22:19 23:8	35:5 36:19 37:4
142:2 157:15	matters 17:21	24:15 34:1,20	38:17 40:1 41:6
166:12 169:4	58:12	37:5 40:20 42:4	45:5,11,16 47:5
	mcaninch 2:14	43:20 44:13,15	48:4 51:6,10,16
215:11,15	44:11,12,13	76:3,5,18 77:3	52:7 53:10 64:13
managing 6:15	149:16,17,19	142:9,13 146:4,7	96:20 103:16,18
56:1,11,17 58:14 68:14 162:13	mdma 87:9	148:7 162:18	103:18 111:19
	141:17	183:9,9 207:3	114:15 127:19
167:2 215:6	mean 24:9 27:9	215:9	128:3,4 129:9,11
mandatory 132:14	38:4 63:14 80:8		134:4,5 166:5
132.14			<u> </u>

[meeting - mode] Page 26

169:12 171:14	mentimeter 45:20	27:14 29:4,4,6,15	milder 163:10
180:9 199:13	46:5	29:17,20,21 30:3	military 164:11
200:2 205:7	mentimeter's	30:17,20 31:13	million 10:18 11:1
208:21 209:1	45:21	54:1 57:3 70:8	11:2 12:2
211:14 212:10,20	mention 156:11	71:15 72:6 79:3	mind 39:8,16
213:2 217:11,16	mentioned 27:13	79:12 81:4 95:9	137:18 156:6
218:10 219:5	28:7 36:13,18	103:1,8 124:8	176:13 177:19
220:10	45:4,18 52:1	156:17 159:18	185:16 192:21
meetings 15:16	64:12 65:11 79:4	166:14 214:9	195:8
18:4,15 19:4,7,10	79:18 93:10 106:4	methamphetami	mindfulness 186:4
19:11,15 20:3,6,7	111:9 120:9	11:6 12:5 13:8	203:11
20:10 21:14,19	154:18 156:9	75:16 76:14	mindy 193:3
22:1,4,7,18 34:19	182:17 185:20	141:17 213:17	194:12
47:6 78:7 91:21	188:16 190:3	218:2	minimize 98:16
92:1 108:14 126:2	214:4,14 215:10	methodologies	minute 40:14 49:6
128:11 132:15,20	217:6	114:20	52:12 79:5 106:20
134:1,2,8 201:11	merzoug 1:4 2:15	methods 31:21	152:17 162:7
210:4,5	45:8,14 81:10	131:17 132:2	minutes 5:15
member 39:6	82:3 91:19 96:21	methylphenidate	23:14 47:2 52:5
40:11 48:21 53:6	101:6 106:6 108:7	30:12	56:6 80:18,20
72:21 144:2	109:6 156:8 157:5	metrics 215:10	92:5 101:20 111:1
165:13 175:19	193:2 211:16	mexican 11:12	113:10 174:21
176:4 179:18	220:4	miami 180:7	213:3
180:4	messages 160:19	michael 3:3 101:3	misconception
members 40:2	met 27:12 60:14	102:1 104:1 106:1	99:1
43:7 53:9 78:13	128:4 171:15	140:10,11 148:12	misinformation
78:15 96:4 114:10	metaphor 55:4	150:19,20,21	165:19
180:16 202:5	meth 6:6 57:3	152:16 158:11	missing 201:6
213:7,19 219:7,9	65:10,14 66:3	162:7 163:18	mission 16:14
memorize 110:4	67:1,3 68:2 73:11	165:5 168:3,7	misunderstanding
memory 168:11	73:13,17 76:5,19	175:10 183:6	10:5 95:11
men 127:18	79:3 81:5 87:9	190:14 194:16	misuse 6:6 10:1,21
128:20 143:19	88:16 92:5 95:10	195:7 198:12	13:15,19 23:18,20
155:6 171:15	100:2 103:1,8	205:4,7 207:20	30:14 44:16 60:13
210:14	125:8,9,11 126:5	michelle 44:21	91:1 213:18,21
mental 24:19 31:3	126:7,11 127:18	michigan 69:12	misused 10:19
61:15 135:15,16	128:2,3 138:16	70:5 156:16 171:5	misusing 49:15
136:19,20 137:3	158:3 213:17	middle 75:7	mixing 11:14
139:11 140:19	methadone 66:11	201:16	mobility 206:20
158:6 193:4,9,21	161:11,15 192:2,7	midwest 51:9	modafinil 180:6
194:3,7,19 196:4	methamphetamine	206:7	modalities 207:16
214:6	6:6 10:14 11:1,7	mild 26:21 147:1	mode 21:21 40:16
menti.com 45:21	11:15 12:10,19,21	163:5 174:16	41:2 195:21
	13:1,10,19 25:12		

	I	T	<u> </u>
model 118:17	mountain 157:8	muted 108:6	neatly 72:18
157:10 166:12	mounting 130:16	149:6	necessarily 87:15
215:10	mouth 67:11,12	mutual 117:6	162:1 196:11
models 169:3	174:17	166:17 169:7	necessary 33:2
moderate 27:10	move 6:8 33:7,12	201:2,7	59:19 118:18
58:18 208:15	48:1 49:8 50:14	myth 98:21 116:9	need 20:1 33:9
moderated 1:4	50:17 52:6 59:8	165:21	38:14 39:12 41:17
moderating 220:5	71:8 77:14 78:19	n	42:2 56:3 57:20
moderation 32:4	79:19 80:2,11	n 2:1 4:1,1 5:1	58:20 69:3 75:18
142:2 169:3	82:13 98:2 102:2	naltrexone 76:8	77:4,9 95:19
molecules 173:18	105:20 106:16	131:11	101:14,15 122:3
mom 53:15 55:12	107:1 112:10,19	name 5:5 38:6,9	132:21 133:13
mom's 59:6	119:3,4 121:18	38:15 39:14,19	134:9 139:6,7
moment 33:15	125:3 134:18	42:20 53:5 64:21	140:3 145:11
79:13 136:1	152:17 158:18	69:9 73:1 114:1	154:17 157:14
192:11 217:14	168:4 175:12	125:7 134:20	167:14 175:12
money 13:15	179:16 186:13	156:11 175:17	193:16,19 197:11
62:11 66:7 68:2	189:4 207:20	name's 59:17	200:13 202:1
87:19 88:8 89:4	211:12	named 158:10	204:15 207:14
128:17	moved 84:5 88:14	names 38:5,5	213:14 215:7,20
monitoring 92:19	126:4 134:1	130:5	216:3
monitors 56:9	151:12 208:19,19	narcolepsy 30:16	needed 62:6,10,11
monoamine 27:15	208:21	44:6	87:11 117:2
monoclonal 13:9	moves 124:18	narrative 58:2	122:19 123:4,5
month 12:7 73:12	moving 33:4 41:2	94:11	129:1 131:8 136:1
84:10,11 125:13	41:11 117:4	narratives 174:10	143:14 200:3
months 11:9 38:21	120:12 154:20	narrow 161:5	201:15 207:17
49:19 63:12 73:6	188:11	narrowing 161:3	needing 24:3
74:3 126:3,10	mrsa 70:14	narrowly 161:7	needs 17:12 21:15
130:11 145:3	mullin 2:6 4:5	161:15	42:3 106:8 142:12
205:18 207:8	5:17 15:13,16,17	nation 109:11	167:6 193:11,14
mood 27:21 28:19	15:19 16:4 22:17	nation's 8:5 9:16	196:17 206:19
54:10 61:7 95:13	33:17 34:11	national 47:9	negative 99:9
214:13	multifaceted 31:2	192:3 217:19	neglect 63:4
moral 10:7 96:9	multiple 46:11	native 147:11	negotiate 120:1
morality 208:3	66:4 67:13 82:17	naturally 212:2	negotiations
morbidity 13:2	178:11 181:19	nature 44:6 91:17	119:21
morning 75:6	184:9 198:9	128:15 141:19	neither 221:10
mortality 13:2	muniz 2:13 44:7,8	nausea 28:3	222:7
motel 153:9	44:9 163:19,20,21	navigate 117:5	nervous 57:14
mother 73:3 76:21	172:2,6 192:12	nearly 10:18	net 202:17
motivate 185:2	194:14,15 198:12	59:20 126:8	nets 201:21
motivations 66:17	mushrooms	140:17	network 132:20
	183:14		171:21
1	1	1	T. Control of the Con

networks 171:20	normalize 138:19	obtaining 18:5	193:3 194:16
neurofeedback	normative 104:9	obviously 22:17	198:19 207:19
131:5	north 157:9,14	78:4 118:5,10	old 49:1,2 73:7
neurological	northeast 51:8	121:1 178:3 183:8	130:6,8
163:7	northern 156:16	185:12 207:7	older 10:20
neurology 45:2	notably 8:17	occasion 75:1	once 43:17 83:12
neurotransmitters	notary 221:1,19	occasional 87:9	84:14 101:1,12,12
10:16 27:16	note 40:18 46:2	88:4	109:16 110:17
never 73:14 84:17	218:14	occasionally 84:3	117:10 125:13
90:18 92:4 121:13	noticed 62:2	209:3	127:12 136:17
122:11 123:10	114:13 138:9	occasions 204:2	164:13 174:19
133:4 135:7	156:16	occur 18:7,13	196:11
179:10	noticing 60:20	115:11	ones 6:10 20:2
new 9:14 13:5,8	number 7:9 25:9	occurred 144:20	34:14 35:3 36:12
14:4 16:17 33:21	25:14 36:7 42:15	ocd 2:3,6,9	39:3 57:12 78:2,4
126:4 128:11	49:1 50:9 52:14	october 1:5	78:14 80:12,14
139:19,20 156:13	67:5,14 77:21	offender 100:13	82:15 91:8 93:19
159:12 160:2	79:10 81:2 83:10	offer 125:21 127:9	106:17 107:17
167:12 188:2	104:16 110:16	132:3	181:12 185:21
189:14 210:11	112:9 117:8 118:2	offered 66:10 89:2	186:8
212:4 218:8,10	140:19 144:11	132:16	ongoing 31:7
news 49:3 201:17	173:11 174:4	office 8:19 12:18	187:4,18 217:12
nicely 72:18	189:21 194:21	15:8 191:3 207:4	online 36:19 40:5
nicotine 104:5	214:2	officer 221:2	50:10 76:13 78:10
166:4	numbers 47:17	officers 7:21	81:9,11 91:14
nida 217:20	165:20	officials 21:19	92:18 93:7 96:19
night 56:17 87:14	numerous 8:15	oh 82:4 107:6	96:20 99:13
95:7 136:12	98:17	179:3 180:3	100:20 102:4
195:19 220:11	nurse 85:13	okay 32:17 39:20	105:20 108:3,8
night's 195:20	177:13 178:10	48:7,13 49:4,21	109:2 111:14
nightshift 203:18	203:17 204:11	79:2,9,13 80:8	112:18 134:1,3,5
204:3	nurses 177:14	81:1 86:20 97:13	205:6 208:19,21
nih 13:4	204:11	97:20 106:14	209:2 210:5,13
nodding 78:6	0	107:3,4,7 108:9	211:10 212:4
nodoz 120:6	o 4:1 5:1	113:17,19 121:10	217:9
non 23:21 31:8	obesity 30:16	134:19 149:9,17	open 18:15 36:6
44:15 94:15	objective 198:7	149:19 158:17	37:1 38:20 88:13
127:13 138:19	observation	163:19,21 165:4,9	97:16 112:13
143:8 148:7 169:5	201:10	172:4,6 176:2	113:8 123:13
196:10 218:13	observed 71:10	179:21 180:3	201:13 202:13
nonlinear 152:19	obsessive 88:5	181:17 182:19	opened 209:3
normal 20:8 92:14	obstacle 133:11	183:5 186:13,20	opening 5:13,15
119:15 184:15	obtain 145:9	188:21 189:9	5:16 7:16,18 35:1
	218:5	190:17 192:13	98:6 149:1 220:8

openminded	217:4	overdosed 75:6	panelists 33:15
139:19	oral 63:3 214:15	135:13	40:13 45:6 52:3,5
operating 118:9	218:13	overdoses 55:15	52:9 53:10 70:9
opiate 70:11 94:7	order 18:13 24:1	overhaul 118:14	71:18 72:4 79:8
135:6 160:16,16	62:11 65:21 76:1	oversee 17:19	79:20 80:5,6 82:8
218:17	82:10 87:10 88:8	oversight 16:17	83:2,18 86:17
opiates 71:12,14	128:7 138:5,19	17:3 146:6	91:10 92:16 93:4
76:8 84:16,19	209:15,16	overturned 141:1	93:6 96:17 97:14
135:9 178:8 216:1	ordered 143:7	overview 15:21	103:12 107:9
218:2	organization 8:12	16:6 19:18 20:11	108:6 110:8,18,19
opinion 116:14	69:11	20:12 22:21 23:5	111:12 113:3,7
opinions 41:3,4	organizations	23:12 53:21	119:2 148:18,21
94:5 188:6	97:3	overwhelmed	149:1,20 150:15
opioid 13:6,13,15	organized 20:4	38:10	157:7 165:17
55:14 58:1,2	94:18	oxycontin 100:3	182:9,21 203:4
66:10,13 100:6	organizer 102:19	р	212:6 213:7 219:8
122:6,7 124:11	organizing 220:9	p 2:1,1 5:1	220:9
159:20 160:6,9	organs 167:8	p.m. 1:6 220:13	panels 35:6 36:6
166:2	orientation 34:9	packs 72:18	paper 205:14,16
opioids 9:21 11:18	216:12	page 4:2	parameters 32:8
11:20 13:3 53:15	oriented 163:13	paid 131:4	paramount 41:7
65:21 66:4 68:11	orphan 142:17	pain 2:8,11 6:3	paranoia 54:9
94:10,13 214:9	outcome 221:15	23:9 43:15,21	135:19
opportunity 7:6	222:12	73:8 193:7 214:7	paranoid 28:4
36:21 37:9 42:16	outcomes 45:1	painful 150:6	parent 155:11
43:6 44:18 59:16	outdoor 209:4	paired 158:5	parents 53:13
64:8 72:11 100:13	outpatient 131:1	pam 2:20 69:5,6,7	114:8
101:2 108:20	137:11 138:14	69:9 72:14 77:9	part 5:9 16:15,18
111:8 112:4,11	outside 29:21 47:9	84:1,1 86:13 92:8	33:19 34:5 39:18
113:21 137:2	50:20 129:11	pandemic 133:20	56:7 71:20 81:20
145:6 149:12	144:3 159:9	134:7 200:8	84:4 112:7 114:6
158:21 213:12	overall 16:14	201:17 202:5	115:9 122:12
opposed 105:7	56:20 215:19	206:8	123:14 128:16
131:17	overcome 91:7	panel 6:21 20:17	129:9 142:9 174:8
opposite 144:4	129:16	21:4 36:5 37:1	174:10 175:14
option 19:8 46:4	overcoming 163:2	42:16 50:17 51:20	182:7 195:15
options 20:13 21:3	overdose 9:13	64:15 71:4,4	198:5 216:4,9
21:6 31:4 32:15	11:5,7,8,19 29:13	99:17 113:15	217:12,16 219:17
79:2 80:15 82:17	30:7,19 44:17	134:13 180:16	participant
83:15 133:16	67:16 73:4,5	188:14 198:15	139:17
139:9 155:4	153:5 200:8	199:1,1,2,2,14	participants 64:13
156:17 165:15	206:11,16 207:1	panelist 69:3	78:12 138:6
178:9 200:10	214:12	72:19 81:12 92:8	participate 18:14
201:3 202:12		97:17 99:6 137:13	37:10 44:18 51:13

65 0 105 5 105 0	11.601	104 10 11 105 4 4	102 0 14 107 1
65:3 125:7 137:3	pathways 116:21	184:10,11 185:4,4	192:9,14 195:1
137:17 140:4	207:17	185:9 187:7	199:5,21 201:9,18
participated	patient 1:1 5:4,6	peers 184:12	202:15 205:21
131:1 197:17	5:10,20 9:1 14:19	pennsylvania	206:4,13,16,17
211:14 217:20	15:14 16:6,7 17:9	121:6	207:11,18 208:8
participating	17:10,17 18:9	people 7:4 8:6	208:14,15,17,20
14:21 48:4 53:9	19:2 20:4,7 21:14	9:14,21 10:11,12	209:9 210:11,13
96:19 142:8 201:7	21:17 22:3,5,19	10:18,20 11:1,2	212:3 213:10
214:4,19 215:16	78:7 94:3,21	12:11 13:18 18:14	216:7 217:7
217:8,9 219:4	95:18 111:18	19:9 20:16 28:13	people's 46:3
particular 18:7,8	142:8 146:9	31:13,17 38:2,19	47:15
18:11 35:15 51:6	175:15 182:8	47:1,7,7,9,12 50:2	perceivable 197:3
95:3 120:3 122:4	212:15 217:11	50:4,5,10 51:9	percent 11:6,8,17
173:10 195:16	220:4	54:18 62:19,20	48:10 107:21
196:21	patient's 13:21	63:21 64:2,5 70:5	108:1 189:17,18
particularly 57:2	193:11 194:3	71:5,21 72:4 76:8	189:20 200:8
93:4 96:10 117:10	patiently 172:11	77:2,13 79:11,14	202:4
164:9 173:14	172:15	79:17 80:3,18	perception 99:9
180:14 183:14	patients 17:11,19	81:2,3,4,18 82:6	percocet 100:1
219:5	18:6,18 19:14	83:6,11 85:1	perfect 107:3
parties 60:7 65:11	20:15,17 21:4,20	90:16 92:11 94:6	113:18
65:15 221:11,14	22:3,8 27:6 32:13	96:8,19 99:9	perfectly 90:14
222:8,11	43:7 53:4,7 54:5	100:10 101:11	116:13
partner 125:16	54:11,14 56:7	102:3 103:19	perform 28:12
127:21	57:5,17 58:4 59:2	104:13,16,18	performance
parts 118:5	71:13 75:19,20	107:4,11,21	28:13 126:9
169:14	94:19 95:9 102:13	108:20 109:13	period 52:12
party 45:19	102:20 167:7,10	111:15,19 112:9	60:18 66:9 144:20
partying 120:13	167:18 178:10	113:11 114:21	154:2 162:13
pass 88:7	193:15,18,20	115:2,14,19 116:3	170:1 171:12
passed 29:17 73:4	194:11 199:20	116:12 123:5	183:11,15
73:7	202:1 204:13	124:11 125:15	periodically 40:15
passionately	pattern 90:16	128:5 133:9 135:1	periods 90:3
93:11	104:15 143:16	139:14,19 140:2	152:20 162:14
paste 173:21	patterns 94:16	143:20 144:4	permissive 164:9
path 68:14 71:20	145:20 147:20	152:12 154:10	persisted 145:20
90:1 117:4 118:19	153:19 196:2	157:1 158:13,16	persistent 104:11
119:10 129:18	paula 2:21 72:20	159:6,14,16,20	person 41:1 52:18
169:6 176:19	72:21 73:2 77:7	162:4 169:11	59:17 62:9 67:16
187:6 195:15	77:10	173:14 174:18,19	70:21 99:21 107:7
paths 71:18	pay 209:12	174:21 178:18	119:11 122:13
pathway 117:6,8	pediatric 8:20	181:3 185:8	134:1 136:11
142:1 169:4 187:8	peer 70:6 138:3,5	189:17 190:2	141:20,21 142:10
	138:18 182:15	191:5,14,15,21	147:10 165:20

104 10 106 11	120 0 160 20	101 4 200 2 0	00 10 05 15 16 01
184:18 196:11	120:9 160:20	191:4 209:2,8	82:13 85:15,16,21
210:5 217:3,8	162:6 186:11,11	places 104:13	86:2 87:18 97:15
person's 196:16	200:15 205:4	138:13	103:15,21 105:19
personal 7:4 39:11	207:20 209:14,20	plan 19:11 56:3	110:16 115:17
39:12 40:8,9 41:3	210:10	137:9 179:12	117:11 121:9
41:4 50:10 70:21	philip 3:2 114:1	planet 10:15	123:14 128:10
93:19 116:14	phone 7:9 36:17	planning 118:8	135:11,13,20
130:13 190:19	38:11,13 42:15	215:8	136:16,19 139:5
205:10 208:6,18	45:13 46:1,6,17	plant 30:1 147:11	145:13 146:10
personally 176:5	52:14 127:5	147:15 148:2,4	148:3,17 150:7
perspective 9:1	139:21 140:1	173:15 174:2	152:1 154:1
13:21 14:13 22:13	149:8,10 172:9,10	206:6	158:11 180:10
32:15 41:5,10	203:1,5	planted 143:9	181:14 182:12
118:7 164:11	phones 92:19	platform 22:2	183:10 187:5,15
186:7 203:16	physical 24:2,6,8	46:20	187:17 196:21
215:7	24:9 26:11 31:3	play 16:17 40:6	198:9
perspectives	53:21 54:3 57:16	played 141:10	points 7:2 37:21
17:12 18:18 36:2	61:5,15 95:14	152:7 206:11	105:1 157:7
113:1 219:8	140:20 143:21	plays 97:3 106:9	police 74:2 75:3
pertaining 192:6	193:8 214:12,15	154:15	policies 43:2
peru 173:11	physically 26:9	pleasant 120:17	112:10
pfdd 18:4,15 19:8	95:16 144:2	please 16:9 17:8	policy 37:6 53:7
22:18 52:21	physician 8:21	17:16 19:1,17	poll 46:5 47:11,17
ph 91:20 97:1	127:8	20:5 21:13 22:10	polling 7:5 36:7
158:4,10 193:3	picked 116:7	33:9 37:8 39:11	36:16 45:18,20,20
pharmacist 204:9	picking 54:14	39:15 46:2,17	46:12,16,20 48:19
pharmacological	55:10 89:21 127:4	48:5 49:14,16,19	50:12 51:17 78:8
28:15,17,19 31:5	piece 124:12 155:8	52:10 71:4 78:18	78:11,18,20 82:14
215:21	pieces 35:6 54:15	92:18,18 97:19	158:19 168:5
pharmacologists	55:10 56:2 57:14	99:14 102:6 112:1	181:11,13,17,18
17:2	200:16	112:3,11 113:13	186:14,17 188:1
pharmacology	pigs 208:4	149:6,14 175:19	polysubstance
175:2	pill 91:6	178:20 179:19	11:13 72:16 95:2
pharmacotherap	pills 67:3 75:10	183:4 190:7 205:7	95:4 154:4 160:4
142:20 163:16	120:3 143:5	209:17 212:13,21	160:13 214:8
pharmacotherapy	pin 143:5	pleasure 7:17	popped 100:16
167:11	pinpoint 99:4	59:21	population 31:10
pharmacy 204:1,7	pit 95:5	pledge 97:4	31:19 94:3 198:5
phentermine	pivotal 166:6	plenty 187:5 205:1	207:2 212:2
119:16 120:12	169:14 184:3	plummeted 61:7,7	populations
122:21	place 7:2 22:18	pocket 128:17	206:12
phil 97:21 98:2,4,5	77:11 117:10,13	131:4	portion 52:7
99:12,12,14	127:15 179:6	point 16:1 48:18	158:13 198:5
113:16,16 119:1,7	184:14 185:3,14	58:16 66:20 72:15	212:1

position 8:18	prefaced 119:12	press 220:2	problem 31:2 51:3
93:20 195:17	prefacing 180:18	pressed 203:20	68:12 69:17 70:12
positioned 17:20	prefer 70:19	pressing 9:17	75:17 88:15,17
positions 8:16	122:17	pressure 27:19	89:12 100:1,3
positive 12:4,5	preferred 215:5	presumed 145:9	120:10,11,18
56:15 63:10,14	pregnancy 156:3	pretty 78:21 81:14	121:9,12 125:20
67:20 169:10	156:10,19	88:11 115:18	125:20 126:20
positivity 12:9	pregnant 156:12	128:6,19 145:20	150:9 151:5,16
possibility 63:20	156:18	192:4 204:16	152:7 154:19,21
121:2	preparation 35:11	205:6 210:2	155:13 159:19
possible 38:2,12	preparations 30:2	prevent 91:8	160:9,15,16,17
78:5 93:1 115:6	prepare 33:16	prevented 127:4	176:9 209:18
123:6 178:18	prepared 222:3	preventing 8:9	problematic
180:13 202:15	prescribe 120:2	prevention 12:14	105:10 141:18
213:11	prescribed 23:20	14:10 15:8 97:8	143:10 145:20
possibly 85:11	30:15 49:13 58:3	167:1	152:20 183:17
89:2 119:18 149:1	60:19 70:17 92:12	preventive 191:1	202:2
191:2	154:20	prevents 67:12	problems 25:3
potencies 30:2	prescriber 139:6	previous 118:2	26:2,11,15 29:12
potent 29:7	prescription 9:21	137:13 149:2	29:13 30:6 31:3
potential 178:7	10:1,13,19,21	previously 36:18	32:5 63:5 66:5,16
217:6 218:11	25:12 27:5,15	45:4 182:2	67:5,17 68:7
potentially 57:21	29:3 30:9 31:14	price 209:12	70:13 90:5 95:15
167:12 191:5	49:15 60:16 61:21	primarily 11:20	174:6
potently 10:15	62:3 79:12 81:5	13:18 69:10 72:8	procedures 191:7
powder 105:8	85:21 92:9 94:13	primary 127:8	proceed 33:5
powerful 140:9	94:16 103:2,4	191:1	proceeding 222:4
powerless 184:5	119:14 120:3	principal 8:2	proceedings 221:3
practice 131:15	135:10 140:18	principles 132:7	221:4,6,8 222:6
142:1	154:18,19 176:7	prior 74:14 221:5	process 6:20 16:19
practiced 117:8	178:2 204:5	priorities 17:12	17:19 22:20
practices 29:11	213:18	54:20 55:5 96:6	137:19 138:10
117:9 174:4 175:3	prescriptions 6:7	prioritize 201:15	144:16 169:14
practicing 131:12	79:3 123:21	prison 121:6	184:1 185:15
pre 192:18	127:10 217:5	155:2	187:18
precisely 10:9	present 25:9,15	proactive 207:15	processes 131:21
161:21	26:21 37:13 169:1	probably 104:15	187:12
precursor 29:18	185:16	106:3 114:10,13	procrastinating
predisposed 92:13	presentation 23:4	114:16 117:2	84:9
predominantly	61:6	129:2 141:15	produce 173:18
69:14	presentations	153:12 168:19	produced 147:19
preface 164:3	33:17 34:21	173:16	producers 106:20
180:6	presenting 105:9	probation 121:19	182:3

18:8,11 22:20 properly 111:10 34:1 37:5 40:20 121:14	24:2,6,8,11,13 26:11	q qr 46:7
34:1 37:5 40:20 121:14	26:11	
		qualified 221:7
42:4 104:20 175:4 properties 218:12	psychosis 28:3	qualifies 152:21
production 29:16 prosocial 56:16	29:13 54:9 57:13	qualify 27:4 194:1
29:19 166:19	73:18 74:6 75:13	194:5
products 44:10 protect 16:15	95:13 214:13	qualities 105:10
45:2 protection 209:6	psychosocial	quality 133:12
profession 62:5 protections	196:17	163:14 170:3
professional 71:1 104:19	psychostimulants	187:13 198:10
71:11 193:12 protective 123:3	11:5	quell 65:21
205:11 200:20	ptsd 194:20	question 46:16,18
professionals prove 145:4	public 1:1 8:1,2	46:20 48:2,3,7,19
34:20 96:5 101:11 proven 133:17	9:17 10:7,9 15:16	49:1,6,8,11 50:16
profound 54:2 provide 6:4 7:18	16:15 38:18 39:9	50:18 78:21 79:20
program 13:13 15:14 17:3 20:12	39:9 43:3 47:6	80:11 82:14,14
15:15,16 17:7,15 23:4,12 38:9	57:17 99:9 115:2	83:1 93:5 105:21
19:13 42:21 85:13 45:13 93:14	155:15 218:4,9	106:16,21 107:2
125:18 127:6 provided 71:15	221:1,19	109:3 113:8,12
128:2,7,20 129:7 212:10	publicly 219:10	150:3 151:2 152:3
131:17 132:7,17 provider 40:21	published 12:1,7	161:1 163:19
133:5 138:4 146:4 131:4 194:6	24:20 218:15	165:9 180:10
146:10 156:15 providers 21:18	pull 182:2	181:11,18 182:21
158:4 205:20 96:4 133:7,8	puppies 98:18	183:4 186:14,17
programs 13:12 190:20 216:17	pure 215:17	187:16 188:1
127:11 130:17,18 provides 20:19	purpose 128:18	189:10 192:18,18
131:1,2 133:12,16 21:8,11 118:18	purposeful 34:13	question's 194:16
133:18,20 142:9 providing 5:15	pursuit 68:1	questions 7:6
165:21 194:10 50:8 169:12	push 15:3 211:21	32:14 36:7,8
212:1 215:17 pseudoephedrine	pushed 85:18	40:16,17,19 41:15
progressed 151:6 29:19	145:2	45:7,19 46:10,12
progresses 99:7 psilocybin 183:14	put 40:9 74:10	46:19 50:13 78:8
progressing 91:1 psychedelic	90:10 104:7	80:7 101:21 102:3
progression 80:16 194:19	128:17 136:17,18	110:6,13 119:3
125:19 psychedelics	136:18 140:18	125:2 148:19,20
project 95:21 183:13 195:15	156:10 171:17	149:6,13 157:4
projects 8:20 13:4 196:15 197:18,19	178:1 180:6 182:7	159:1,3 163:19
102:15 psychiatric	184:16 200:15	168:5 172:6
promising 181:6 117:21 130:21	puts 28:7	181:14,17 189:6,7
promote 16:15 psychiatrist 44:9	putting 7:9 15:7	190:6 192:13
promoting 8:4 psychiatrists	74:21	198:14
prompted 113:9 173:12		quick 15:21 19:18
proof 115:4 psychiatry 2:12		102:8 115:18
2:13 44:4,10		186:18 203:10

quicker 55:8	readiness 129:15	90:7 91:12,16,18	196:5,6 197:4,10
122:6	reading 103:11	92:21 94:1,20	197:14,16,20
quickly 54:6 65:9	205:15	95:14,21 96:14,14	198:1,6,10 199:2
128:19 154:13	ready 46:17	97:9 101:17,17	199:6 200:12,15
155:21 176:14	126:17	102:5,8 103:7,14	200:20 201:6,14
210:3	reaffirm 14:8	103:17,19,21	202:2,8,11,19
quiet 102:10	real 38:19 103:21	105:2,11,15,18	205:13 206:3,8
quit 126:17	107:20 151:14	106:2,15,16 107:6	207:14 210:11
135:14	191:17 203:10	107:10,15,20	211:6 212:8,10,19
quite 19:21 74:1	208:1	108:14 109:2	213:3
93:11 99:3 122:4	realize 61:3 63:9	111:8,10,10,18	realm 148:3
183:16 200:3	74:20 120:19	112:4,6,8,20	reason 39:10
quitting 126:17	135:15	117:11,12 120:7	58:15 60:4 114:18
129:19	realized 136:10	120:11 121:13,15	122:8 138:18
quotation 127:7	137:20 146:16,21	124:15 127:2	139:3 142:9
r	193:13	128:9 135:5 136:5	147:21 161:7,8
	realizing 123:8	137:4,14,19	162:12 177:2
r 2:1 5:1 race 154:15	really 5:11 6:13	138:20,21 139:11	208:8
216:12	15:10,15 18:5	139:12,13,13,18	reasonably 125:17
radtke 222:2,15	19:12,21 20:8,9	140:8,8,9,17	reasons 11:10
radike 222.2,13	22:2,11,18,20	143:9,17 144:5	28:10,11,14 29:1
rails 58:3	32:18 33:1,14,17	147:12,16,17	31:14 122:15,20
	33:19 34:7,12,12	148:13,13 150:5,5	193:7,10 214:3
ran 185:4	34:16,17 35:18	150:14 151:6,11	reassess 98:2
range 19:21 50:6	36:8,14 37:1 38:7	151:17,19 152:3	reassure 57:17
ranges 104:9	38:19 39:1,16	153:11,16,18	recap 108:17
ranging 50:3	40:2,12,16 41:6	154:5,8 156:4	receive 18:2
	46:12 47:4,10,15	159:11 162:14,19	139:10 160:14
rapid 108:10	47:19 48:3 49:10	162:19,21 167:1	196:19 219:19
rapidly 207:7	50:4,7,9 51:1,2,3	167:19 168:10,17	received 75:12
rare 141.4 rarely 115:16	51:12,15,17,21	169:13,17 170:1	100:20 108:18
rate 12:3 27:18	52:9 53:1,4 54:4	170:12,14,19,20	112:17 157:1
rates 12:10 206:20	54:15 55:1 56:3	170:20 171:11,21	194:2,17
rationale 186:5	57:9,12,16 58:9	175:6,9 179:1	receiving 142:19
reach 154:16	58:12 59:3 60:1	181:16 183:10	168:14
165:18	60:19 64:1 69:1	184:3,10 185:7,10	recognize 120:18
reached 144:8	70:1 71:7 72:1,7	185:17,21 186:6,6	162:1 219:10
reaction 115:18	72:15 73:19 76:14	186:8 187:14,17	recognized 142:6
reactionary 196:1	77:9,12,12,13	187:20,21,21	150:8
read 99:14 181:20	78:5,14 79:15	188:7,10,17,19,20	recommend
194:18,21	80:15 81:6,15	188:21 190:12,19	127:11 132:9
readily 58:21 70:3	83:4,16 84:8,20	191:8,18 192:7,12	recommendation
71:14 84:4,6	85:2,8,14,17,18	192:12,19 195:16	14:5 192:5
/1.17 07.7,0	86:14,14 89:3,5,6	195:19,21 196:2,3	

recommendations	201:15,21 202:6	regularly 127:20	remains 148:3
192:7	202:16 205:17	regulated 104:6	remarkable
reconvene 110:16	207:17 208:2,9,10	104:20	191:18
record 221:9	210:1,7,11,12,15	regulation 186:5	remarks 5:13,15
222:5	212:1 215:8	196:3 203:19	5:16 7:16,18
recorded 7:12	recovery's 114:12	regulatory 17:3	15:20 35:2,12
221:6	recreational 26:16	32:15 191:13	180:6,18 211:12
recording 7:11	88:4 104:10	rehabilitated	212:20 213:5
221:8 222:4	116:13 141:16	137:4	220:8
records 144:13,19	recreationally	reinforcing 97:10	remember 60:9,10
recover 209:7	89:11	reiterate 209:19	91:2 112:3 139:4
recovered 115:11	recurrence 153:20	relapse 180:5	140:17 153:10
recoveries 206:13	154:2 206:13,21	216:8	193:6
recovering 26:6	recurrences 173:8	relapses 202:7	remind 15:6
98:10 99:1 125:8	red 182:15	relapsing 171:1	reminder 77:17
recovery 12:14	reduce 189:20	relate 43:3 68:3	77:18
54:14 55:13 56:3	reduced 221:6	related 11:5,7,8	remission 117:16
59:18,21 63:1,5	reducing 131:13	12:20 13:2 67:14	repeated 26:8
63:11,12,15 65:1	reduction 69:10	67:16 68:9 81:8	replace 67:9
70:15 92:4 98:12	69:12 158:5 169:8	87:5 90:5 97:19	report 8:5 22:5
99:10 102:14,20	218:7	103:20 104:12	111:17,18 112:7
113:9 114:2,4,5,7	reference 23:15	108:18 153:5	175:15 182:8
114:9,14 115:6,7	references 133:3	160:3 214:15	200:8 212:15
115:9,10 116:19	referred 125:18	221:11 222:7	reported 1:20
116:21 117:7,14	refilled 204:5	relationship 62:16	11:1,2 200:6
117:16,18 118:1,8	reflect 20:17	114:9 126:4 138:1	201:1 202:7
118:19 119:10,11	78:17	141:13 183:20	reporting 202:4
122:14 124:5	reflected 78:3	196:6	representatives
126:1 127:1 128:3	reform 192:4	relationships	18:10 22:3 37:5
128:8,17 129:17	refreshed 168:11	26:15 54:11 56:15	representing
130:6 131:10,12	refuge 132:6	215:3,17	34:14
131:17 132:7,8,10	137:14	relative 221:13	represents 8:11
133:8,11,20,21	regard 21:1	222:10	32:19
134:9 137:9,14	regarding 93:11	relax 145:18	reprioritize
138:2 141:21	93:13 131:19	release 27:15	177:19
150:10 153:17	158:10 205:12	released 169:18	require 216:14
154:14 158:4	regards 129:3	192:3 206:8,16	required 88:7
163:13 166:20	region 30:19	reliable 117:20	requires 173:17
167:14 169:6,15	50:18	relief 173:14	rescue 56:10
185:5 186:9 187:6	register 38:18	relies 200:17	research 5:7,19
187:10 190:11	212:14	relieve 170:15	8:20 12:15 13:1,4
193:12,16 195:16	regular 29:20 68:7	remain 21:21 38:3	31:7 45:3 76:12
198:6 200:7,11,12	170:1	124:4 211:18	102:15 197:21
200:13,19,20			198:10 206:9,15

212:19	resulting 31:2	208:12,19 211:17	rushes 10:16
researched 148:2	results 12:2 29:8	rights 104:18	rutherford 3:2
researchers 21:17	48:11,13,15,15	142:11	99:15 113:17,19
37:6	82:21 182:7,20	ripple 207:9	114:1 161:2
resentful 197:13	202:20	rise 171:4	186:18,21 198:17
residential 130:12	retention 191:19	risk 12:11 29:10	207:21
resilient 210:8	retrain 131:20	30:5 74:15 148:6	ryan 205:16
resistant 190:21	return 96:16	174:14 206:16	S
resonate 64:12	116:10	218:3	s 2:1 4:1 5:1
resonates 52:9	returning 56:13	risky 25:3 26:2,8	s 2.1 4.1 3.1 sad 74:11
resort 115:15	111:5,8	29:11	sate 104:20 191:4
resources 117:19	returns 116:10,14	ritalin 6:7 30:12	195:5 202:14
118:6 123:17	reversed 35:1	49:13 92:12	209:4
134:7	review 16:21	road 129:17 177:1	
respect 14:5 41:6	23:14 111:21	robust 128:7	safety 16:16 44:16 201:21 202:16
41:7	reviewed 198:10	robyn 1:4 2:3 5:5	salts 147:17,21
respectfully 41:9	reviewer 23:8	15:17 16:4 22:14	sants 147.17,21 samhsa 12:18
respiratory 30:8	43:20	81:10 91:19 97:1	samples 12:4
respond 79:6	reviewers 111:21	101:6 106:7 119:7	samples 12.4 sat 151:20
192:14	reviewing 32:20	125:7 156:9 193:2	save 77:5
respondents 200:1	112:17	209:18 211:16	saved 168:19
responding 47:1	reviews 43:13	213:1 220:3	savings 127:15
101:7 113:12	rhode 206:15	role 8:10 16:13,18	saw 65:17 81:2
165:8,12 182:1	rhythms 196:3	28:21 42:4 141:10	98:1
response 13:13	rid 55:9 73:8	141:11 145:12	saying 33:13
28:14 31:11,20	ride 100:7	147:17 152:7	81:13 82:5 85:13
32:1,10,11 160:21	right 6:20 7:8	169:3 215:17	91:21 97:2 101:9
191:16	16:11 46:17 47:18	room 133:10	106:8 107:4,6,21
responses 46:3	47:18 50:5 60:15	153:8 204:17	108:2 109:8 116:1
47:3,3 49:5,21	64:19 75:7 81:1	root 71:7 122:12	156:5 157:8 158:2
50:8 79:10 81:11	82:13 88:10 90:2	122:12	158:12 178:17
83:10 115:20	93:21 95:12 97:12	rope 177:10	180:7 189:20,21
181:19 189:1	99:6 106:6 110:3	roughly 27:12	193:4 195:3
responsibilities	110:3 122:5	rounded 131:8	says 107:7
26:13 68:7	123:12 134:20	routes 31:18	scare 97:7
responsiveness	138:13 143:15	routine 190:21	scared 73:19
116:18	144:21 146:17		schedule 30:13
rest 62:16 94:15	149:9 161:14,20	routinely 143:19 rules 39:20	110:4
restrained 144:2	162:11 166:10	rules 39:20 run 20:4 45:20	scheduled 97:17
restricted 177:8 result 27:16 28:14	178:5,15,15		scholarship 76:17
29:12 30:14 55:15	179:17 182:14	123:4,5 134:4 running 186:13	school 26:14 28:12
59:21 62:9 63:15	196:13 199:19	running 180:13 rush 60:11 61:12	60:7,19 61:4,11
67:9 120:20	206:8 207:13,13 207:13,19 208:9	112:14 170:16	69:20 84:8,10
07.7 120.20	207.13,19 208.9	112.14 1/0.10	102:11 214:20

[science - shared]

scientific 46:14 scientifically 166:18 scope 104:12 159:9

scoping 192:4

scott 2:19 64:16 64:17,21 68:21 77:9 90:6,15 screen 7:8,10 16:11,11 42:12 48:10,16 77:20

106:19 114:16

152:16 165:11 screening 18:13 screens 140:4 script 34:18 seattle 88:14,17 second 6:14 30:18 37:19 107:1 110:19 164:8

182:1 190:5 198:1

199:2

82:19

seconds 47:15

secretary 5:14 7:19 10:9 **secretary's** 8:2

section 134:14

see 16:10 19:20

23:13 29:5 32:10 32:10 33:6 36:3

37:7 40:15 42:12

45:6 46:3 47:13 48:11,12,14,15,17 48:17 49:4 50:9 51:16 60:17 63:2 73:19 78:5,6 79:9

80:1,18,21 81:8

90:8 91:1,20

179:17

206:9

133:18

science 8:2 131:20

Public I	Meeting	October 6, 2020
		Page 37
96:17 97:21,21	senior 20:11 44:13	settles 178:5
101:11 104:15	44:21 70:4	setup 35:5
105:5 107:4	sense 20:6 80:9	seven 25:5 116:5
108:14 109:1	128:18 155:10	severe 27:10 29:12
110:21 113:1	164:12 201:6	58:18 104:10
131:16 134:17	sent 146:3	152:21
147:4 148:18	separation 115:10	severities 25:8,14
149:3,4,9 150:19	sepsis 70:14 85:12	severity 18:18
157:21 159:13	septic 70:14 85:16	sex 62:12 154:15
165:9 176:12	serious 126:16,21	sexual 28:13 29:11
177:4 178:7 179:8	129:6	58:15 216:12
181:19 182:2	seriousness 40:1	sexuality 30:4
188:4,5 189:4	serve 5:8 8:18	sexually 143:19
205:1 218:19	185:6	shadows 57:6
seed 143:9	served 8:15	shame 127:4
seeing 36:13,15	service 8:1 124:6	129:15 155:12
47:4,4 49:21	128:19 144:15	193:8
89:11 91:14,16	services 2:5 7:21	shannon 2:16
107:4,7 108:15	8:15 12:15 123:3	45:12 81:7
124:7 135:19	134:1 139:15	shaped 144:7,9
185:17 189:1,13	192:8 194:7	share 7:6 14:16
193:20 200:19	196:19 200:4	22:21 33:4 34:8
206:11,20 207:3	201:15 202:13,14	35:7,10 38:13,14
seek 57:6 136:1	217:1	39:12,16 48:10
150:9	serving 8:17 154:9	52:10,14,16,17
seeking 104:15	session 6:12,14,16	53:16 59:2,9,15
114:19 115:16	21:3 33:10,12	60:1 64:17 68:20
143:17 147:20	52:4 97:18 100:17	72:12,20 77:21
190:21 213:14	106:5 108:17,19	78:17 81:9 86:12
215:18 219:16	110:7,9,16,18,19	92:21 97:15,19,20
seen 71:12 73:14	113:8 149:2	102:4,9 107:18
191:8 213:21	158:19	108:21 109:4
seizure 28:5	sessions 6:11	112:4,5,12 113:16
seizures 30:7	131:2 201:5	119:5 125:4
153:11	set 34:10 51:18	134:21 140:10
select 86:4	105:14 117:15	157:2 165:1,20
self 29:9 54:17	136:3 200:12	175:18 185:20
55:1 102:21	setting 7:3 37:19	190:9 192:17
146:12 183:11,15	78:5 108:15 132:4	199:3 203:6
183:19 193:8,9	175:5 212:4	211:11
215:15	settings 62:19	shared 22:8 68:17
semester 84:12	137:8 148:7	69:20,21 77:17
Deficition OT.12	15/.01-70./	70.20,2177.17

161:16 211:21

78:3 80:10 81:15

82:5 110:20

send 36:9 38:16

39:2 74:9 204:9

October 6, 2020

[shared - sooner] Page 38

148:15 174:11	shows 208:12	situations 54:12	social 25:3 26:2,12
183:1 212:10	shut 201:12	63:18 160:11	26:16 28:11 31:2
217:10 219:8	shutdown 199:20	177:15 211:19	58:14 105:2 115:8
sharing 45:10	sick 10:12 84:19	six 12:5 63:11	141:15 147:19
50:13 52:4,6,11	side 54:3 124:2	113:3 126:2	153:15 167:14
53:11 59:6 69:1	134:6 203:16	131:12 207:8	169:16,21 171:19
77:10 81:14 82:11	sidenote 203:10	size 132:13 198:2	196:18 206:4
86:17 103:17	sign 216:9	skill 151:10	211:21 212:3,3,4
106:13 109:20	signature 221:17	skills 28:20 139:4	214:4 216:12
113:5,11,13 140:8	222:14	185:1,2 221:10	socially 26:16
148:16 149:20	significant 11:11	222:6	28:16 209:5
156:7 164:1	12:9 55:16 69:17	skin 115:13	societal 209:11
165:17 168:10	70:13 72:7 198:4	sleep 87:14 141:6	216:4
178:19 179:15	200:7	141:8 174:21	societies 147:18
186:12,14 192:21	signs 25:21 28:2	195:20 204:4	169:7
194:12 195:8	29:13 62:2 168:15	sleeping 56:16,17	society 14:19
205:3 211:8 212:8	silent 21:21	slide 16:9 17:8,16	201:13
212:13	silver 1:10 211:20	19:1,17 20:5	socioeconomic
she'd 109:8	217:6	21:13 22:10 33:6	161:20
she'll 45:10,11	similar 13:3 21:11	46:7,9	sokolowska 2:9
sheldon 2:19	25:10 30:3 58:19	slides 23:13	4:7 42:18,19,20
64:18,21,21 86:19	58:20 76:9 91:17	slipping 176:17	93:4,8,9 212:17
86:21 87:6	91:18 104:15	slips 56:7,12 202:7	213:1
shelter 144:15	105:9 109:13	slowed 137:17	solution 81:20
shift 124:7 154:9	115:19 176:10	small 83:10	198:3
204:1	216:1	102:15 119:9	solutions 15:4
shifted 144:10	similarly 55:18	136:3 205:19	167:12
shipped 121:3,4,5	56:11 105:9 147:8	smart 117:7	solve 161:4
shooting 135:12	194:21	131:10,12,16	somebody 73:21
135:14	simple 208:1	133:21	84:7 89:2 99:13
shopping 119:20	simply 71:8 89:19	smith 3:5 130:5	105:7,20 107:14
shops 104:13,17	115:2 143:8 162:5	smoke 104:13	175:18 178:11
short 21:7 32:11	208:18,19,21	smoked 173:21	197:15 202:21
84:13 128:7	simultaneously	smoker 123:14	somebody's
133:18 159:3	140:21 194:6	smoking 67:4	162:11
193:15 214:12	single 25:8,13,20	123:15 124:1	son 73:4,6,7,12,20
show 10:18 11:4	31:16 116:5	162:21	74:3,12,14 75:2,5
34:8 138:5 169:3	187:17 196:13	snack 111:7	75:9,12,15 76:2
showed 12:9	sir 9:4 15:5	snorting 67:3	76:17,20
158:14	site 45:21	69:19	soon 33:11 66:4
showing 48:9	sitting 35:9	sober 128:1,12	84:5 134:17 sooner 129:6
185:1	situation 126:19	129:1 171:16	
shown 31:6	127:12 156:18	sobriety 128:6 206:18	150:2,10
	159:6	200.10	

[sorry - stigma] Page 39

sorry 16:2 26:7	219:10	springboard	starting 36:5 61:4
91:3 98:18 102:9	specialist 101:10	21:12	115:17
108:7 110:3	138:3	stability 169:18	starts 20:16
148:14 165:10	specialists 17:1	stabilized 146:9	state 13:13 38:5
175:11 178:16	specific 19:7 21:15	stable 117:18	68:4 69:11 157:11
179:2,3,4 186:17	42:6,7 99:4 100:9	127:15 214:20	196:1 197:7
192:11	119:13 123:21	staff 20:12 143:5	221:20
sort 19:18 54:14	124:15,17 188:18	144:2 218:20	state's 142:8 146:4
56:9,9,15 59:1	specifically 63:17	220:5	146:9
62:8 63:21 94:1	64:1 65:4 67:15	stage 66:16 134:9	statement 48:7
94:12,14 95:12	86:21 90:17,20	150:12	192:3
102:12,18,21	98:8 100:5 122:1	stakeholder 45:1	states 8:11 13:17
103:3,5,10 118:7	155:3 181:1 192:6	stakeholders	50:18 51:4 159:9
118:15,19 150:3	205:12 213:9	219:2	177:8
161:3 166:5	spectrum 104:9	standard 21:16	statistical 24:19
167:20 199:19	105:15 114:6	standing 129:11	statisticians 17:1
200:10,19,21	153:1	standpoint 161:18	status 65:17,18
201:1 202:8	spend 6:1 41:10	stars 34:7	133:13 216:13
sought 115:14	71:21	start 5:13 7:15,16	stay 37:13,17 41:1
125:17 130:11	spending 26:5	21:4 33:11,13	65:14 84:10 87:10
sounds 159:16	spent 136:9	42:18 46:18 51:19	118:16 121:17
160:13	142:21	52:4,15 58:16	122:20 123:5
source 173:18	spike 71:16	78:20 79:1 81:2	140:3 145:4,16
south 173:10,20	spiraling 130:13	98:1 108:17 113:4	187:9 202:1
174:18	150:5	113:4 123:15	stayed 68:5,5
southern 151:7	spiritual 128:15	129:16 136:21	staying 65:12
space 102:11	132:9 133:16	150:18,20 152:16	steal 99:20 100:2
161:5 209:4	166:20	165:8 169:20,21	step 91:21 117:7
218:18	spoke 91:11 93:10	172:10 188:10	127:14 128:2
spain 177:3	216:16	started 49:18,18	131:2 132:15
spark 89:19	spoken 70:9	58:12 60:20 61:21	142:4,5 171:14
spawned 126:9	182:10 183:8	65:7 69:10,18	197:6 201:2 210:4
speak 35:10 37:20	spondylitis 141:3	70:6 73:8,10,12	215:16
37:20 38:2 40:10	sponsor 128:14	73:13 75:3 76:14	steps 128:8,14
45:12 59:5 77:6	210:15	79:11,14,14,17	197:11 202:10
93:13 101:2	sponsoring 128:20	92:1 119:13	stick 56:6
106:11 203:2	sporadic 32:11	122:21 125:11,14	sticks 208:5,16
speaker 22:15	87:7	125:21 126:12	stigma 54:17 57:1
175:20 176:2	spot 81:14 90:11	127:18 128:14,20	57:5,20 58:6
178:21 179:3,20	173:1	128:21 135:5	93:11,15,16,21
180:3 203:9	spotlight 8:8	140:17 146:8	94:12,17 95:21
speakers 78:4	spread 157:10	147:6 160:9	97:2,3,7,10,12,15
speaking 14:16	spring 1:10	173:13 176:17,17	97:19 98:9,9,11
38:3 82:8,8 169:5		176:19,20	98:11,12 99:2

[stigma - stuff] Page 40

100:9,15 105:1,13	120:8 122:1,12	147:4 158:14	144:20
106:3,7,9,12,21	123:7 130:7	160:6 162:12	streets 62:4 74:10
109:4,7,15 110:20	137:21 139:2	180:17 188:8,9	88:15,18 144:17
115:12 119:12	140:16 141:11	190:1 213:18	145:17 191:15
129:15 138:15	147:8 153:5	214:4,9 215:21	strengthen 12:15
152:6 216:17	156:14 157:15,16	216:6	stressful 201:17
stigma's 57:7	159:17 160:8,10	stimulation 31:8	201:17 202:17
stigmatize 97:4	162:20 163:3	stock 204:7	stressors 201:20
99:8	166:8 170:8 173:3	stone 208:5	strictly 132:9
stigmatized 100:4	174:15 178:6	stop 26:8 32:3	strides 9:20
219:14	180:8,11,14,18	33:11 77:5 86:3	stringent 203:19
stimulant 1:25:5	181:3,13 187:3	95:21 101:13	stroke 29:15 30:8
6:4,9,13,16,17 7:4	188:3 189:14,20	123:18 125:17	74:14
10:1,21 12:17	190:11 192:1	126:3,20 135:14	strong 25:15 26:7
13:15 14:9,12	199:4 203:6 213:9	151:18 170:13	26:7 51:7 70:9
15:9 22:13 23:5	213:13,21 214:10	171:1 188:8	202:2
23:18 25:13,20	214:17 215:1,6,19	189:18	stronger 84:17
26:14,17,20 27:1	216:3,13 217:13	stopped 24:10	strongly 198:1
27:5,6,9,10,13	217:15,21 218:7	27:8 49:18 164:14	structure 34:10
28:2,7 30:14 31:1	219:1,6,11,13,18	stopping 131:13	struggle 57:8 95:3
32:21 34:7,15	stimulants 6:5	store 67:6	103:7 151:17
35:4,14,16 36:1	10:13,13,19 23:11	stores 201:12	165:14
36:12 37:6,8	25:12 26:9,15	stories 14:17	struggled 53:13
40:11,12 41:16,19	27:14,15,15 28:10	35:11 41:4 59:2	53:14,15 94:7
42:9 44:5 48:8,20	28:13,16,18 29:2	149:21 174:5	127:2,10 130:7
50:11 51:3 52:2	29:3 30:10,15,17	story 41:5 69:1	147:7 176:6
52:18,21 53:2,14	30:20 31:14 48:21	84:13 134:21	200:20 213:16
54:17,21 57:1	49:3,10,12,16,20	157:18 183:10	struggles 58:19
58:17,18 60:3,4	54:1 55:7 58:5,13	straight 84:11,14	164:15
65:4 66:1,15	60:5,13 63:18	176:15	struggling 55:18
67:19 68:9,14,19	64:1 65:9,13	straightforward	57:3 58:4,8 59:3
71:3 75:5 76:1	67:16 70:7 75:16	78:21	94:15,19 95:1,9
77:2,14 78:13	75:19,20 76:6,14	strata 161:20	96:11 102:21
79:1,4,17 80:17	76:16,19 79:12	strategic 5:18	198:6 210:12
82:16,17 83:7,8	80:13,13,19 81:5	strategies 142:3	213:16
85:21 92:9,11	86:9 89:18,20	174:9	studies 32:10
94:7,10 98:8,16	90:17 92:12,14	strategy 14:17	180:12 206:5
99:3 100:4,11	93:12 96:11 100:9	97:8 146:16	study 12:1,6 31:16
102:12,16 104:7,8	100:10 103:2,3,13	217:17	31:18 32:11
104:12 105:4	104:7,14 107:8,18	stratification	159:12 206:9
106:12,18 107:12	122:16 124:8	105:4	stuff 99:21 100:2
108:2 112:21	135:4,7,17 141:10	straw 208:5,9	100:16 117:7
114:19 115:3	141:12,17 144:20	street 72:1 75:7	187:11
116:13 119:13	145:12 146:13,17	136:12 138:11	

[style - take] Page 41

style 20:10	212:18	support 41:17	swallowing 67:3
subject 37:2 99:16	substantial 169:11	42:2 82:10 126:2	swings 54:10
161:6	substitute 147:8	132:20 137:12,17	95:13 214:13
submit 39:6,7,9	159:21	138:3 139:18,21	switch 71:14 83:1
42:13 77:17 92:20	success 14:4,12	145:14 166:17	switching 200:9
102:4 112:3	32:7 56:6,13,13	169:12 171:21	217:3
submitted 17:6	56:14,19 59:2	181:4 182:15	sworn 221:5
111:13,16 157:2	successful 114:20	184:11,11 185:6	symbol 65:18
submitting 38:8	116:4,6,17	185:10 187:7	symptoms 20:14
suboxone 76:7	sucks 139:18	202:16 204:19	24:6,7,11 25:2,5,9
subsequently	sud 75:21 94:5,20	208:17 215:18	25:15 26:12,21
206:21	202:14	217:3,9	27:2,3,18,20
substance 8:9 9:13	sudden 135:20	supporting 173:13	37:15 56:11,18
9:16 10:4,5 12:11	206:19 207:11	supportive 117:19	57:12,16 58:19
14:11 15:9 24:3	suddenly 104:17	167:4 169:15	95:12,12 160:8
24:15,20,21 25:1	suffered 55:14	supposed 60:21	syndrome 141:2
25:2,3,4,7,10,16	115:3 152:2 211:1	91:2 120:4 195:6	synthetic 11:20
25:21 31:17 43:5	suffering 8:8	sure 48:10 50:4	syringe 156:15
58:8 61:9 71:3,8	13:18 135:2,16	58:12 79:4 103:6	system 14:10
76:1 82:7 93:12	152:2 184:17	150:17 151:1,21	105:5,7 109:18
95:18 101:14	sufficiently	156:8 157:5	120:9,15,21
107:12 109:14,17	143:14	159:15 161:2,19	121:16,17,18
115:18 116:12	suggest 31:15	162:9 172:18	136:18 138:4
122:4 124:15,17	suggested 129:8,9	178:18 181:20	155:16 159:8,8
132:14 137:10	suggests 11:18	183:7 190:16	171:6 191:21
161:8,12 164:7	suicidal 73:21	193:2 202:14	214:21
168:15 173:4,20	suicide 136:16	204:4	systematic 17:11
176:21 183:17	suitable 32:3	surely 109:12	18:17
184:5 185:3 194:4	sulphate 173:19	121:11	systemic 209:8
194:20 196:7	sum 118:4	surgery 179:8	systems 12:16
200:7 202:1	summarize 38:12	surround 175:3	55:20 122:1
204:21 205:21	213:6	surveillance 12:16	139:20 153:14
206:1 213:8	summarized	survey 10:17 11:1	154:7 155:2
215:14 216:18,21	111:17	46:8,9,14 199:20	200:11
218:21 219:15	summary 111:19	202:20	t
substances 10:15	summit 72:9	survival 145:11,14	t 4:1,1
25:11 30:10 42:21	180:7	195:21	tablet 46:1
43:3 54:8 57:4	sun 171:4	survive 153:13	tackle 58:10
62:10,18 63:17	supplementing	168:20 197:9	tactics 97:8
64:1 71:3,21	142:18	survived 116:6	tactile 28:4
103:7 124:16	supply 11:12	survivors 192:6	tailored 21:14
183:18,20,21	29:21 104:20	suspect 64:11	196:16
184:2 194:19	133:18 191:14	sustainable 14:10	take 26:13 37:8
195:2 202:8		15:3	42:15 43:6 46:7
	C 't ID		12.10 13.0 40.7

	·	,	<u>, </u>
60:21 61:13 76:9	talks 80:9	163:2 167:6	155:18 156:20
87:16 91:5 93:2	tall 201:2	193:15,16,20	157:17,20 164:1
96:3 99:8,18	target 217:21	200:12 214:12,14	168:9 170:4 172:2
111:7 112:3,11	tased 75:2,4	terms 24:17 34:3,9	172:5,18 175:8,11
119:9 120:4	task 12:19	35:9 63:13 100:14	179:14,15,15
124:15 143:4,6	taught 116:10	105:10 148:4	181:7,8 186:10
144:11 148:14	teach 96:3 131:20	170:2 173:15	187:19 194:13
149:11 151:9	132:1 193:15	184:3 191:18	195:11 198:12,13
162:19 163:8	teachings 132:11	195:9 202:10	198:17 202:18
172:6,10 205:6	team 9:8 12:6	206:11,18	205:2,2,3 211:14
213:2 217:14	43:13 44:15	terrible 101:9	212:4,9 213:1,3
taken 62:1 134:3	126:11 133:4	terrors 195:19	213:10 220:3,7
135:21 151:18	teas 147:15	test 12:2 32:1	thanking 82:7
160:17 221:3,12	technical 49:7	159:12	219:4
222:9	techniques 132:3	tested 12:4	thanks 44:18
takes 192:17	teeing 190:7	testifying 221:5	45:17 47:13 50:14
talk 5:19 23:17	teenage 60:6	testing 8:14 12:4	59:4,5,13,15
33:7 38:20 55:3	teenager 65:8	104:20 121:19	64:10 68:20,21
55:12 57:2 69:13	teenagers 102:10	191:13	69:4 72:14 77:7
72:16 80:1 83:18	teeth 63:3 67:6,7	tests 12:8	81:10,21 86:13
83:21 84:2 90:15	tele 102:11	thank 5:3 9:3,6	90:6 92:17 96:13
98:10,11 99:17	telehealth 191:9	14:20 15:5,5,10	96:21 99:11,15
100:8 102:17	202:12 217:1	15:17,18,19 16:5	100:18 101:6,18
110:12 112:18	telephone 36:20	22:11,15,16 23:7	106:6,14 109:21
117:14,17 123:10	tell 16:4 35:8 49:3	32:17 33:3,16	111:1,5 118:21
172:12 173:5	60:8,17 61:10,19	43:6,9,11,17	125:5,6 130:1
181:15 190:7	62:12 85:1 107:16	44:11,19 45:15	134:11 140:7
195:13 199:10	114:7,8,12 123:12	50:7 51:10,14	148:12 149:19
talkativeness	217:14	52:19,20 53:10	150:21 151:1
27:17	telling 139:6	59:4,14 64:8,20	152:13 154:11
talked 26:19	155:12 157:18	65:2 69:6,7,8	158:17 160:19,20
103:15 119:12	174:5	72:12 77:6,9,15	162:6 163:17
155:20 156:2	tend 21:16 98:16	81:13 82:11,12	165:11 168:2
157:7 188:20	163:5 175:5	86:20 90:14 91:15	172:1 184:7
214:7 215:7	tense 187:2	91:19 93:9 98:3,6	192:10 193:2
talking 21:5 33:11	term 24:14,15	101:16 102:7	194:12 198:19
37:14,15,16 61:6	32:11 54:3 55:11	104:1,2 105:21	199:17 207:19
80:3 84:8 92:8	55:21 59:17 64:5	106:1,12 109:19	209:14 211:6,7,16
98:8 103:16,19	70:15 102:12	110:17 113:20	212:7
114:18 118:11	103:12,20 114:2	119:6 124:20,21	therapeutic 23:20
147:19 157:19	114:14 115:6	130:3 134:9 140:6	23:21 137:3
158:12 189:4	119:11 122:14	140:8,13,13	173:12
198:9 199:8 212:6	128:6 129:18	148:10,15 149:20	therapies 166:16
	130:6 141:21	150:16 152:14	167:17 182:13

[therapies - tired]

198:2	51:15,20 53:20	201:14,14 202:10	throwing 195:21
therapist 127:17	55:11 56:21 57:1	202:19,21 203:1	thunder 209:21
127:19 129:8	57:11 58:9 59:1	205:6,9,13 207:21	ticks 57:15
137:7	65:3 69:2 71:10	208:2,6,14,18	tie 91:13
therapists 131:3,5	71:18 72:3 79:6	209:6 210:6,9,11	tied 153:21
therapy 28:19	80:8,8 82:21	210:18,20,21	tiffany 2:12 44:2
131:2,5 137:8	86:13 89:13 91:13	211:5 212:5	till 66:18 123:15
181:5 185:21	92:10 93:3,5,21	thinking 66:17	tilley 169:9
theresa 2:6 5:17	94:3,10,17 95:5	90:20 99:18	time 6:1 15:6 19:5
15:13	95:19 96:9,11	131:21 161:8,9	22:21 26:5 35:18
thin 95:14 122:17	97:16 98:7,21	167:3 168:21	41:10 45:5,5,7
122:20	99:3,13,19,19	193:5	47:21 49:14 60:17
thing 98:7 106:8	100:20 102:17	thinks 33:2 74:18	61:11,13 62:6,10
108:11 115:20	103:3,12,14,21	third 6:16 45:19	63:1,7 65:19 66:5
120:21 126:16	104:21 105:18,19	thorazine 74:8	67:8 68:20 69:15
137:1 155:9	106:3,8 107:9	thought 120:18	71:21 72:12 73:17
164:18,21 170:7	108:10,10,15,16	121:8 139:12	74:16 75:5 77:11
171:3 177:11	110:1,7,9,10	151:3 161:12	80:21 83:4,6,20
180:20 185:13	111:9 115:20	185:10 201:10	87:3,12,15,17
187:4 195:4	118:3,8,9 119:1	thoughts 6:15	88:9,20 89:14
196:10 203:15	120:10 125:1	50:14 87:16 96:18	90:3 96:3 99:8
210:21	127:3 132:1	97:15 108:4,5	101:19 107:20
things 36:13 37:12	134:15 137:5	110:20 112:5,12	108:13,20 110:1
38:1 41:8,15 44:6	138:12 139:3	119:2 121:13,14	110:15 112:9
44:16 46:16 56:5	150:1 151:3,7,19	150:7,15 162:8	127:8 128:5,10,16
56:21 57:15 60:15	151:21 152:4,10	172:13 183:3	129:13,21 139:2
66:7,19 67:5	153:4 154:8,14,17	188:14 198:16	141:16 142:7
71:19 73:19 88:8	154:19,21 155:3	199:3,8,10 203:4	144:8,14 151:10
94:8 112:11 116:1	155:14,18 156:1,3	threatened 74:16	152:8 167:7
118:3 129:3	156:21,21 159:11	three 6:11 25:2,4	183:16,16 186:13
135:19 138:9	159:16 161:7,18	27:2 33:8 35:5	187:10,17 188:12
139:14,20 140:5	162:15 166:10,14	38:1 49:1 50:5	196:18 200:19
145:10 151:9,13	167:3,9,12,15	56:6 73:6 91:3,3	202:9,17 209:2
152:5,11,12	168:4 170:7,19	95:1 114:5 120:4	timeline 19:2
162:10 166:13	171:13 172:12	121:17 171:12	times 9:10 47:5
176:11 177:9	173:16 174:11	200:5 210:3	49:17 61:4 66:8
184:17 185:7	175:6,9,16,17	threshold 148:5	74:1,1 84:20 86:4
187:1,2,5,9 191:7	178:13,19 179:17	153:18 154:8	124:5 130:20
197:5,12 209:8	180:1,8 185:21	192:8	132:15 133:13,15
210:6 216:7	187:14,15,20	threw 128:7	143:21 148:5
think 9:9 22:17	188:9,18,20,21	thrive 117:12	tiny 173:17
27:12 32:18 33:18	189:9 190:4,5	212:4	tired 86:8 132:19
37:16 39:3,11	191:20 192:14,17	thriving 138:2	152:2
41:2,16 47:4,10	192:19 200:5,15		

October 6, 2020

[tiredness - try] Page 44

tiredness 86:7	touch 42:6 64:13	treat 32:21 43:14	157:14 159:6,8
today 5:11 9:4	80:7 91:18 106:4	53:2 57:19 147:3	160:15 162:4,18
10:12 14:7,16	111:9 182:9	166:1,1,7,7	164:6,10,17,18,20
15:7 22:11 23:7	touched 79:21	180:17 194:19	165:1,15,19
34:4,17 35:1 37:4	107:9 175:10	treated 75:21	168:14 171:3
40:1 41:3,8,19	188:18	95:17 96:12 105:6	172:12,13 174:9
42:2 44:18 45:15	touching 92:15	120:21 121:3,13	178:9 180:19
45:19 46:13 50:2	tough 37:2 57:12	129:6 191:6	181:5 182:11
50:2,14 52:20	103:7 204:16,21	treating 8:9 57:8	183:2 185:14
53:10 60:1 63:16	tourette's 141:2	75:4 124:14	188:2,15,17
69:6,12 72:11,13	163:6	127:17 166:13	190:12 193:13,15
104:3 111:11	town 136:3,6	193:5 214:5	194:6,9 199:5,5
112:2,3 114:3,18	151:8	treatment 9:15	202:15 213:14
130:10 131:9,10	townhall 20:10	12:14 13:7 14:4	215:8,12,21 218:1
135:4 148:11	toxicity 11:14	14:11 15:8 20:14	218:8,11,16
165:17 166:16	toxicologists 17:2	21:3,6 28:15,17	treatments 13:5,9
167:16 174:11	tracking 46:2	28:19 29:1 30:15	18:21 31:5 32:4
211:15 212:12	traditional 142:19	31:4,6,12,20 32:1	36:4 41:13 42:6
213:6,12 219:13	163:15 174:4	32:3,6,7,10,14	77:4 112:10 113:2
today's 5:9 7:13	train 74:17	36:1,3 42:1,7 43:5	116:5,16 157:1
13:20 14:21 33:16	trained 197:19	44:5 53:12 66:10	183:3 189:14
166:5 212:20	training 134:4	68:19 74:11 75:12	192:2,19 213:15
219:4	185:7	76:4,5,15,18,19	tremendous 9:12
told 132:21 156:3	trajectory 144:10	77:15 97:18 98:14	trends 11:14
209:15 214:19	153:17 170:2	98:15 110:12	12:16 13:1,3
216:6 217:2	tramadol 178:12	112:21 113:2	trial 170:21
tolerance 24:2	transcriber 222:1	114:19 115:5,15	trials 16:20 31:11
25:5 26:18 27:3,7	transcript 222:3,5	115:17 116:4	tricky 167:15
toolbox 58:21	transcriptionist	117:16 118:8,10	tried 76:16 123:17
166:7 167:19	221:7	118:15,18,19	128:9 131:5,18
tools 58:20 117:15	transcripts 7:13	119:10 120:16	trigger 10:16
166:7 167:18	transformative	121:7 122:3,7	triggers 185:13,14
191:13 193:16,19	164:18,19 171:3	123:20 124:9,14	201:20
208:10,17	172:1	127:5,11 129:3,10	trouble 120:19
top 160:10	transition 191:9	130:11,12,17	troubles 130:16
topic 33:7,8,8,10	trauma 138:20	131:6,8 132:13,16	true 60:13 109:9
37:13,14,17,17	154:6,7 196:7	132:17 133:3,14	221:9 222:5
52:1 104:5 112:19	197:16 207:9	136:1,5,8,21	truly 33:14 122:11
topics 42:3 64:14	214:7 215:11	137:5,10,11	154:7
69:2 108:19	traumatic 143:3	138:14 142:13	truths 35:10
total 178:6	143:18 153:21	144:13 147:13	try 22:5 37:16
totally 177:5	168:17 195:18	148:8 150:9,10	38:11 41:9 48:11
195:1	traveling 65:12	154:7 155:4,5	51:10 54:16 84:10
		156:13,17 157:11	102:8 128:10

Public Meeting October 6, 2020

[try - use] Page 45

159:3 164:12	two 11:1 24:21	underlying 71:6	unit 144:21
181:6 182:2	27:1,3 33:8,12	160:5 162:12	168:18 184:20
trying 49:11 56:2	35:6 38:1,21 46:6	193:6 215:13	united 8:11 50:18
56:5 58:13 61:17	48:7 50:3 56:5,21	underneath 155:7	51:4 159:9 177:7
71:5 100:7 123:20	70:12,16 92:16	204:12	university 70:4
129:9 132:1 147:3	97:12 100:1	understand 12:16	unmedicated
167:7 171:1,13	108:17 110:17	13:1 33:1 34:10	69:18
174:2 183:12	112:19 113:15	36:15 41:21 42:8	unmute 15:13
197:8 203:20	115:10 128:16	48:4 49:11 57:15	23:3 52:16 149:7
207:5	138:4 139:8	77:12 80:16 81:18	unmuted 149:15
tuesday 1:5	152:17 153:5	83:5 94:4 96:8	unpack 69:3 77:8
turn 15:13 22:14	162:7,10 171:12	107:15 129:20	unpleasant 27:21
23:3 42:17 45:6	217:20 218:9	158:20 159:15	unprecedented
52:16 64:16 69:5	twofold 145:13	164:4 165:2 172:4	9:10
79:20 81:7 83:2	type 33:1 58:8,15	199:14 216:3	unsafe 145:17
89:15,16 91:15	139:14,15	218:3	153:11 191:15
93:3,3 97:19	types 43:14 94:4	understanding	207:1
99:12 100:19	94:20 219:14	17:17,20 23:11	unscientific 47:11
104:1 140:10	typewriting 221:7	54:19,21 88:21	untimely 168:17
148:18 157:3	typical 119:15	95:20 106:2	untreated 115:3
158:19 167:20	173:20 206:12	116:19 160:19	135:16
168:3 172:8 182:8	typically 18:10	166:15 173:9	unwilling 125:19
183:4 184:8	95:2 123:6	understood 14:1	upper 123:8,9
186:11 188:14	typing 108:10,21	106:9	upper 123.8,9 uppers 123:7
189:3 192:14	189:10	undiagnosed	upward 170:2
194:14 198:14,20		214:6	urban 161:16
198:21 205:3,5	u	unexplored	192:5
207:3 211:8,10	u 70:1	147:16 148:4	urge 25:16 26:7
212:16	u.s. 2:4 7:20 8:1	unfolding 62:15	76:10
turned 68:19	29:20 50:21	unfortunate 54:12	urges 193:18
126:15 135:17	ultimately 62:7	105:11	urine 12:2,7
152:15 158:3	63:19 168:12	unfortunately	usage 87:1,1,2
161:9 194:8,9	unaddressed	48:9 100:11 170:9	131:19
199:12	193:9	181:21	use 1:2 5:5 6:4,5,9
turning 40:14	unbeknownst	unidentified	6:13,16,17 7:5
144:16 146:10	69:15 136:8	175:20 176:2	8:10 9:13 10:4,5
172:7 183:10	uncertainty	178:21 179:3,20	11:2,2,13,13,20
196:21	206:19	180:3 203:9	12:11,17,21 13:6
turns 100:12	uncomfortable	unintended 94:18	13:17 14:9,11,12
turns 100:12 twenty 70:12	138:17 163:8	union 192:4,6	15:9,9 22:13 23:5
twice 70:14	217:7	unique 15:16	23:11,18,18,21
125:13 164:13	uncovering	unique 13:16 uniquely 17:19	24:1,3,12,13,15
twisted 201:13	168:16	196:16	24:20 25:3,3,7,10
twistcu 201.13	underline 109:9	170.10	25:10,11,13,16,19
			23.10,11,13,10,17

Public Meeting

October 6, 2020

[use - walk] Page 46

25:19,20 26:1,2,7	121:10,11,20	users 78:13 105:4	view 10:3 18:16
26:8,10,14,17,20	122:1,4,6,7,13	153:8	46:6
27:1,9,10 28:8,10	123:6,7,17 125:13	uses 28:18 48:21	viewers 168:6
28:10,13 29:1,15	126:7,8 127:3,7	49:2 105:8 131:19	211:10
30:14 31:1,13,15	130:7,7 131:10,11	142:1,10 180:21	viewing 40:20
31:17 32:2,4,7,12	131:14 135:6	182:16	96:20
32:21 34:7,15	137:10,21 138:16	usual 119:7	views 18:20 41:2,8
35:4,14,16 36:1	139:2 140:16	usually 20:16 78:6	vigilant 124:4
36:12 37:6,8	141:17 142:17	89:7	vilified 115:1
40:11,12 41:16,19	143:10 145:20	utilize 61:18 65:21	violence 144:2
42:9 43:5 44:15	146:13,16 147:2,4	68:12 123:17	violent 100:5
46:6,8 48:8,20	147:8 152:20	171:21	violently 143:21
50:6,11 51:3 52:3	153:5,12,19 154:4	utilized 65:17	virtual 1:9 7:3
52:18,21 53:2,14	154:19 156:14,17	utilizes 132:7	9:10 37:18 47:5
54:17,21 55:14,16	157:15,16 159:17	utilizing 65:11	78:4 108:15
56:10 57:1 58:2,8	159:21 160:1,6,13	v	200:10 202:12
58:17 59:19 60:3	166:2,4,4,8,12,12	vaccination 8:4	217:3
60:4 61:20 62:13	166:14 168:15,16	vaccines 31:7	virtually 210:14
62:18 63:8,17	170:8,11,16 173:3	vacuum 115:11	vision 176:8,14
65:4,13,13,20	173:4,20 174:2,18	vacuum 113.11 vague 133:3	vivid 27:21
66:1,5,13,15,15	180:17 181:13,14	valuable 19:12	vivitrol 76:8
66:21 67:4,10,11	183:12,17 184:2,5	205:13 212:11,13	voice 17:16 22:5
67:13,19 68:5,10	185:3 187:3,6,7,7	value 19:13	22:19 111:18
68:14,19 71:4	187:8,9 188:3	value 15.13 van 121:5	115:8 175:15
72:16 73:17 75:5	189:14,19 190:1	van 121.3 variability 30:19	182:7 212:15
76:1,1,6 77:3,14	190:11 192:1,9	varieties 153:2	215:18
78:8,13 80:17	193:7,18 194:4	variety 50:1 141:9	voices 14:7 40:3
82:7 83:3,6,6,7,14	196:2,7,9,10	142:3 164:17	165:7
83:19 87:9,13	199:4 200:7 202:1	194:19 207:15	volume 113:17
88:3 89:12 90:4	202:4 203:6	various 90:4 218:8	volunteering
90:21 91:1 92:2,2	205:21 206:1	vary 28:15 31:15	128:21
92:11 93:12,12	208:7 213:9,9,13	varying 23:10	vomiting 28:3
94:7,7,10,16 95:2	213:17,21 214:8	vast 105:5	vulnerable 209:9
95:4,18 97:4,11	214:10,17 215:1,6	vent 177:17	w
98:8,16 99:3	215:14,19 216:3	versus 150:12	wait 84:9 86:9
100:4,6,11,13	216:14,18,21	161:11	171:8
102:12,16,17	217:13,15,21	vicious 85:8 126:9	waiting 82:20
104:8,8,9,10,11	218:7,17,21 219:1	viciousness 84:18	171:5 172:11,15
105:10 106:11,12	219:6,11,13,15,18	video 15:13 23:3	189:8,11 192:13
109:14,17 111:6	useful 21:12 32:2	42:17 52:16 90:8	wake 51:11
114:19 115:3,21	131:21 132:6	97:20 98:1 100:21	wakefulness 29:9
116:10,10,11,13	167:18	101:3 114:15	walk 5:12 74:19
116:15 117:12	user 105:6 163:12	172:7 183:4	74:19 76:3
119:13 120:12,14			
L	I .	I .	

October 6, 2020

[walked - words] Page 47

walked 132:15	wants 111:13	webinar 33:9 50:2	william 205:16
171:14	war 142:17	website 7:14 23:15	willing 83:18,20
walsh 2:21 73:1,2	warehouse 65:15	38:17 39:10 192:6	84:1 89:4 127:14
want 14:5,8 16:12	warm 194:7	week 86:4 132:21	181:6 199:9
34:8 38:2,4,5,15	watching 92:18	136:9,10 171:12	willingness 14:16
39:8,12,16 40:1	171:4 190:9	209:1 218:14	94:2
42:2 43:5 52:10	water 74:19	weekend 92:2	winchell 2:10
59:15 65:2 66:12	wax 73:14	weekends 125:12	43:11,12,12 149:3
77:3,4,5,5 78:17	way 10:8 18:17	weekly 126:1	149:7 155:21
86:2,10 87:13	22:6 23:19 34:11	127:19	157:3 158:20
90:7 97:18 101:21	38:19 42:8 57:18	weight 15:7 29:12	159:2 163:18
102:3 107:20	66:12 75:4 78:6	62:2 119:16,17	winchell's 161:1
112:1,2,8 113:7	86:12 94:11,17	welcome 15:1 39:5	window 99:20
113:19 119:9	97:2 109:13	111:4	wish 150:2 177:12
130:9 134:15	114:17 117:21	welcoming 104:3	wishes 211:18
135:9 136:11	126:5 136:3	wellbeing 56:20	withdrawal 24:5
149:20 155:9	138:15 143:12	186:2 200:14	24:11 25:6 26:19
157:13 158:19	144:9 145:4,8,15	214:11	27:3,8,20 54:7
159:15 160:21	146:5,18 153:7,13	wellness 117:9	61:5,16 91:6,9
161:19 162:7	160:14 173:13	137:9 146:21	189:21 214:14
164:3,3 165:6	174:17 182:3	187:8	withdrawals
167:20 171:9	184:15 187:16	welsh 2:18 59:14	146:15
179:1 180:15	188:6,10 193:15	59:17 90:9,13	withdrawing
186:15 188:13	208:1 209:5	went 58:3 60:18	146:13
189:17 195:2,3	ways 31:11 46:6	67:2 70:1 73:11	witness 221:4
198:14 203:5	59:1 71:19 94:12	84:14 116:5	wo 197:15
205:11 208:7	98:5,17 109:12	126:10 138:3	wolf 208:1,4,11,15
211:13 213:5	123:19 141:9	164:16 184:12	woman 122:17
217:14 219:3	211:1 219:13	185:4 209:15	154:14 193:12
wanted 10:3 19:9	we've 19:5,20 22:6	west 51:8	women 155:5
33:13 53:1 61:7	34:12 35:1,1 36:7	whim 87:8	156:18
61:14 80:7 85:20	51:7 80:9 82:2	white 205:16	wonder 83:17
86:12 97:14 102:9	94:11,18,21 95:5	who've 94:6	wondered 165:6
104:4 109:4 110:2	99:13 108:19	widely 31:15	wonderful 140:14
111:7 149:21	125:15 147:16	104:6 147:9 148:6	220:10
155:21 160:18	167:16 194:17,17	161:16 191:10	wondering 150:6
165:8 172:8 173:2	200:17 201:18	206:9 207:10	164:17 165:1
173:5 179:5	202:11 217:15	wider 18:16	wonders 131:13
186:19,21 187:4	weaker 24:4	widespread	word 39:9 57:7
195:7 209:19	wear 40:7,7 177:4	207:16	123:7 216:6
213:2 220:7	wears 174:20	wife 114:7	wording 187:16
wanting 151:5	web 52:11	wiggle 204:17	words 34:3 103:9
152:8	webcast 7:12,12	wildly 116:6	132:4
	7:13 38:9		

Public Meeting October 6, 2020

[work - zoom] Page 48

97:4 109:11 128:14,20,21 130:1 131:7 132:3 138:2,7,18 142:5 152:5 154:9 155:5 155:15 157:8,19 165:13 166:11,13 169:21 170:7 184:19,20,20 191:17 195:4 196:15,15 197:6 197:15,21 199:21 201:9 203:18 214:20 219:1 220:9 worked 21:6 75:11 117:9 128:9 129:21,21 138:6 187:11 200:6 working 8:6,7 13:16 18:21 56:14 57:18 111:20 124:5 125:21 146:8 157:10 169:21,21 177:13 177:14 184:21 204:1 217:18 works 69:11 158:6 167:1 169:8 196:14 workshops 218:5 workshops 217:20 world 8:12 9:10 38:19 51:1 115:11 136:14 144:3 155:10 176:13 95:7,8 worse 57:21 94:17 yesterday 60:10 yoga 142:3 183:12 young 65:8 143:19 151:8 156:10 z zoom 134:1,7 140:1 182:4 201:3 201:5 202:12 yeph 207:21 yesterday 60:10 yoga 142:3 183:12 young 65:8 143:19 151:8 156:10 yom 134:1,7 140:1 182:4 201:3 201:5 202:12 yeph 207:21 yesterday 60:10 yoga 142:3 183:12 young 65:8 143:19 151:8 156:10 z zoom 134:1,7 140:1 182:4 201:3 201:5 202:12 yeph 207:21 yesterday 60:10 yoga 142:3 183:12 young 65:8 143:19 151:8 156:10 z zoom 134:1,7 140:1 182:4 201:3 201:5 202:12 yom 65:8 143:19 151:8 156:10 yom 154: 13:10 151:8 156:10 yom 158: 143:19 151:8 156:10 yom 65:8 143:19 151:8 156:10 yom 134:1,7 140:1 182:4 201:3 201:5 202:12 yom 65:8 143:19 151:8 156:10 yom 65:8 143:19 151:8 156:10 yom 134:1,7 140:1 182:4 201:3 201:5 202:12 yom 134:1,7 140:1 182:4 201:3 201:5 202:12 yom 134:1,7 140:1 182:4 201:3 201:5 202:12 yom 134:1,7 140:1 182:3 15 15:18 156:10 yom of a vising 165:20 176:19 young 165:20 176:19 young 165:20 169:17 140:1 182:3 15 15:18 156:10 young 165:20 150:18 140:1 182:3 15 151:1 15:8 156:10 151:8 156:10 151:8 156:10 151:8 156:10 151:8 156:10 151:8 156:10 151:8
